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I. INTRODUCTION† 
It is our pleasure to present a panel of such distinguished 
people.  We have put together a truly international conference.  
We have speakers from Geneva, Germany, France, Ireland, the 
United Kingdom, China, and Japan. 
The objective of today’s conference is to delve into the Patent 
Cooperation Treaty (PCT).  As you all know, the PCT is the 
premier patent law treaty in the world today allowing for a single 
forum for the examination of patents that may subsequently be 
filed in 123 nations.  Although the PCT operates largely as a 
procedural treaty, granting no specific substantive rights, the PCT 
is considered to be one of the World Intellectual Property 
Organization’s (WIPO) shining jewels. 
Given that, I look forward to a very fascinating day of 
discussion regarding how the PCT is received in the nations from 
which we have speakers attending. 
That being said, there are many people I need to thank.  First, 
I’d like to thank Mike Schumann for providing a superb forum at 
which we held a pre-conference conference.  Mike owns Rainbow 
Resort.  It can be viewed by going to www.rainbowresort.com.  We 
had a wonderful time snowshoeing, ice fishing, and chatting.  Doug 
and Linda acted as great hosts and guides.  It was an all around 
fantastic get-away. 
I also need to thank some people.  First of all, Adonis Neblett 
 
       †  Kenneth Port, Director of Intellectual Property Law Studies, William 
Mitchell College of Law, St. Paul, Minnesota  
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from Fredrikson & Byron.  The law firm of Frederickson & Byron 
has contributed generously to this conference and made it all 
possible, so thank you very much.  Also, Phil Goldman from 
Fredrikson & Byron is here.  Thank you so much last night for 
dinner.  I’m not sure if that was planned or we just stuck you with 
the bill, but thank you so much.  I really also need to thank Phil for 
introducing me to Jay Erstling.  Phil introduced me to Jay two years 
ago.  It was then that we conceived of this conference.  Therefore, 
Phil deserves the credit for bringing Jay and me together and for 
making this conference possible in the first place.  I am very 
indebted to Phil as well. 
The law firm of Merchant & Gould has also contributed.  
Tonight, they will host a dinner in honor of the speakers at today’s 
conference.  For that, in advance, we are very appreciative. 
Jim Rienke, the president of the Student Intellectual Property 
Law Association (SIPLA), is here.  You saw the people in the 
hallways helping and directing traffic.  These students are all from 
SIPLA.  SIPLA has been exceedingly helpful and gracious.   
And of course I’m very indebted to Jay Erstling for helping to 
put this together.  Jay is the Director of the Office of the PCT.  Jay 
substantively put today’s conference together.  Basically what 
happened was Phil introduced me to Jay; Jay said, “Can we do a 
conference?”; I said “Yes”; then I turned to Meg and said, “Please.”  
That was basically all my role was—to say “yes” to Jay and “please” to 
Meg.  So, it worked out pretty well for me.  And also thank you to 
all the speakers. 
We have a very, very packed day.  We have people from 
Beijing, Shanghai, Munich, Tokyo, London, and Geneva.  Am I 
missing anyone?  Oh yes, Minneapolis.  We even let a few people 
from Minneapolis come across the river.  I hear they had a little bit 
of trouble at the border, but otherwise everything was all right. 
Finally, I’d like to thank some people from William Mitchell.  
Elizabeth Warmka did a very nice job marketing this conference.  
Meg Daniel, of course, played the largest role in administratively 
putting this conference together.  She has worked long hours on 
this conference and deserves your heartfelt appreciation.  So, when 
you see her in the hall, just pat her on the back and say, “a job well 
done,” because she’s done a really great job and deserves a lot of 
praise. 
I think we’re ready.  We have a very crowded agenda for 
today’s conference.  Therefore, I’m going to dispense with long 
3
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introductions of each speaker.  Please refer to the materials before 
you for each speaker’s detailed biographical information.  I will be 
very brief in my introductions of people to allow them time to talk.  
It seems a little funny that we’ve asked people to come from 
Shanghai and Beijing, etc., and given them twenty minutes to talk.  
It’s kind of a long way to go for twenty minutes.  So to extend that 
as long as possible, I’m going to be quiet. 
Without further ado, our first speaker is Jay Erstling, the 
Director of the PCT. 
II. THEME ONE: THE PCT IN THE SHORT TERM 
A.   Topic One: The Current State of the PCT: Accomplishments and 
Challenges, Opportunities and Threats 
1. WIPO Perspective: Jay Erstling† 
What I would like to do is talk to you a little bit about the 
current state of the PCT.  We have, I think, true justification for 
being extremely proud.  I would also like to talk about the 
direction in which we are trying to go and the really important 
challenges that we are facing. 
What I had hoped to be able to do, and I think it was Meg who 
came up with the title, “Accomplishments and Challenges, 
Opportunities and Threats,” is to say, this is a really cool 
opportunity.  Those of you who know me know I am not the most 
structured, linear person in the world.  I thought, great!  Here 
there are these four categories and I can put together a 
presentation that says, here are the accomplishments, here are the 
opportunities, and here are the challenges.  As I started to do that, 
I realized that I absolutely could not because with every 
accomplishment there is a challenge.  And with every threat there 
is opportunity.  So, maybe I am being true to myself and being kind 
of random and scattered, but I hope that you will put up with me as 
I lump things together in talking about basically where the PCT is. 
What it really is—as I think many people recognize, is a 
tremendous success.  I think that the PCT is a success is a surprise 
even to the most ambitious of the founders of the PCT.  In fact, it 
 
       †  Director of the Office of the PCT, Geneva.  The opinions expressed are 
those of the speaker and not necessarily those of the WIPO. 
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really has become synonymous with the international patent 
system.  It has also been in some ways a victim of its success; 
because of its very success, very numbers, the fact that it probably 
has at least twice as many applications as anyone ever had 
imagined.  It creates many challenges and lots of stresses on the 
system that we are trying to deal with. 
The PCT is now well beyond its one-millionth application.  We 
celebrated the one-millionth application a year and a couple of 
months ago.  The PCT has had, since its start, continued growth 
every single year without exception.  It has also grown to an 
extraordinary large number of countries.  There are now 128 and 
we expect actually a bunch more this year.  That has sort of been an 
ironic thing which I want to come back and talk about later 
because about one-half of the countries have no patent activity, but 
they are members of the treaty.  It is our job to make sure they have 
a meaningful role to play in the treaty even if it is a hope for the 
future that at some point in time they will be able to play a 
meaningful role in the intellectual property system. 
We no longer do much to attract new countries.  That job is 
often being done by the United States and the European Union 
which, when they enter into bilateral trade assistance, or free-trade 
agreement negotiations, sometimes include in the negotiations a 
list of treaties that the country should join.  The PCT is usually at 
the head of the list.  We find ourselves, actually sometimes to our 
surprise, with new member countries, some of whom have only very 
basic functioning patent systems. 
There are nevertheless a few countries that are not yet a part 
of the PCT that we think would benefit from it.  Thailand, Malaysia, 
and Argentina are examples of countries that really should be PCT 
member countries in terms of their level of economic 
development, their level of industry, and their level of patent 
activity.  The International Bureau maintains contact in particular 
with Thailand and Malaysia and provides them with information 
and assistance about PCT-related matters whenever they request it. 
As I had mentioned, there has been non-stop steady growth.  
Part of what the International Bureau tries to do is to chart that 
growth.  This year we had an increase of over 9% in PCT 
applications filed.  It was almost double of what we had expected 
and projected.  Of course, what that means is that the Office had to 
do a lot of scrambling.  In fact, the strains that unexpected growth 
puts on the system become particularly great for us at WIPO at the 
5
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International Bureau in Geneva, but obviously also for all of the 
major receiving offices and the searching authorities.  We are 
proud of the fact that we actually did cope with the growth, and the 
way we are trying to cope is by becoming more efficient, 
automating, changing our methods of workflow, working closer 
with the different national offices, and hopefully giving the kinds of 
service deserved by users.  For next year the International Bureau 
expects and has projected an increase of growth of about 5%.  Just 
as we under-estimated growth for 2005, I certainly hope we have 
not over-estimated it for 2006. 
If you look at the chart you see that the PCT is still dominated 
by the major industrialized countries.  If you put all of the 
European Patent Convention (EPC) countries together, they are 
the number-one filer of PCT applications, but just by a bit over the 
U.S., which from the very start has been the dominant filer.  What 
you can also see is that the increases from the U.S. and Europe are 
relatively small while the increases from Asia, in particular, are just 
astonishing.  What we see is that the PCT is moving east.  If you can 
just look at the figures from Japan, the Republic of Korea, and 
China there has been remarkable growth.  We are starting with very 
low numbers because the PCT is only now truly becoming accepted 
and popular in Asia.  Furthermore, over the past two years there 
was over a 40% increase in filings from Japan.  The Republic of 
Korea has overtaken the Netherlands as the number-six filer.  What 
is also truly remarkable is how much publicity this gets.  We 
recently released statistics for the year 2005.  And if you look at 
financial press coverage in Asia, particularly in Japan, China, 
Republic of Korea, also in India (which is a country where there is 
astonishing promise and great increase in use of the PCT), this has 
made front page financial press in the region.  The PCT is taken 
very seriously.  Where we also see great promise is in other 
emerging developing countries such as Brazil and South Africa.  
The numbers are still infinitely small, but there is almost a direct 
correlation between economic development and a take-up of the 
use of the PCT.  I will want to come back to that in a little bit. 
Of the twenty top filers for 2005, 3M is the second biggest U.S. 
filer and the eighth largest filer worldwide.  Medtronic, is I think, 
the thirty-seventh or thirty-eighth largest filer of PCT applications 
worldwide.  What is truly interesting, I think, is that the companies 
that file 100 applications or more, file only about 20% of the total.  
The typical applicant, the typical user of the PCT, is someone who 
6
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files only a few applications a year.  Despite the fact that the United 
States is the largest country filer, there is no U.S. company that is 
within the top five.  Most of the applications that come from U.S. 
companies come in small numbers, not in large ones. 
What is also kind of an interesting aside is that, for example, 
with companies like Philips, Nokia, Ericsson, their filings constitute 
the major bulk of filings coming from their home countries.  For 
example, for Philips, filings are about 90% of the filings that come 
from the Netherlands.  Philips files all of its applications directly 
with us at the WIPO Receiving Office.  You are probably aware that 
the International Bureau has its own receiving office, which is 
currently the fourth largest receiving office worldwide.  Philips not 
only files all of its applications at the RO/IB, but all of its 
international applications are also via the PCT.  They are a good 
client. 
Another great accomplishment of the PCT is in the area of 
PCT reform.  I think the greatest accomplishment has been how 
quickly, smoothly and efficiently all of the 1281 member countries 
were able to agree upon reform.  It is still too early to tell how 
successful that reform really is, and we have to depend on you to 
tell us that.  Isabelle Boutillon is going talk to you in greater depth 
about what some of these reforms have been,2 but what I would like 
to do is tell you a little bit about the reform process, because if you 
know the reform process, the fact that it works is almost stupefying. 
Reform really began as a response to the fact that suddenly the 
number of applications was so great that the major offices, the 
USPTO (United States Patent and Trademark Office) and EPO 
(European Patent Office) in particular, were having trouble 
coping.  The offices began to look for ways to streamline and 
reform the system to allow them to deal more efficiently with the 
growth.  One of the solutions that the PCT countries came up with, 
as you all know, is that you no longer needed to file a demand in 
order to be able to enter national phase at thirty months as 
opposed to twenty months—you were automatically granted a thirty 
month date.  The main purpose of that, as well as the subsequent 
reform, about which Isabelle will go into in greater depth, of 
moving the Chapter II issuance of the written opinion into the 
Chapter I international search procedure, was done with the 
 
 1. Now 130 countries. 
 2. See infra Part II.B.1. 
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primary purpose of decreasing the amount of demand for 
international preliminary examination.  Before the reforms went 
into effect, 85% of applicants sought preliminary examination and 
now the figure is down to below 20% of applicants seeking 
preliminary examination.  Whether that is good or not, I think it is 
frankly a little bit too early to know, but filing patterns have 
certainly changed. 
There is a Working Group on Reform of the PCT.  At any 
given meeting there are usually eighty, or even more, countries that 
are represented by their delegations.  In this huge conference 
room filled with country delegations, including a whole bunch of 
non-governmental organizations like AIPLA (American Intellectual 
Property Law Association) and ABA (American Bar Association) 
who attend as observer representatives, everyone deliberates.  In 
the entire process of reform not a single vote was ever taken.  In 
fact, in the entire history of WIPO working groups and committees, 
I do not think a substantive vote has been taken.  The process is 
one of discussion and compromise.  Countries say a certain aspect 
of a proposal is unacceptable and then it becomes incumbent upon 
WIPO to try to figure ways around it.  The result is ultimately 
provisions that every country can buy into because if one 
delegation raises its hands and says, “No, this is unacceptable to us,” 
then we simply do not proceed to adoption.  You have to reach the 
point where everyone finds the proposal acceptable or else it goes 
nowhere. 
The result is, usually, very complicated, complex, multi-layered 
proposals; which is why we all talk about the PCT not standing for 
Patent Cooperation Treaty, but as standing for “Pretty Complicated 
Treaty.”  One example that is going to enter into force in April 
2007, again Isabelle Boutillon will go into the details of the 
proposal, is a proposal that was taken from the Patent Law Treaty 
that provides for—and it is a really great and important proposal—
restoration, a grace period for restoration of the priority right if 
you miss the priority filing date.  Initially, one generally hoped for a 
very simple provision based on “oops I forgot the priority date so 
I’ll pay some extra money to the receiving office and please now 
grant me my priority date.”  But, some countries felt that this type 
of forgiveness was a significant deviation from the Paris Convention 
and absolutely unacceptable.  There were other countries that said, 
“Well, we think it is okay, but you cannot give restoration away so 
easily, applicants should really have to prove that they exercised all 
8
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due care and despite the exercise of all due care, somehow the date 
was missed.”  There were also a couple of countries that said, “Why 
do you even have to prove anything?  All you should do is pay some 
penalty fees and get your priority back.” 
The end result is a system that has put all of the views together.  
Countries can opt out if they find the restoration provisions 
contrary to their national systems.  Countries that are willing to 
provide for restoration, but only upon a showing of “exercise of all 
due care,” may opt for that.  In addition, countries that are 
comfortable with “unintentional absences of filing” may restore on 
that basis.  Ultimately, we have ended up with a three-layer, 
complex provision.  Although it is still a very good and worthwhile 
one, it will probably require some years of PCT seminars and 
training before everyone properly understands it. 
That is just a simple example.  There is a proposal on the table 
now for multiple-language publication, which really is not so much 
for the benefit of U.S. applicants, except if you want to get 
provisional protection in another country.  It is mostly for 
applicants who file in languages other than English who want to get 
102(e) prior art effect in the United States.  For example, an 
applicant could file an application in German, for example, and 
then give the International Bureau an English language translation.  
We would publish the English language translation and the 
applicant would get 102(e) prior art effect under U.S. law.  
However, we have learned through Working Group negotiations 
that this provision would conflict with the national practice of a few 
countries.  It is very likely that because of that conflict, unless the 
Working Group can get super creative and find a solution that will 
be acceptable to everyone, the proposal will end up dying.  If that is 
the case, it will be a pity for those who do not typically file in 
English, but that is how the reform process has worked. 
Another area where there has been a lot of change, but now 
only starting in the United States, is in electronic filing.  We are 
trying as an office to become paperless, and in our 
communications with receiving offices and designated offices, to 
communicate as much as possible with each other electronically.  
The reason is largely to deal with workload and cost issues.  We 
have an electronic filing system in place, although it is not yet 
applicable in the United States  What we have found is that the 
take-up of electronic filing has been tremendous, mostly in Japan 
and Korea and also in China, where electronic filing has been the 
9
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norm.  The International Bureau has been working very closely 
with the USPTO.  The USPTO has been doing an excellent job of 
developing an electronic filing system and I believe, and Charlie 
will correct me if I am wrong, there is hope that there might be 
electronic filing by the fall of 2006; and if the system does work, it is 
going to be fantastic. 
The International Bureau is also trying to do things, and is 
considering methods, that will have a direct impact on you as users.  
Instead of sending you a paper pamphlet once your application is 
published, we want to be able to notify you that it has been 
published and send you either the URL number or the application 
number so that you can download or print the published 
application.  We are currently seeking the views of major PCT filers, 
including 3M, on what a system like this should entail and what we 
absolutely need to avoid. 
One of the biggest non-starters in improving PCT procedure 
proved to be trying to make PCT forms more efficient.  The PCT 
system contains something like seventy-nine different forms.  I have 
colleagues who can tell you what each one of those is, which 
astounds me all the time.  Seventy-nine forms!  To me this was 
crazy.  I thought we had to get rid of lots of them.  We had to 
change things.  However, offices and users said that the idea of 
rationalizing and making forms more efficient was unrealistic.  The 
forms made sense to them and they saw no reason to change.  So 
even though the International Bureau hopes to be able to 
communicate forms more electronically and more efficiently, the 
seventy-nine forms, I think, are probably here to stay, and they will 
likely increase considerably by the time we are finished reforming 
the treaty. 
I think the most challenging element of our accomplishments 
has been the fact that there is a much larger group of countries 
that are now members of the PCT than the PCT’s founders ever 
imagined.  The PCT has gone through, I guess as all of 
international intellectual property has gone through, a major 
process of decentralization and democratization.  The initial idea 
of the PCT was that there should be only one International 
Searching Authority that would be the international searching 
authority for the world.  We now have twelve international 
searching authorities.  Nevertheless, whether you think of that as a 
negative or as a positive development, the number of international 
searching authorities is likely to grow within the next couple of 
10
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years.  Some growth will come from industrialized countries.  For 
example, there is a likelihood of a Nordic international searching 
authority.  More particularly, the growth will come from emerging 
countries—emerging developing countries. 
Egypt has made it very clear that it wants to be an international 
searching authority and it wants to be the first searching authority 
to search Arabic language applications.  Arabic is now a publication 
language under the PCT.  Some Indian officials have mentioned 
that India would like to achieve capacity to be a searching authority 
by the year 2010.  For some people, both within WIPO and outside 
of WIPO this is an absolutely positive development.  Countries that 
have generally been suspicious of intellectual property or patent 
protection and hesitant to grasp it are now saying they think that 
intellectual property is important enough that they want to play a 
central role in the international patent system.  I personally think 
this is wonderful and I hope that the offices will continue to be 
encouraged in order to help reach the technical level that is 
necessary so they actually can serve as searching authorities and 
play more meaningful PCT roles. 
What this increasing democratization also means, when we do 
have these conferences and meetings, is that there may have to be 
some new sharing of power and authority among the traditional 
PCT countries and the newer PCT forces.  In the early days there 
were only a few country delegations that would actively participate 
in meetings and a lot of countries that would be rather passive.  
Now more and more country delegations are playing active roles in 
the deliberations.  The number of players in making PCT policy 
has grown significantly.  What that means, obviously, is that some of 
the authority, some of the power that the major industrialized 
countries have had traditionally within the system is going to have 
to be given up so that the voices of other countries can be heard.  
For the continued expansion of the PCT, I think we will all need to 
pay increasing attention to ensure that the perspectives and ideas 
of emerging countries get the respect and attention they deserve. 
With that, I would like to focus on just a few things that I feel 
really are the major challenges that the PCT has to face, some of 
which I have already mentioned. 
The biggest challenge that I think the PCT faces is how to 
succeed as a truly multilateral system when there are huge gaps 
between the industrialized world and the developing world.  As you 
can see on the two pie charts—the industrialized countries only 
11
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make up 21% of PCT membership.  Seventy-nine percent of PCT is 
made up of either developing countries, countries that are 
designated as least developed countries, and another group 
composed of the former socialist countries of Eastern Europe and 
Asia.  These latter groups make up almost 80% of the membership.  
If you look at filings, the group that is 80% of the membership only 
filed 7% of the applications in 2005.  If you remove Korea, 
considered a developing country in WIPO practice, and China and 
India, the two largest emerging countries, that 7% shrinks greatly. 
So our major challenge, and I think the future of the PCT, will 
perhaps depend in large part on our ability to make sure that the 
divide between the players in the system and the members of the 
system who are not yet players does not continue to grow and 
subvert the system.  This means that WIPO should, for all who are 
responsible for the administration of the system and for promoting 
intellectual property protection, maintain a focus and emphasis on 
trying to provide training and opportunities for countries with little 
or no patent activity to begin to develop that activity. 
From the perspective of users of the system, I would say that 
the most difficult and greatest challenge facing the PCT is the 
question of timeliness and quality.  Unfortunately, it is a challenge 
that the International Bureau has the least control over.  Only 
slightly more than half of International Search Reports are issued 
at the time—sixteen months from the priority date—when we 
expect those search reports to be issued.  Almost half of the search 
reports are issued late.  Unfortunately, the almost half that are 
issued late tend to be search reports issued by the USPTO and to a 
lesser extent by the EPO.  Now, there is a very good reason why 
those are the offices that are more often late because they are the 
ones under the most pressure and the most strain.  The EPO issued 
almost 50% of all search reports last year and the U.S. Patent Office 
issued almost 20%.  Nevertheless, in terms of users of the system, 
the International Bureau is mindful of the fact that applicants are 
not getting the service that they deserve.  In fact, looking at the 
more dramatic side of things, about 14% of all search reports 
issued come after the twenty-first month, and 3% issued become 
effective after applicants have already been obliged to enter the 
national phase—that is the bad news. 
The good news, to the extent that there is good news right 
now, is that the USPTO and EPO are also mindful of the problem; 
they are aware and realize the difficulty, and they are attempting to 
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take measures to rectify it. 
Most American applicants are generally aware of only a few 
International Searching Authorities, USPTO and EPO, and 
perhaps JPO (Japan Patent Office) and CIPO, and we tend to think 
that the numbers of searching authorities are very limited, but in 
fact, there are a considerable number of them.  In taking advantage 
of the considerable number, I think that the USPTO has been 
quite progressive and visionary in trying to find solutions that are a 
little bit “out of the box.”  For example, as of January 1st, U.S. PCT 
applicants can use KIPO—the Korean Intellectual Property 
Office—as an International Searching Authority.  KIPO is a very 
good office.  It is possibly the most technologically advanced office 
in the world.  It has excellent searching software.  It issues search 
reports in English and it issues search reports on time.  I think the 
cost is something like $218 to get an international search report 
from KIPO.  I believe USPTO obviously would like people to use it, 
to relieve some of the pressure, and I would venture to say that it 
may be worth the try. 
In addition, the USPTO has undertaken to subcontract out 
some international search reports to the Australian Patent Office, 
and the USPTO announced a pilot project to subcontract out 
international search to some private search agencies, all in order to 
relieve pressure. 
The EPO is also making progress.  For those of you who use 
the EPO as a searching authority, you may realize that your search 
reports are beginning to come a little bit earlier.  There has been, 
again, a real recognition of the need to speed up the process.  One 
solution the EPO has adopted has been to institute an enhanced 
European search report system that parallels the enhanced PCT 
international search report system, which allows workflow to take 
place more efficiently within the European Office. 
To finish, there are other challenges that the International 
Bureau faces.  On a daily basis, we strive to work effectively and 
efficiently with the PCT’s member countries to ensure that the 
system works harmoniously.  We spend considerable time 
consulting with countries concerning PCT obligations and 
requirements, for example, reminding countries that they may not 
under the Treaty demand legalizations for entering national phase, 
or informing them about new procedural changes.  In particular, 
for newer receiving Offices, providing training is an important 
activity of the International Bureau. 
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As successful as the PCT is, there is a looming question: Is 
there a better system?  Currently some discussion has taken place 
and ideas have been floating around the JPO and the USPTO 
about means to supplement the PCT or to provide alternatives to it.  
These ideas focus primarily on improving coordination among a 
small group of industrialized countries. 
As the International Bureau, our role in such discussions must 
be one of neutrality.  At the same time, in keeping with WIPO’s 
mission to promote respect for intellectual property throughout 
the world, WIPO actively supports the establishment of more 
efficient intellectual property systems that would allow greater 
recognition of search reports and of the work of different offices.  
At the same time, going back to the fact that the PCT membership 
is 128 countries and WIPO has 183 member countries, effective 
intellectual property protection should not be seen as leaving a 
large part of the world out and widening the divide between the 
industrialized and developing countries.  Any new improvements 
should bring those worlds closer.  Moreover, it is in the 
International Bureau’s best interest to make sure that the so-called 
improvements do not make your life as PCT filers more 
complicated and burdensome. 
Dealing with the political climate becomes a challenge.  At the 
same time, the International Bureau knows—and partly because of 
the political climate—that we just cannot rest on our laurels.  The 
International Bureau needs to continue to innovate, to think of 
improvements that can add value to the system.  For example, 
improving the PCT patent and statistical information database, now 
known as PatentScope, so that you can more meaningfully and 
easily use it to get important information or beginning to provide 
information on national phase filing so that you can use 
PatentScope to track where a competitor’s application has gone 
once it has left the international phase.  Trying to put things into 
place so that you can say, “The PCT is increasingly worthwhile.” 
The International Bureau also has to be mindful of keeping 
the PCT free of the policy quagmires that right now are appearing 
in the international patent system.  We have to keep in mind and 
remind others whenever necessary that the PCT is a technical 
procedural system and it is not there to solve substantive 
intellectual property policy problems.  For the most part, we have 
been able to steer a pretty clear path.  There is generally a positive 
sense of cooperation among PCT member states, particularly as the 
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discussions in working group sessions have remained at a fairly 
technical level, focusing on how to make the PCT a more efficient 
and streamlined system.  If the PCT and the International Bureau 
can continue on its path, then it hopefully will have paved the way 
for the future and the PCT will continue to be an effective 
mechanism that you will be able to use with pride. 
I just want to end by paraphrasing the Director General of 
WIPO, Dr. Kamil Idris, who recently spoke on behalf, not only of 
the PCT, but also of the Madrid Trademark System, which also had 
good results in 2005.  What the Director General said was that the 
overall performance of WIPO services to the private sector in 2005, 
and particularly the PCT, had been exceptional and reflected the 
growing integration of the PCT into business strategies.  He also 
said that he was confident that these trends would continue as new 
countries come to realize the concrete business advantages offered 
by the PCT. 
There is a Yiddish expression that when loosely translated 
states, “From your mouth to God’s ears.”  When I read the Director 
General’s quote, that was what came in mind.  I hope that all of us 
involved in the PCT will be able to do our job properly, so that in 
fact we do play, and are able to continue to play, a central role in 
patent strategies and business strategies.  Furthermore, I hope that 
we will be able to continue to be meaningful to you.  If we start to 
be meaningless, then I guess I have to end with a plea that you let 
us know because our mission is to serve you.  It is nice to know that 
we are doing it well.  It is probably more important that we know 
when we are not doing it well.  For the future of the PCT, we are 
really going to depend on you. 
2. Practitioner Perspective: Ted Ringsred† 
My name’s Ted Ringsred.  I’m an assistant chief patent 
counselor at 3M.  My primary role there at 3M, I handle the 
pharmaceuticals and drug delivery systems division.  But I am also 
what we call our OUS, or Outside the United States, portfolio 
manager.  So as part of that responsibility, I spend a lot of time on 
things like selecting law firms that we’re going to use outside the 
United States.  Then if issues come up regarding the procedures, 
including PCT, I get involved in discussions and we help work 
through whatever procedures we’re going to use on those types of 
 
       †  Assistant Chief Patent Counselor, 3M, St. Paul. 
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issues. 
When I was asked to speak at this symposium, my initial 
reaction was, “boy it’s kind of hard to think of what to talk about 
with the PCT” because so much of it to me—and I think one of the 
greatest compliments I can give right now to the PCT—is that it is 
potentially transparent.  Or at least I take it for granted and I think 
most my colleagues do as well, because it’s really just going so well. 
But, of course that wouldn’t be very much fun to talk about so 
I did go through and think about a lot of different issues that are 
important to 3M and that we face.  I do a lot of prosecution with 
the PCT but I’m not really an expert on the details or procedure, 
but we use it a lot.  And I thought what I would do is divide up my 
topics into three.  Sort of just to give some context to all of this and 
for people who sort of want to benchmark, I’d talk about what 3M’s 
usage overall of the PCT is like.  Then I would talk about my 
perspectives and I think overall 3M’s perspectives of what the 
benefits are with PCT, and Jay actually mentioned a lot of them.  
There are a few things that we think—that I think—are worth 
talking about.  Then finally I’ll end as well on trends and 
suggestions and improvements and challenges for the PCT.  I don’t 
have a lot on that, but I have some things that are a little bit 
different maybe. 
So to begin, and as I’ve kind of alluded to, the PCT is very 
important to 3M.  We’re the second highest PCT user in the United 
States.  We kind of assume that a typical patent family can easily 
cost over its lifetime more than $300,000.  Because of that, it’s very 
important that we make sure that the decisions along the way are 
good ones because we don’t want to waste that money.  We spend 
about $20 million a year on our portfolio.  For 3M, anyway, about 
50% of our business is outside the U.S., so our international files 
are extremely important.  I’m sure that this is true at a lot of 
companies but it’s certainly true at 3M that IP is considered to be 
quite critical to a lot of our businesses.  So the message is: the PCT 
is actually very important even though we take it for granted. 
A few statistics.  In 2006 we expect to file around 700 PCT 
applications.  That translates, as far as national stage filings off the 
PCT, into about 3400 cases.  That’s increased quite a bit over the 
years.  You can see in 1995 it would have been about 1200 cases and 
it’s gone up quite a lot to about 3400 now.  Part of the reason for 
that is the number of countries.  We spend quite a bit of time 
actually agonizing over what is the right number, which countries 
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to file in and that sort of thing.  It is a question I get pretty often 
from colleagues: “What’s the formula we should use to decide 
whether or not to go into a country?”  It’s hard, but the bottom line 
is that in the last decade we have gone from an average filing list, 
and this is just cases that come off of the PCT.  But on average we 
started in 1995, about a decade ago, having an average of 400 filed 
off the PCT in national stage to now where we are at 500 to 600, or 
we expect that to be this year.  That might not sound like a big 
increase, but it’s actually quite a large increase as a percentage 
basis.  It’s costing a lot.  So we are under a lot of pressure to answer 
questions about, if we are filing in too many countries, is the PCT 
the right path actually.  I’m going to talk about that in a little bit. 
You know this list of 3M’s top countries for filing matches 
pretty closely with Jay’s (Cargill’s), I think, in a lot of respects.  But 
it is different in some.  At least to me the more interesting issue is 
how it has been changing.  What’s happened, the list on the left, 
China moved up to file a lot of cases.  Nearly all of our cases now it 
seems like are going into China.  That’s changed over just the last 
couple of years.  I think it was only in about 2002, I think only 24% 
went into China.  And part of the reason for the change is this list 
on the right.  China, Brazil, India, Russia, and Poland.  Now to 
some extent that’s 3M-specific because those are areas where we 
think business is likely to grow.  That’s a major part of the equation 
in determining where we file.  But the other part of the equation is 
respect for patents.  I think we’re foreseeing that all of these 
countries are increasing well past the threshold where we’re filing.  
So that’s changed the mix quite a bit.  Countries that just a few 
years ago would have been on the top-ten list that aren’t now, and 
it’s nothing against those countries, it’s just that others have 
increased.  Italy, and I guess Australia, are not on the list and they 
both would have been before. 
Something that I doubt is very interesting, but it’s something 
we kind of look at, is our conversion rates both at the stage of the 
first step in situations where we could file a PCT—in other words 
we filed an original, or an application in the United States, and 
then it could be converted to a PCT—what percentage do we 
convert?  Well you can see that it is somewhere between 80-90%.  
We watch that because it’s an indication of things like: Are we 
properly looking at cases that really don’t have any business being 
converted because they’re just not worth it?  During that year 
period you can sometimes find that out.  On the other side of the 
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coin is if we were to have a very low conversion rate then I think 
some anyway would surmise that maybe we’re filing a lot of cases 
that aren’t very good.  They aren’t even worth converting into a 
PCT application.  Right now I actually think that 80-90% probably 
is right in about the right zone. 
Similarly, the next step of this is how many cases that get filed 
in PCT actually get converted into national stage filings?  This 
number is higher than I think I would have guessed.  You can see 
that has been 87-97%.  One of the benefits of PCT that we often 
cite is a delay in decision making.  If that delay is so important, 
then why are we actually not dropping more cases?  I think, again 
these cases are so good, so valuable, that we keep getting it right in 
ninety plus percent of the times.  The other side of the view could 
be that we’re not critically reviewing the cases.  All that said, again I 
actually think this is probably in the right zone where we’d like to 
be. 
Some other observations about 3M’s use of the PCT anyway, 
because of the changes, we have gone from basically going Chapter 
II nearly 100% of the time down to about 20% of the time.  Now Jay 
expressed some, I think, reservations about whether that’s a good 
thing.3  I don’t harbor any of those reservations.  I think the reason 
we were going Chapter II, 100% of the time, is to get thirty months 
delay and it’s also very nice that an international search is being 
performed without having to go Chapter II.  Also, by the way, it’s 
nice that if you sort of want to half prosecute your case, but not go 
Chapter II, you can at least file some informal comments.  So if 
you’ve got something about international search and international 
search opinion that you don’t like, you can at least plant your 
response by filing a response informally and then that will go to the 
national stage when the case finally goes national stage.  We aren’t 
using that much, but I think we’re going to look at it and see what 
people think. 
3M overall uses the EPO primarily as our search authority.  At 
the beginning I mentioned that I handle pharmaceuticals and drug 
delivery systems at 3M and we don’t actually use EPO as our pri-
mary search authority.  For the two divisions that I’m responsible 
for, we have shifted now and we much more often use the United 
States to do our search.  There’s a lot of debate about that and I 
could probably talk for a half an hour about at least the percep-
 
 3. See supra Part II.A.1. 
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tions, and that’s what it seems to be—a lot of perception. 
Also we get about 30% of our cases that we file as PCT we get a 
positive search report and I guess they are called now but prelimi-
nary.  And I don’t know if that’s good or bad—30%.  I’d actually 
like to know how that compares to other companies.  But what I 
find interesting is that even though cases have a positive report, 
only about half actually go straight to grant.  That’s a little bit of a 
disappointment.  It would be nice to think that if you get a positive 
and preliminary exam that your case is really good.  In most in-
stances, more than half of them, it should go and sail through, and 
it doesn’t.  That’s not a major concern but it’s a disappointment I 
think for us. 
And also, by the way, we happen to use outside counsel in 
situations where we are going to EPO for our search authority, if 
we’re going to Chapter II, we typically use outside counsel just be-
cause we think they’re more familiar, sort of, with dealing with the 
EPO.  That may change and I don’t know if it’s a good thing or a 
bad thing, but that’s just how we do it. 
Okay, I get this question all the time: what’s the ideal sort 
of . . . what’s the best route for filing?  It is a practical issue, it used 
to be pretty standard at 3M that we would file a U.S. regular case 
and then that U.S. case would just go through, it would be our U.S. 
filing all the way.  And then in parallel we’d file a PCT case and that 
PCT case would not go back into the United States.  That would be 
for everything outside the United States.  Then that shifted and I’d 
say probably the majority still do something like that, although 
provisionals have been added to that process.  But there is a 
definite trend at 3M to add provisionals more.  But the real change 
is no longer filing a parallel U.S. application.  The reason for that, 
or reasons for that, I would say relate to the fact that people are 
comfortable doing that now because of the fix to § 102(e) in the 
United States.  We used to, at least in my mind, one of the good 
reasons to use the upper paths was because you didn’t get your § 
102(e) date for your case going PCT until you went national stage 
with the PCT, so it was delayed.  Now, that’s been fixed.  You get 
your § 102(e) date all the way back.  That’s been a huge reason.  
Right now I can’t see the interest—that people had a good reason 
other than when you want to get a case granted earlier and you 
think it’s faster to through the United States or if you want to get 
two searches basically—use the EPO as your search authority and 
then also have the United States.  Those are perfectly legitimate 
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reasons but I think that at 3M we have a dramatic trend forming to 
switch to this last route. 
Oh, incidentally, why not just start with the PCT?  Anybody 
know?  I actually get this question sometimes: “Why don’t we just 
skip all this and start with the PCT?”  If you think about it, if you 
start with the provisional in the United States you get twenty-one 
years from your filing date and if you go straight into PCT you 
won’t get that.  So, at least, that’s my reason. 
So why has the PCT been so successful with 3M?  This is a 
summary, and I’m going get into at least some parts of this in a 
little more detail.  We regard it as cost effective.  It’s not the 
cheapest; at least, on the surface, we would say that it’s not the 
cheapest.  Pretty much every time budgets get tight, somebody 
suggests, well, shouldn’t we drop the PCT in some of our cases and 
start going direct because we’ve calculated out that it will save this 
much for the patent family.  I think the consensus view though is 
that when you factor efficiencies and administration, and at least 
what is often cited is a sort of a hidden benefit in that the delay in 
decision making by going through PCT, it allows you to drop cases 
before you have to national stage that you otherwise might spend 
money on.  If you were forced to make the decision right out of the 
gate, you might file in a lot of countries that by having a delay of 
thirty months you decide later not to go into.  I’m not sure that our 
numbers actually bear that out, but I am sure that overall the 
benefits are there.  So we think it’s cost effective.  Of course we’d 
like it to be cheaper, but still efficient to administer. 
There are some legal benefits, at least one in particular, that I 
want to mention because I think it’s probably not as widely known 
as maybe it could be.  Also the recent improvements have been 
tremendous.  Jay’s mentioned a lot of them and I’ll summarize 
some of those as well. 
Of course the usual benefits of the PCT: one application/one 
language; receiving office; centralized document location—which 
is very convenient for administrators; preliminary search and 
examination of course is great; making amendments as well as 
corrections from inventorship or to the applicant and which comes 
up with some frequency; it’s very nice to PCT since you can just do 
it one time and then it carries through in all your national stage 
filings.  Of course, there is the delay in the cost which is good. 
Filing your national stage cases via the PCT, in terms of 
documents and standardization, is actually easier.  That’s another 
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one of the usual benefits.  Then it’s flexible.  If I had to pick 
something that I’m not sure we at 3M think about and take 
advantage enough, maybe we’re starting to but I think we probably 
don’t, it would be the flexibility.  I think we get used to a particular 
filing and a particular search authority and whether to go Chapter I 
or Chapter II and those things just don’t change as much as they 
probably would if we spent more time understanding our options 
and understanding the benefits of the different options.  I think 
the PCT offers a lot more flexibility than we probably take 
advantage of.  Actually just having seen and heard some of what Jay 
said I think one of the things I’ll probably do is go back and say, 
you know, we should really try out using KIPO.  We should really 
think about doing some of these other things; like instead of going 
Chapter II, let’s just see how well it works if you file some written 
comment at the end, after you get your international search 
opinion, instead of going Chapter II.  So, that’s an area that we 
have to work on. 
The thing I alluded to regarding the favorable legal effect of 
filing a PCT is I like this a lot.  Hopefully a lot of people are 
familiar with it.  Okay?  So you may think, “Hooray I filed my case 
before our competitor” and you’re disappointed to find out that 
you chose not to file your case in certain countries where they did 
and then you’re not prior art.  They can go and get a patent claim 
on exactly what you had already filed on.  Now what I like about the 
PCT, especially with the recent changes, is that in many countries, 
not all, just having filed a PCT that designates “all” automatically 
creates this prior art on behalf of the application.  Sometimes you 
have to go in actual, but it’s a big benefit from a legal perspective 
and I think, in my mind, a fairly decisive reason to use the PCT. 
I mentioned the important timing benefits but just to quickly 
break them down a little bit, you know it gives you time to assess the 
patent value.  You can also assess the commercial value of whatever 
the technology is that you are talking about.  The other less-stated 
time benefit that I see is that you have sort of a natural portfolio 
management tool.  And that really ought to be a good portfolio 
tool, a good geographic decision-making tree that you can map 
very nicely with the business.  That’s pretty much how I think we’re 
using it.  Although I think doing that deliberately, and I’d say over 
the last year or two we’ve started to look at it much more 
deliberately that way. 
Okay.  I only have two slides on this, and actually the first slide 
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is really more a matter of saying how much we like the recent 
improvements that come with automatically designating “all.”  The 
fact that we don’t need to go check in thirty months, the 
preliminary opinion is very nice to have.  Our administrators very 
much appreciate that PCT declarations are accepted by most 
countries, so you don’t have to go through and get a fresh 
assignment document.  And my favorite has been, and I think the 
second most impactful, behind getting the automatic thirty 
months, has been the 6012B, which has really driven a change in 
our practice. 
Now I will spend a fair bit of time on some of these points—
but not a long time because I don’t have it.  What are the areas that 
we might improve the PCT and what are a couple of challenges?  
Translations Jay did not mention.  At least from the perspective of a 
big corporate user of the PCT, translations are a major headache 
and expense.  And what we’d really like to see, because we spend so 
much on translations, is whether or not the PCT could run a 
centralized sort of official translation service so we didn’t have to 
hire different translation companies or go through the law firms in 
various countries.  It would be a . . . if it could be done cost 
effectively, and that’s of course what we wonder about, would it be 
more expensive in which case it wouldn’t get used . . . but if it 
could be done competitively I think 3M would welcome a change 
like that. 
This is more in the realm of the challenges; the calling of the 
searching in the preliminary advantage.  I will say for myself that I 
am worried about this because I am finding, and I’ve heard a lot of 
colleagues start grumbling about this, that maybe the search 
qualities are pretty good but the preliminary opinions are really not 
that good any more.  A decade ago we would have said that they’re 
quite good and that a lot of times we agreed and looked that up 
and said, “That’s probably what I would have done.”  Now I think 
we’re finding more and more often it’s spotty.  I kind of feel like 
they are just pushing it off to national stage now.  I also, and maybe 
it’s just me—maybe the cases I’m dealing with are just not very 
good—but I don’t think so because I’m hearing it from colleagues 
as well, I think it’s probably perhaps because examiners are busy 
and maybe stretched a little too thin. 
It also seems like even if you think you have a really good 
response for that, in those situations in particular where maybe the 
opinion was not great in the first place, those are the hardest ones 
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to change the examiner’s mind.  So that’s an area.  Of course Jay 
said this is the area of most importance that we have least control 
over.  I understand that, but it is critical. 
The lateness, of course, is important.  Harmonization as well is 
very important.  I think it’s really quite good, but it is important 
and it makes a big impact when you’re talking about a large 
number of cases.  The harmonization in terms of forms, whether or 
not you’re being required to have a legalization for documents, it 
really translates into something that is quite important to us, at 
least as practitioners. 
Jay already mentioned this, so I don’t need to belabor it, but it 
would be so nice to get some of the straggler countries into the 
PCT.  It just creates so many headaches to have to separate those 
out.  In my practice, for pharmaceuticals and drug delivery, we file 
in these countries a lot.  So it really is . . . it seems unnecessary and 
you just think, “What a waste!”  We would like to see that changed. 
The electronic filing issue actually came up, a little bit to my 
surprise, but we are watching that.  It’s nice to hear that hopefully 
by the end of 2006 the USPTO will accept electronic filings.  We 
calculate that, roughly, it would save us around $50,000 a year. 
Here’s one that I don’t think I’ve ever heard suggested.  At 
least at first blush it sort of makes sense.  It wouldn’t be bad to have 
what amounts to PCT division.  It would make things easier.  I think 
it would make sense; I don’t know, maybe?  I’m getting some 
nodding.  So we’d like to see that.  It’d be a nice benefit.  Not 
critical but it would be nice. 
With that, that’s the end of my discussion unless people have 
questions? 
B. Topic Two: A Deeper Look at Some of the New Developments 
1. WIPO Perspective: Isabelle Boutillon† 
The PCT system in the international patent law context is a lot 
of different things, a lot of influence and impact of different 
cultures; different ways of doing things, ways of explaining things, 
ways of understanding.  At WIPO, we are confronted with that 
mixture every day.  When we call a meeting for whatever reason, of 
course it’s PCT, it’s either operational, legal, or policy making, and 
 
       †  Office of the PCT, Geneva. 
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around the table you would most likely not have more than two or 
three people of the same country or speaking the same language.  
The language of the meeting will often depend on who are the 
main persons involved in the discussion.  It can switch from English 
to French.  But it can also be Japanese or Chinese or German or 
Spanish and then switch back to English at some point, because 
English is the only real common language for discussions on such 
matters in the Office of the PCT in WIPO. 
In the office of PCT, we have employees of about sixty 
different nationalities.  Jay was saying before that the major 
industrialized countries are in the PCT as well as many other 
countries now that have made their voices heard.  For us, the 
diversity has been there every day for years and years. 
So now, PCT reform.  I’m only going to be talking here about 
the question of search and examination.  There are other aspects 
of reform like the automatic designation system and a few other 
features that I will not cover here.  The main purpose of this 
discussion is to explain why the ongoing reform has meant a 
change to the PCT search and examination procedure, which 
basically amounted to shifting from the Chapter II procedure a 
part into the Chapter I procedure.  There is something very 
awkward about this shift, as the system was not conceived for that.  
Why did this happen?  Because major patent offices are involved in 
the system and do a substantial amount of the work.  The PCT 
system has been very successful, in particular, until about five years 
ago when the increase in use was exponential (which is luckily no 
longer the case).  Offices have had in some cases to take steps to 
deal with this increased workload. 
In 2001, the EPO changed the time limit for entering into the 
European regional phase from twenty-one to thirty-one months, 
which meant that the need to file demands for Chapter II in a large 
number of cases decreased tremendously.  And of course it has 
meant that the EPO as an examining authority had less Chapter II 
examinations to carry out, which was one of the expected results of 
the change. 
In one way it meant that the objective, which was to reduce the 
workload of one of the major offices, was met.  But immediately a 
problem was raised by small and medium-sized offices, which found 
themselves receiving PCT national phase entries with only a search 
report and no longer what they used to get, that is in 85% of cases, 
also an examination report. 
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Now, whether the examination report was useful in all cases, 
complete in all cases, had been based on applicants’ amendments 
or arguments, and was as close as possible to a positive report, of 
course, that can be discussed.  But the issue, at the time, was that 
these small and medium-sized offices got only PCT search reports 
for their national processing.  One of the most vocal delegations on 
that point was Singapore.  The Singapore delegation very early on 
said that their office counted on those examination reports.  Years 
ago the legislation had foreseen that the applicants would generally 
come with a Chapter II examination.  So it was much more difficult 
to adjust the procedure to deal with these concerns.  Of course 
major offices did not have to worry too much about the matter, 
because they generally re-do most, if not all, of the examination in 
the national phase (especially if the national office was not the one 
that acted in a PCT capacity).  That was the case for the United 
States, European, and Japan Patent Offices.  However, when the 
same office acted as searching and examining authority, the fee 
structure takes that into account, and the first office action received 
in particular from U.S. or EP could be almost a grant decision.  You 
can make amendments, of course, but the examination is basically 
over because the same office, and often the same examiner, did 
most of the work before.  But when you go to another office, it still 
doesn’t work that way.  Of course, this is a reality. 
The bottom line as far as the effect of reform when seen at the 
pre-reform stage was that small countries would only receive a 
search report.  How do these countries get what they expect?  The 
alternative of creating a full-blown patent office is not workable—
having examiners and other staff, search facilities and whatever is 
needed to carry out examination in all technical fields all year 
around.  So the PCT system has to be there for them.  In the same 
way that the system has to cater to certain national peculiarities 
(and Jay will come back to this, this afternoon), at WIPO we have to 
always be aware of the practical, logistical and every day reality of all 
patent offices. 
So, this is one side of the background.  In general, the heavy 
workload and on-going backlogs of the major offices showed that 
about 60% of all search reports were not on time.  Now we are at 
about 50%; it’s getting better.  The other side of the background is 
that since the year 2000, other things had been going on in the 
framework of the PCT Assembly.  Discussions had started, in part 
with initiatives from the USPTO, but also from the EPO and other 
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countries, to streamline and modernize the system.  So, the 
framework was about making changes to take into account the 
reality—how the work was being carried out generally, and not only 
from the viewpoint of workload, and it was about many other issues.  
And, of course, the year 2000 was also the year when the Patent 
Law Treaty (PLT) was adopted in Geneva.  Since then, it has 
entered into force—about a year ago now—since ten countries 
have joined or ratified.  The PLT is also a subject of today’s 
discussion per se.  And, of course, some PLT discussions were going 
on with some of the same delegates as came to PCT meetings.  So, 
all of this created a good environment to proceed.  The PCT 
Assembly reviewed proposals drafted by WIPO on the basis of more 
or less formal proposals presented by USPTO, but also others such 
as, in particular, EPO, JPO, and a number of other offices, as well 
as some others which had been in our drawers for some time.  The 
PCT Assembly had to very quickly examine a large package of 
changes.  In summary, we had committees and working groups 
meeting—sometimes three or four times a year—to prepare the 
work of the PCT Assembly. 
In terms of what the PCT Assembly had to do, it was really the 
largest ever package of changes—and a more substantive package 
of changes than it ever had to review in its entire history going back 
to 1970, the date of the treaty adoption, and the start of operations 
in 1978.  It’s pretty remarkable to realize that within about three 
years’ time, let’s say 2000 until the end of 2002, this actually was 
discussed, prepared, proposed, discussed, rediscussed, and re-
rediscussed, and eventually adopted at the end of 2002 to enter 
into force on January 1, 2004.  This, as such, is a major 
achievement.  And, of course, the member states in their diversities 
and their constraints, preoccupations and objectives, had to come 
to the meetings for sometimes lots of intense discussions.  And 
there were a lot of side meetings and a lot of discussions between 
some of our colleagues, as International Bureau officials and 
delegations, to try to work out details of some of the proposals. 
So, now we have this reform in place.  What does that really 
mean?  Well, it means a major change to the system per se.  But 
looking at it now and looking at it backwards, we can see that it was 
mainly done to address workload problems.  If the PCT had not 
been that successful, it would not have created so much work, 
workload and backload for major offices.  We would most likely not 
have the kind of complex system we have in place today.  
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Discussions would have been going on, changes would have been 
made, but there would not have been the pressure to deal with 
workload that basically put us all against the wall and forced us to 
do something about it.  Now, whether the result is good or bad is 
another issue.  We heard from some users that it’s good, basically; 
we have other users that say it’s not that good.  We go to certain 
countries, like India, or certain other countries in Asia or Africa or 
smaller countries in Eastern Europe, where the results do not all 
appear too good.  But that has to be an issue because we have so 
many different stakeholders in the system.  And we cannot expect 
everyone to agree with one same thing or another, every time.  We 
should not have this as a goal because we would never achieve it.  
So, what do we really want to make out of this? 
One way to address it is that whoever is the stakeholder in 
question gets the best out of the system under the circumstances, 
whether you are in a corporation, a law firm, or the patent office, 
or whether you are another type of user.  All of this is possible. 
But when we look at it from the legal viewpoint, from the 
viewpoint of the system based on the Treaty, with the Regulations 
and quite an extensive set of legal documents and provisions, we 
can see that what we have today is a system being stretched to the 
limits.  As you know, a treaty cannot be changed, basically, without 
a diplomatic conference.  Now, you might wonder, how did we get 
to change the time limit for national phase entry under Chapter I 
without a diplomatic conference?  Because the Treaty expressly 
provides in one of the later articles that the change of time limits 
can be done by the PCT Assembly, by the member states meeting in 
assembly, without a need for a diplomatic conference to revise the 
Treaty.  The writers of the Treaty had foreseen that situation.  And 
some of you may remember that in the early days, the time limit for 
Chapter II was not thirty months, but twenty-five, and that had 
been changed in 1985. 
We have changed the system and we have to live with it.  So, we 
have again to look at all the stakeholders.  Now who do we do this 
for?  Or, “For whom do we do this?” maybe is better English.  And 
people will say, “the offices,” “the member states,” “the staff,” and 
so on.  And some of us, like Jay and I, would be saying, “What about 
the applicants, the agents?”  You could lose sight of all of this. 
Patent offices are users of the system because they get the 
applications, other documents, in electronic form or on paper; 
they get assistance from us, legal advice when they need it, and also 
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training for their staff.  Member states’ delegations too have asked 
us occasionally to provide them with information about, for 
example, what can they say about the PCT to their parliament?  
How can they sell the system, what is good in upcoming changes?  
And so on.  WIPO is really the only place where all of these 
viewpoints get confronted, and have to be heard. 
One reason why we have more of this kind of meetings now is 
that, while we think we know what we can expect, we are faced 
regularly with something that no one predicted and we have to deal 
with it, find some solution.  And sometimes we should say that we 
shouldn’t just imagine what we should expect, we should ask the 
users.  Some of us in the PCT area come from the private sector, so 
we know what the users in the private sector expect or should be 
able to expect.  We know a little bit about the offices because we 
meet them a lot, we visit many of them.  We know the staff in many 
of these offices.  We know people in the diplomatic missions in 
Geneva. 
We may never have any change that big unless we reach the 
point of a diplomatic conference to revise the treaty altogether or a 
protocol to the treaty or some other instrument.  Who knows?  
Maybe all the countries will denounce the treaty when, as Jay was 
saying, there will be no need for a PCT one day.  We don’t know.  
But in the meantime, we don’t stop looking at the system and 
trying to still improve it. 
As soon as the Rules package for 2004 was adopted—that was 
at the end of 2002—we had a year and three months to put it in 
place.  That was done.  But it didn’t mean that we stopped 
discussing the remaining issues which had been left aside.  We 
started to look at some of them.  However, we were faced with the 
lack of interest by a number of offices and particularly the large 
ones.  They said basically that we had to slow down.  They could not 
absorb this amount of change and train their people and so on, 
while, at the same time, start discussing seriously so many other 
new issues. 
We slowed down; we had to.  We made proposals for various 
changes.  As you have noticed lately, every year there is a more or 
less small package of changes entering into force.  Last year, there 
were a few changes relating mainly to unity of invention, the 
purpose of the procedure, the process when there is lack of unity.  
Some of the procedures were simplified, mainly for the big offices 
which have a particular protest system (the two-way review in case 
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of lack of unity).  And there were a couple of other minor 
“housekeeping” type of changes. 
Then we had another package, which mainly related to 
electronic publication.  This April 1, electronic publication will 
become the legal publication.  The paper versions will be available 
in some cases, but the true version of the full text of the PCT 
application and the PCT Gazette will be the electronic versions on 
WIPO’s website.  The practical details are still being worked out by 
our colleagues.  For example, when you, as the applicant, or the 
agent will receive the notification telling you your case has been 
published, you will have the URL or some other indication as to 
where to find the document, so that you can download it if you 
want or just know it is available. 
Also, Arabic becomes an official publication language on April 
1.  It is already an official filing language, because a number of 
offices in the Arab region have specified it.  In WIPO, at our own 
receiving office, we have received in past years a number of cases in 
Arabic already, because that’s accepted at our office.  Of course, 
those cases have to be translated for any future steps.  They will still 
need to be translated, but only for search (as today no searching 
authority can search in Arabic language) and examination, but not 
for publication. 
There was a loophole in connection with the self-designation 
system relating to, in particular, the Japanese designation.  This was 
a situation relating to the national laws of Japan, Germany, the 
Russian Federation, and the Republic of Korea.  A system was put 
in place as part of the 2004 Rules package, but, as happens in legal 
packages, there was a loophole.  We drafted quickly and were able 
to obtain quickly the agreement of all delegations concerned.  We 
went back to the plenary session; the text was adopted.  And, of 
course, a few weeks or a few months later we tried to implement it, 
and we could see that there was a major problem with it.  Still 
today, it is not possible for applicants to exclude Japan, which was 
the major candidate for this exception.  Maybe I should just recall 
what it is about. 
If you have a PCT application, subsequent to an earlier 
national application designating the same country—so Japan, 
based on a Japanese priority, or Germany, based on a Germany 
priority, etc.—the mere fact of making the designation has an 
effect on the previous national application.  If the designation is 
maintained in the subsequent PCT application, the previous 
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application goes abandoned automatically, by effect of the national 
law, at some point in time, unless you do something to prevent the 
designation in the PCT application to proceed.  Those countries 
could not accept the fully automatic designation system as far as 
their designation was concerned.  They wanted a way out for their 
applicants. 
That’s different from saying a country is designated and then 
the designation is withdrawn.  To withdraw the designation, you 
have to assume there is first a designation.  These countries wanted 
a procedure allowing applicants not to designate them at all, 
otherwise the law would apply and the national application would 
then go abandoned.  The solution was to permit to exclude the 
designation. 
So, at the same time as we invented the principle, we had to 
invent the exception, which is often the case. 
But there was a loophole in that regulation.  I won’t go into 
this now, but you need to know that as of April 1, and for all 
applications filed from April 1, you will be able to exclude Japan, 
Republic of Korea, Russian Federation, and Germany for national 
protection.  But you will have to first have a priority application 
from that same country, of which you will have to claim priority 
from it. 
Then the declarations.  We heard about them a little bit 
earlier.  The famous declarations in which you can indicate who is 
the inventor, who has the right to the patent (for example, 
following an assignment or chain of titles), the inventorship 
declaration, which applies only to the U.S., and finally exceptions 
to novelty, which relate to non-prejudicial disclosures, such as those 
made six months before filing.  All of these declarations have been 
available for a large number of countries, for national purposes, 
since 2001.  They haven’t been used much so far.  We had only a 
few thousand cases, but it’s increasing. 
These declarations are filed by applicants with the application 
papers, usually in the request.  We process them and pass them on 
to the national offices concerned.  And in very many cases, they 
were taken as such.  No need to provide further evidence, or no 
need to provide new declarations.  There are still a number of 
countries that have opted out, so for those countries you still need 
to provide new declarations. 
These were mentioned in the published application, but they 
were not published per se.  The change as of April 1 will be that 
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they will be published as part of the application papers in the PCT 
published application at eighteen months or shortly after eighteen 
months.  So they will be available immediately to all; that is, not 
only to national offices that will need them in their national 
processing, but also to third parties. 
Next year, we are going to have another package of changes.  
They were adopted also last year.  But the member states asked that 
not everything be put in place at the same time, as some changes 
will require more preparation in the vast majority of the offices.  
Four major subjects are covered. 
We have missing elements and parts of the application and 
restoration of priority rights.  These two matters have their bases in 
the PLT discussions.  And, in fact, some of the language introduced 
in the PCT is very foreign to the PCT terminology, and it comes 
straight out of the PLT concepts and PLT principles.  These 
changes are features that will help applicants.  Why?  Because 
mistakes happen.  You can take all the care and attention you can 
possibly take in all your work; things happen.  So this is recognizing 
that things happen, and there should be ways for remedies, and 
these will be some of them. 
The point here is not to go into too many of the details of what 
these are about.  The first change will allow you to basically make 
an incorporation by reference in terms of missing elements and 
parts.  It happens that a page of drawings or a page of specification 
is missing when the papers are filed.  You will make a reference to 
the priority application, and if you miss pages in your PCT filing, 
you will quite easily in the future get back into the PCT application 
the part or parts that were in the priority document but which you 
missed in the PCT application.  Of course, it’s not going to be just 
automatic from the start.  Some of the offices will have the 
possibility to opt out of this provision. 
Restoration of priority rights.  Same thing.  You basically will 
end up with twelve months plus two, that’s fourteen months.  You 
will have to either show due care or non-intentionality.  Non-
intentional and non-avoidable—it’s basically where the line is.  The 
words are a bit different, but that’s really what it means.  Some 
offices have said that they could not accept the change at this 
point.  But, of course, for offices like the United States, which 
knows this kind of provisions for various other areas of the patent 
law—the non-unavoidable and the non-unintentional types—it 
would work at the receiving office. 
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The next question is, what if a receiving office agrees and then 
the case gets to the national phase, what about each designated 
office?  In some cases you will have the guarantee that in the case 
where you showed due care, and the receiving office accepted it, 
then the designated office would have to accept that.  Of course, 
unless they opt out altogether.  If they opt out altogether, they 
don’t have any obligation to accept.  But if they did not opt out, 
and they accept either showing, if the more strict criterion was 
observed, they would of course be bound by that.  If it’s the other 
way around, if the receiving office agreed to on a non-intentional 
basis, but the designated office requires due care, then the 
designated office can say it’s not acceptable to them.  So, once 
again, you see we had to cater for the different types of approaches. 
Now, why do we bother?  Because altogether we advance on 
making the system better and safer.  And one after the other, some 
of the countries will eventually make a change in their national laws 
and policies and will take out the reservation they made in the PCT 
system.  So we think it’s anyway a good thing. 
What could be done for rectifications of obvious errors to be 
made much easier?  It used to be that anyone should agree that 
there was an obvious error, and anyone should agree that there was 
only one rectification possible—that’s the one you provided.  
Almost impossible to meet.  So now it’s going to be something like 
“the person skilled in the art.”  Someone in the office concerned 
who will make a judgment about the issue.  That will be sufficient. 
And then we have Korean patent documents becoming part of 
the PCT minimum documentation.  Some offices will introduce 
those earlier on, but by April 2007, they must all include them 
when they search PCT applications. 
The last part of the presentation is for new developments for 
the future.  The multiple language publication is still being 
discussed, even though, as you heard this morning, maybe it won’t 
go much further.  The meeting is planned for May.  Supplementary 
international search, which would be beyond the current search by 
the main searching authority, would generally be another search 
done in other languages or in certain types of art by certain offices. 
A quality framework will be introduced.  It has been 
introduced somewhat in the discussions of all the International 
Searching and Examining Authorities, which are all working on 
defining what are the criteria.  And the International Bureau, for 
its own activities, is also looking into the matter. 
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And finally, USPTO has been discussing proposals relating to 
the font size of the text part of the application and color drawings. 
Maybe some of the proposals will come through.  But you will 
see already the latest news on the state of discussions in the PCT 
Newsletter that is published after the May meeting. 
2. Practitioner Perspective: Steven Keough†  
Seriously, I’m very honored to be among many colleagues and 
former friends.  Former colleagues and friends.  I was hoping to 
make it humorous being the closer for the morning. 
Also, we’re very much indebted to the people in the 
international area.  This is really an international conference; an 
international legal conference.  When you step back and say, well 
it’s the mundane view of this but there is also a very powerful view.  
Over several decades of being in this area, I look back at some of 
the contributions with Jay, by Mr. Keough, Mr. Nagaoka-san and 
many of the other individuals—Mr. Berry and William Mitchell, for 
that matter.  When you look at it as this area of contributing to 
world peace and economic development, it puts a different light on 
what we’re doing.  So, in that context I am very honored to be 
here. 
SurModics is going to talk in this presentation about business 
development tools using the PCT.  We’re going to talk about 
business and PCT planning and securing new markets. . . . 
What do we do?  We’re not talking about PCT in the context 
of what we do at SurModics.  We are a public company.  We’re 
heavily, heavily dependant on the PCT.  You’ll see later in our 
slides that about 100% of our foreign cases and its OUS are via the 
PCT route.  So, somebody said to me, “Well Steve, you ought to go 
up and introduce yourself as: ‘Hi, I’m Steve and I’m addicted to the 
PCT.’”  But I’m not because that would be trite. 
What are the issues that important to us?  The designations?  
The classifications of IPC’s?  We watch that pretty carefully.  We’re 
concerned about that, that the categories of examination, the 
classifications of our inventions—many of which are combination 
inventions.  Many of which are nuances on medical device 
improvements.  Many of which are with medical device partners.  
Some of those companies are in this room today.  We worry about 
the classification system.  It may seem arcane to some of you but it’s 
 
       †  SurModics, Inc., Minneapolis.   
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a very important issue. 
We improve the functionality of medical devices, but as I just 
alluded to, we enable new product categories.  That’s where we 
sometimes have difficulties with the PCT.  Frankly, with the United 
States office as well. 
Improving clinical outcomes; well, many of you know that is 
hard to claim.  You have to be very creative.  So working with our 
foreign associates, who are prosecuting international states cases, 
it’s often difficult to have people understand except in person how 
you can claim improved clinical outcome. 
Today we’re going to talk about some examples of our 
product, but first we look at the picture of the company.  Without 
getting into detail, what it shows us is that it’s a very innovative 
company, relatively new, public company, only since 1998.  But in 
relatively recent time, you’ll see the break in the time-line, in 
recent time the pace of filing has increased quite a bit.  In fact last 
year we filed fifty-one patent applications.  I had great pleasure the 
other day when the announcement of the world’s greatest patent 
filers came out—we were twenty-first with a little fudging—we 
added a zero to our filings from last year.  We were right up there. 
We really do file a lot of patents.  We file a lot of patent 
applications internationally . . . .  Our patterns have changed 
though.  In the past it was almost rote as to where we would be 
filing.  Currently we are trying to file more consciously in North 
Asia, when in the past we haven’t.  I’m still trying to push filing in 
India . . . that’s a difficult sell, though, until we get the medical 
device products that we’re on sold there.  We can in turn relate to 
the economic system and reimbursement system for the medical 
products.  Nevertheless, we’re actively looking for partners.  We’re 
actively looking, particularly in North Asia and southwest Asia—
China, India, Japan, and Korea. 
You’ll also see that some of our recent partners and 
investments in companies are with OUS companies.  So we get into 
the combination portfolio analysis.  How do the Dutch file their 
cases both in Europe as well as in other regions?  How does that 
relate to our cooperative partnership?  It’s a very interesting 
discussion for patent lawyers. 
I put this up because it summarizes last year’s revenue.  We’re 
into our second fiscal quarter, but last year’s revenue breakdown, 
which is public, is very fascinating.  It really goes to the heart of “are 
we an IP company?”  Do we depend on the PCT?  Absolutely!  
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Seventy-five percent of our revenues are directly related to royalties 
and license fees.  Well you don’t get a license for a promise.  You 
get a license fee because you have something—something tangible 
that our customers want.  It’s very, very important to us—patent 
filing. 
A little bit of customer device examples here: a small sampling 
of some of the items that are out there.  Again you look, where do 
we file?  We’d love to file in more places but the products are not 
sold there, unfortunately.  Many of these products are not sold in 
many countries.  You come back to the economic development 
aspect of this and improvement of people’s lives.  I just wish more 
of these products were sold in other places. 
When we look at our customer base, particularly the top four 
up there—Cordis, Guidant, Medtronic, Boston Scientific—I think 
you’ve read about a few of those recently.  We really have to 
exercise discretion within our company.  We have very 
compartmentalized code work type environment in order to 
maintain confidentiality among companies.  But more importantly 
it reminds us that we are very international, we’re very much the 
Swiss model of licensing in that we have customers that are often 
going at each other competitively in the market place.  We bring 
different technologies to each of them—sometimes slightly 
different, but certainly different.  Most of the time we’re very 
successful at that.  But at any given time . . . there are a number of 
companies that are going at each other right now in the courts.  It’s 
nothing personal I’m sure, but they have a lot of fights.  So we have 
to be very careful with our own intellectual property so that we can 
continue to license in a very litigious patent oriented environment.  
Of course then we do internal development with our customers.  
They, in turn, have their own patent filings per arrangement with 
us.  This is a list of our business units. 
What drives growth?  It’s a pretty simple question, but it has a 
complicated answer.  For us there is a short list here, literally a 
handful of items that we’ve identified as the growth drivers for 
SurModics in our industry.  We’re a small company, relatively 
speaking, but we have to be able to partner with many companies 
in the same industry.  I’ll show you an example in a few minutes of 
the drug market. 
So, we’ve found multiple ways to partner and participate in the 
drug market, but again, patent-based.  Of course the DEF market is 
huge in Europe, huge in Japan, and huge in the United States.  
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Those regions sound familiar?  It’s very important to us, the OUS 
patent filings there. 
We have a growing pipeline—I’ll show you an example of that 
and why that’s relevant to today’s discussion.  The convergence of 
drugs and devices, my colleagues to the left at the table, work in the 
pharmaceuticals and drug delivery areas are well aware of that.  
Tom’s well aware of it.  Many of you are aware of that.  A lot of the 
practitioners in the room are heavily employed by many of the 
previously shown customers in this region and working in this area.  
It’s very active.  But, do the colleagues at the examining offices, in 
the countries other than the United States, understand the 
nuances?  I’ll show you an example of the nuances related to this 
field. 
Climbing the value chain, that’s really internal jargon for 
owning more of the piece of the end product.  No U.S. patent 
portfolio.  This was not put on there just for their brief.  This is 
real.  We really believe that.  You can see from our revenue 
breakdown why that’s so critical to us. 
These are just some simple examples of how we participate in 
multiple aspects or areas in one market, the U.S. market.  We’re 
very honored to be with one of our customers, the Medtronic 
Endeavor Product system, a drug eluding stent system.  We help 
with one of our products of hydrophilic coatings in the delivery 
system part of that.  Cordis, J & J Company, we’re very proud our 
drug eluding polymer is part of that system.  So in both instances, 
heavily patented areas and we’re fortunate to have both United 
States and international coverage, and a lot still pending. 
This is my favorite.  Is this an example of Bryce Canyon 
National Park in the United States, or is it just a micro-graph 
(which it is) of a surface defect on one of the medical device 
surfaces where the drug is crystallizing on the surface and it’s 
broken through? 
Our surface defect characterization specialist, Dr. Warmath, 
loves these pictures.  He gives them away as gifts.  But I’ve come to 
like them too because they stand for—and you’ll see a few more in 
a minute—how important it is to get down to the real small issues 
that make things work.  Or, getting down to the real small elements 
in patents.  The nuances, I keep saying that word, in the patent 
areas in medical technology that make the difference between a 
successful, non-harmful, healthful product in patients and one 
that’s harmful and should never see the light of day.  Often you 
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don’t see this level of detail.  That’s the realm we’re in, we work in 
the space that is a very small scale. 
Let’s go to an example of a good drug eluding coating.  This is 
an example of an actual device that’s out there.  It’s a stent with 
drug eluding coating on it.  Out of that stent when it contacts the 
tissue in the body, it helps prevent re-stenosis, or re-clogging of that 
stent—opening up the lumen of an artery.  You can see the nice 
consistent appearance of the surface, there aren’t any of those 
previous Bryce Canyon-like objects blurting out which would result 
in the dumping of drugs in an unregulated manner into the 
person’s tissue area. 
The topography of the devices are very important.  How you 
are able to get coatings on a turn, or on a piece of a device that’s 
going to expand.  What are the mechanics and physics of that?  
Without having the surface coating, you’re lost. 
In a similar manner, this is an example of what you don’t want.  
You can make it out there is a web of polymer that is there after this 
particular device was put in and stretched out, and deployed inside 
of a person’s body.  Well that web is just like a spider’s web when 
it’s inside your blood stream: it will clot up pretty quickly and 
maybe cause a stroke or other problems.  You can also see there’s a 
reference arrow there.  That’s pointing to bare metal where some 
of the polymer has been chipped off to bare metal.  That’s also a 
potential problem depending on your view of this device.  It’s very 
important—this means patentability for this.  It means non-
enabling perhaps for this device and the claims that go with it 
because it isn’t doing what its claimed to do, in the way it’s 
supposed to.  Those are the issues we talk about with foreign 
examiners.  That’s why we need slides . . . . 
All right.  Why is a robust pipeline relevant?  Well it’s relevant 
particularly in showing our business planning, and of course our 
investors look at this and say, “Well how many do you have licensed 
but not launched?”  They project ahead on earnings per share for 
the future.  It’s important for the nexus between business planning 
and PCT planning.  It’s a very important nexus . . . .  [O]verall the 
percentages are getting better in terms of the line up and the 
alignment of those planning tools.  Of course it also requires you to 
be diligent in prosecution in any office. 
Now we’ll look at another product of ours that is actually in 
trials right now.  Just a little bit of basic anatomy here before lunch.  
At the back of your eye is something called the macula.  The 
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macula helps you to be able to see well.  Well, when the back of the 
eye diseases occur, we can’t see well.  Here’s an example.  This is 
diabetic macular edema, or swelling in the macula or around the 
macula.  We’re all trying, in the medical field, to try and prevent 
that.  This is classic for people, of course diabetics, but also 
happens with non-diabetics in a different form of this—typically as 
they advance into their fifties and beyond.  It’s a very significant 
cause of blindness right now.  Many companies are working at 
solving that, as are we. 
This is an example of trying to move up the value chain using 
intellectual property.  We have an intra-vitreal implant that we have 
with three customers now—of these three, at least one of which is a 
major pharmaceutical company.  You can see the blowup of the 
device to the upper right.  But it’s placed in the vitreous space.  You 
can actually see it in a patient if you look close.  I’ll just give you a 
sense of the size.  That’s a U.S. dime—and the device inside it. 
If you look at the distal tip of that, the sharp tip, there’s IP 
around that.  If you look at the coil structure, there’s intellectual 
property around that.  There’s fundamental intellectual property 
around the coating that’s on that coil.  That’s a coated coil with the 
drug eluding coating on it.  Prime-syalone or another type of 
material to prevent that swelling, that inflammation, that edema in 
the back of the eye.  It goes right to the location so it doesn’t in the 
front of the eye, just at the back of the eye, just where you need that 
drug.  Then there’s IP around the tip of the proximal end—that 
screw-in piece, that looks like screw top—that allows us to remove it 
if we have to.  So, that little tiny screw, it’s so critical with so many 
different portfolios of IP around it, from different sources. 
So quality of examiners is very important to us.  Quality of the 
examining core in any office is extremely important to all of us, but 
particularly in the medical arts area.  Medical providing in many 
countries is very political—profit, reimbursements, medical 
structures, and access to it.  Even in most countries now there is a 
very vibrant cash-pay-for-service system and so we’re seeing that as 
at least hope of getting more of these technologies to other people. 
This is just an example of one of the charts that we’ve used to 
talk about, for example, that product with examiners.  Trying to 
show them efficacy in ways that you may or may not really put in 
your patent application.  Also an example of the type of 
commentary you can now put into the PCT process that was 
referred to earlier. 
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One more product.  This is a product we’ve been working with 
a company called Novacell—which has recently merged with Cell 
Source company—they’re out on the West Coast.  This is basically 
to create an insulin pump within your body.  So the way it works, if 
you look on the right you can see the eyelet cell and it’s 
surrounded with (the native eyelet cell it’s called) a corona of sorts.  
That corona that’s around it is our coating that we put on that 
individually.  What this enables is the eyelet to create the insulin 
and for the insulin to come out, which is what you want, for the 
nutrients to go in, but the antibodies and immune cells will be 
repelled.  So it doesn’t self-destruct.  So it’s really, I call it, a little 
insulin pump.  It’s an insulin pump made of natural cells and 
manufactured agents.  It’s a combined portfolio with one of our 
customers.  But is the corona a device or is it a mere coating?  
Which classification would you put this in?  Would it be chemical 
arts?  Would it be a device?  That’s maybe off the charts, but not 
really, it just depends on your perspective.  That’s in human trials 
now. 
One more that we just announced.  It gives just another 
example of the challenges in the medical area.  This is the natural 
scaffolding in your tissue for growth of cells.  Looking a little closer 
on that box from the previous slide, you can see a cell body 
growing along in a longitudinal way—a lengthwise fashion—not 
just that . . . but if you can look to the upper left it is extending in a 
long direction up to the upper left of that view and to the lower 
right.  But there’s a problem.  When researchers try and recreate 
that cell in labware—plastic labware in laboratories, in vitro—to try 
and test the many drugs pharmaceuticals or other techniques and 
try to emulate the disease pattern, for example, they don’t get the 
same growth.  The labware is flat planer.  So you end up with what’s 
on the left in these views.  It’s very planer, spread out, surface 
rather than three-dimensional and longitudinal in its growth. 
Through combining of intellectual property portfolios and 
working as partners, we have a very unconventional relationship by 
medical standards with one of the leading companies in the world 
on filtration.  One of our leading community leaders in corporate 
in the Twin Cities is named Donaldson—Donaldson Filters.  When 
I was back at M & G in the 1980s, I remember they were our 
customers, they were our clients.  I remember working on tank 
filters.  It’s a far cry from tank filters to the technology and the 
ability to make repeatable structures of nano-fibers and then the 
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ability of SurModics to be able to coat those with very thin coating 
without clogging the pores.  It enables a remarkable outcome. 
What this does, combining nanotechnology, chemical 
coatings, labware—we’re able to get artificially grown in this 
example, neurites.  You can see the length difference.  With just 
nano-fibers, three dimensional rather than a flat plane, and the 
nano-fibers with a SurModics coating on it, those coatings can 
promote any number of different features of cell growth.  But 
doing that, without clogging pores, you end up getting a much 
more in-vivo like structure in the labware, resulting in more 
accurate analysis, diagnosis and therapeutic development using 
that labware.  It’s very exciting.  It’s just announced about two 
weeks ago. 
Here’s another example of the ability to take those 
combinations of IP portfolios, because why make the investment 
otherwise if you’re not protected, international portfolios and 
United States.  An example of a flat generated breast cell and then 
breast cells forming into a conical more human shape using the 
three dimensional structure.  It’s very interesting science. 
There are some patent offices where I couldn’t even show that.  
We don’t have that in the patent application.  We can’t show that.  
That’s a problem.  We can show that carefully to male patent 
examiners in some countries—most countries.  It would be 
offensive to others.  We will use other examples.  Just a reminder 
on the international aspects that we’re dealing with. 
So again the types of things we do.  In summary, for this 
particular example, these are the different types of functions that 
result from relatively common technologies being merged together 
for new purposes. 
Some examiners don’t like to say that’s an inventive step.  
They might say, well the combination is novel, but where is the 
inventive step?  You ask the people who benefit by this and they’ll 
say it’s definitely an inventive step.  You ask the scientists in a lab, 
it’s definitely an inventive step.  But we’re fighting that.  It comes 
down to quality and experience of the examining corps, including 
in search reports. 
Okay we’re just about done.  The PCT.  Long time user of 
PCT—SurModics.  Virtually 100% apply to PCT.  We are moving to 
electronic filings.  We’re hoping that in about one year from now 
we’ll be at about 90% electronic filings.  We’re just barely getting 
there, but we have the pieces starting to come together.  We think 
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that’s the way to go for a lot of reasons—many of which Ted 
mentioned.4 
Intellectual property is essential to our customers.  We’re a 
marketing tool for the PCT.  We need it because our customers are 
generally large medical device companies or biotech or 
pharmaceutical companies that rely on international protection.  
Also, obviously when you look at the OUS opportunities for many 
of these devices, pre-FDA clearance is very important.  That fund, 
when you think about the royalty revenues from pre-FDA clearance 
sales, OUS, that’s a very good justification for filing those cases 
alone. 
Comparative numbers?  We’re at about three-to-one of our 
prior filings from about four years ago, three years ago but we’re 
going to be entering fewer national stages.  We’re finding that the 
relevance of entry in a number of countries that used to be normal 
is just relevant—it doesn’t pay.  That’s an interesting framework for 
us.  We’re very similar with 3M in terms of fewer Chapter II 
demands.  We’re backing off on those quite a bit—in a strikingly 
similar conversion rate from filing to converting to national stage as 
3M. 
Ongoing concerns for us are new developments.  Capabilities 
of examination corp—we’ve hit on that extensively—the nuance 
and the criticality of minute differences.  More unity of invention 
challenges.  We’re seeing that as just continuing.  That is a cost of 
doing business rather than, I think, anything else.  Although it 
could be lack of detail by the examiners, I don’t want to lay it on 
their team. 
Cost of claims?  You know the requirement to have fewer 
claims, increased cost of claims, it’s a cost of doing business that 
we’re all aware of.  Nevertheless I keep reiterating it as other 
companies do, let alone individuals trying to file.  Relevance of 
states versus cost?  I’ve mentioned that. 
Search report delays?  Also we’ve noticed an interesting 
phenomenon where even though the English language, or 
Japanese abstracts—English language/Japanese Abstracts—are part 
of the critical or essential document searches, we’re finding that 
often our searches are preliminary exams, don’t have Japanese 
language abstracts.  If you just looked at the patent you’d see it’s 
probably relevant.  Then we get into the national exam and we 
 
 4. See supra Part II.A.2. 
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have a lot more references than we counted on.  Interesting little 
issues here and there.  If you recognize them then you’re much 
better off. 
So, pretty good track record for us using an intellectual 
property model.  We’re fundamentally a lot of scientists, IP geeks 
and we’re proud of it.  It works for us and that’s not a bad model.  
Some of the shareholders in the room here have already told me 
that today—keep it up! 
 
III. THEME TWO: THE PCT IN THE LONG TERM: LOOKING AT THE 
BIGGER INTERNATIONAL PATENT PICTURE 
A. Topic 3: The PCT, Patent Law Harmonization, and the Future of 
International Patenting 
1. WIPO Perspective: Jay Erstling†  
I have to start this talk with a disclaimer.  What I am about to 
say is very much a personal perspective, although I trust that it is 
not a unique one.  The subject of patent law harmonization and its 
respective viewpoints, I think, come from two angles.  The efforts 
that have taken place to embody substantive patent law 
harmonization in a multilateral treaty, in other words, to legalize it 
globally, have so far been unsuccessful and, if they were to be 
graded, would receive a low one.  At the same time, there has been 
a remarkable amount of harmonization of patent law and patent 
practice worldwide. 
So while the structured multilateral treaty efforts, or for lack of 
a better term, what can be labeled de jure harmonization, have not 
made much progress, de facto harmonization is bringing the 
patent laws and practice of countries closer together.  Furthermore, 
from a de facto harmonization perspective, the role of the PCT in 
bringing about harmonization has, I believe, been crucial. 
As a result, if de facto harmonization continues or better yet, 
the pace quickens, sooner or later the need to have de jure 
harmonization is either going to be such a “no-brainer” that it will 
 
       †  Director of the Office of the PCT, Geneva.  The opinions expressed are 
those of the speaker and not necessarily those of WIPO. 
 
42
William Mitchell Law Review, Vol. 32, Iss. 4 [2006], Art. 8
http://open.mitchellhamline.edu/wmlr/vol32/iss4/8
13PCTTRANSCRIPT.DOC 6/5/2006  8:33:09 AM 
2006] 2006 PCT SYMPOSIUM 1645 
occur quite easily or there no longer will be the necessity of de jure 
harmonization because of its execution through informal means.  
The future of international patent law might not any time soon be 
an international patent, a global patent that we all dream about 
having, but it will be one in which international practice will flow, I 
believe—I hope, in a relatively easy way. 
What I would like to do very quickly is to talk a little bit about 
de jure harmonization and a little about where it seems some of the 
de facto harmonization is taking place. 
As Isabelle alluded to earlier, there is now a Patent Law Treaty, 
which deals with procedural harmonization and which Brent 
Routman was very much involved in negotiating.5  The Patent Law 
Treaty came into effect in April of last year when ten countries 
ratified the treaty.  There are now thirteen member states.  The 
member countries that have the most active patent systems are 
Finland, Denmark, and the United Kingdom.  The PLT itself has 
not yet made that much of an impact except for the important fact, 
as Isabelle also mentioned, that the PCT incorporated, as a part of 
PCT reform, some of its provisions dealing with safeguards for 
applicants, reinstatement of rights, and relaxation of formalities.  
Now, interestingly, the PCT also incorporated some of the advances 
in the PCT framework concerning electronic filing and electronic 
processing of applications. 
The treaty has not yet been terribly successful in terms of 
numbers of countries that are jumping onboard.  It is in its 
influence on PCT reform that the PLT is having an impact.  The 
cross-relationship is likely to remain strong, because the PCT 
member states are invited to participate in the discussions at PLT 
meetings on the PLT regulations and other matters of PLT 
governance. 
Efforts to harmonize substantive patent law have been 
anything but conclusive.  There is in WIPO a body called the WIPO 
Standing Committee on the Law of Patents, which is responsible 
for elaborating a substantive patent law treaty acceptable to 
member states.  This committee has made little progress.  One of 
the issues, although not the only one, concerns the scope of the 
treaty.  Should the treaty focus on traditional notions of patent 
law—for example, definitions of novelty and inventive steps; or, 
should it (as many developing countries believe) encompass 
 
 5. See supra Part II.B.1. 
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additional elements—such as, disclosure of the source of 
traditional knowledge of genetic resources or flexibility for 
considerations of public health or economic development?  Despite 
the fact that discussions have been going on about substantive 
patent law harmonization, I believe, for at least twenty years, 
deadlocks persist. 
There are current efforts to break the deadlocks.  One of 
them, under the leadership of the Ambassador of the Philippines 
to the international organizations in Geneva, is the organization of 
an open forum on harmonization in Geneva from March 1 through 
March 3 this year.  It will be the first time that many of the leading 
scholars in the area of patent law harmonization, representing all 
points of view, are going to come together at WIPO to talk about 
the issues in an open setting.  Regardless of the outcome, this is a 
positive step.  Nevertheless, overall, on the de jure side, there is lots 
of unproductive talk, lots of frustration, and little progress.  If you 
look at the de facto side, there is a surprising amount of progress.  
The very fact that in the PCT system there is a common patent 
application, one application that is the equivalent of 128 
applications, is extraordinary. 
Efforts are now underway to establish a common application 
format for national patent applications.  If successful, there will be 
a nationalization, so to speak, of the PCT application—a commonly 
accepted standard for all patent applications.  One of the layers of 
the PCT’s dense legal framework, and the PCT probably has one of 
the most complex and dense frameworks of any treaty system ever, 
is a set of guidelines—the International Search and Preliminary 
Examination Guidelines (ISPEG).  They have been around since 
the earliest days of the PCT, but often ignored, particularly by 
examiners at the USPTO.  The guidelines were very 
straightforward, but little thought or attention was given to them. 
Under the leadership of the USPTO, together with the 
contributions of the other searching authorities, the ISPEG were 
recently re-written.  The ISPEG made an effort to come up with 
mutually agreeable guidelines that all the offices could apply.  This 
proved, in practice, more difficult than it had appeared. 
Instead, rather than trying to force agreement, which was 
probably one reason why the earlier guidelines were ignored.  It 
was decided that where there was not agreement, for example, in 
questions of unity of invention, the guidelines would simply 
acknowledge there was not yet full harmonization.  The guidelines 
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now tolerate a certain amount of flexibility from authority-to-
authority, but the differences in search and examination practice 
now require clear demarcation.  In terms of the ultimate goal of 
harmonization, maybe the new guidelines are not that great, but 
the fact that there are now clearly stated guidelines being used in 
all the authorities, with clear statements of where the 
disagreements are and are not, is a considerable step forward. 
Isabelle also alluded to a quality framework.  The new Search 
and Examination Guidelines now have a full chapter on quality 
framework, which is a further step forward.  Moreover, under that 
framework, the authorities must report regularly on the steps they 
are taking to improve quality control and share those reports 
among the twelve authorities. 
The PCT establishes the set of patent and non-patent 
minimum documentation that need to be included in search and 
examination.  The newest addition to that minimum 
documentation is Korean patent documents.  Under the 
championship of the EPO, the authorities are attempting to 
rethink and re-look at what minimum documentation should 
consist of in today’s world, as opposed to the world of 1978, when 
the PCT came into operation. 
The purpose of PCT minimum documentation is to bring 
about a commonality of international search results.  The 
minimum documentation also serves to influence national search 
and examination.  The availability of minimum documentation as 
well as the whole body of published PCT applications, is tending, I 
believe, to bring about a common sense of the prior art, which in 
turn should lead to greater respect and mutual recognition of 
international and national search reports.  While progress is less 
swift than what one might hope for in terms of mutual recognition 
of search results among the major offices, the impact of 
international search and examination is quite noticeable among 
some of the smaller and medium-size offices. 
The International Bureau recently informally polled some 
Indian agents to find out whether they perceived a difference when 
they were prosecuting either a Paris route application in India or 
an Indian application in India, as opposed to an Indian national 
phase application.  They all said, and said instantly, when the 
application includes a positive search report, the agents examine 
the claims much more positively.  There is a sense of confidence in 
the opinion of a major office.  As that happens more and more, 
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what is indirectly happening is that examiners all over the world are 
recognizing, identifying and accepting harmonized notions and 
harmonized standards of search, examination, and patent grant. 
Finally, I should mention that possibly the biggest 
harmonizing impact of the PCT has been its contribution to 
WIPO’s enormous program of technical assistance to developing 
countries.  That program has had an important influence on the 
creation of new markets for intellectual property and the 
development of systems that effectively grant and enforce 
intellectual property rights.  The growing emergence of modern 
intellectual property systems the world over bears witness, at least in 
part, to the success of that technical assistance. 
So what will happen in the future?  I personally think that 
despite what might happen in these next couple of months in 
terms of substantive patent law harmonization, the process of de 
facto harmonization will continue in a positive direction, and that 
from a de facto perspective the future is good.  As long as countries 
like India, China, Korea, Brazil, South Africa, and others continue 
to emerge as economic forces, the more recognition there will be 
that an effective patent system serves a nation’s own self-interest.  
There will be strong incentive to put into place internationally 
compatible patent systems and to grant appropriate levels of 
protection. 
I think there is an important caveat, however—that is, what is 
the burden on us?  It cannot be all-for-nothing-in-exchange.  There 
has to be some form of quid pro quo.  In this context, I really need 
to speak in my personal capacity as a former American practitioner.  
From my perspective, and again this is very personal, I think the 
quid pro quo is that we have to take a step back and look with 
much greater seriousness than we have previously looked at the 
demands of developing countries, who wish to use intellectual 
property as a tool for development.  I think we have to take the 
development agenda seriously, particularly in the area of 
traditional knowledge and genetic resources, and carefully look at 
the prevailing international framework to see whether it fully meets 
the needs of developing countries.  We should at least be more 
open to examining and questioning, so that, without necessarily 
coming to any conclusion, we can be sure that there is a balanced 
global approach to moving forward. 
I think that if we are able to take that step back and be more 
open to recognizing the legitimacy of the demands of developing 
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countries, then the harmonizing movement that is taking place is 
destined to continue. 
I am often asked, particularly when I am in developing 
countries, when will there be a global patent.  My usual answer is 
not in my lifetime, but it will not matter because we will all be 
moving in the right direction towards that goal. 
2. Practitioner Perspective: Brent Routman† 
As the last of five speakers on this panel, and having had my 
time expire before speaking, I have very little new to add at this 
time.  I’m not going to bore you with talking about the PCT and 
the PLT as you have already heard the most important aspects of 
each.  But I do want to say a couple of things. 
On our perspective as users, I’m not a corporate 
representative.  I’m not a government agency.  I don’t represent a 
trade association.  I’m a lawyer representing clients, trying to get 
them efficient, cost-effective patent protection around the world, 
and billing for it accordingly.  What I’m looking for is 
harmonization.  I think harmonization makes sense. 
I had the honor to attend the Diplomatic Conference for the 
PLT as Jay had mentioned earlier.  You have to appreciate the 
difficult role WIPO has to play in coordinating a treaty negotiation 
of that type.  If you thought we were having problems in our Senate 
with potential filibusters, you should attend one of these 
conferences and see what that’s like.  There are representatives 
from 160 countries sitting there.  Everyone has a say.  It’s a one-
person-one vote system.  It takes time—an inordinate amount of 
time—to give everyone their say, and things do have a tendency to 
bog down. 
It’s unfortunate that the tone of the debate seems to have 
ended up a North/South (or rich/poor) debate related to 
traditional knowledge and genetic resources.  I think that it’s 
important and equitable for the developed countries to address the 
issues and concerns of developing countries.  Practically speaking, I 
believe that it is necessary if we really want to move forward.  
Whether we do that in a trade agreement such as an amendment to 
the TRIPS Agreement, or through harmonization of the patenting 
process, these critical issues need to be addressed.  The 
harmonization process has languished for years due to these few 
 
       †   Merchant & Gould, P.C., Minneapolis. 
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important issues.  In some ways very little progress has been made 
since November 2000 when the negotiations on the Substantive 
Patent Law Treaty (SPLT) were first started. 
In the minute that I do have, there are several ways to move 
forward that would be possible.  Let’s consider centralized filing of 
a patent application outside the PCT system utilizing WIPO as the 
centralized filing authority.  Not everyone is a member of a PCT.  
Many countries are not.  We could come up with some kind of 
regimen where there’s a centralized filing system. 
I think it’s also important that the United States ratify the PLT.  
The United States was a signator in June 2000 but has made no real 
progress in moving the treaty through the Senate. 
Similarly, the U.S. agreed many years ago to adopt the Unity of 
Invention standard rather than restrict practice, but has failed to 
implement those changes—waiting instead for it to be part of a 
larger harmonization process.  Perhaps revenue has something to 
do with that decision. 
Another concern I have is that there should be full recognition 
of search and examinations by the tri-laterals.  I know there are 
perceived quality issues.  Why can’t we adopt a system, similar to 
the Madrid system for trademarks, where a country has a certain 
number of months, after reviewing an application, to object or 
refuse to grant the patent?  Absent a timely objection, the search 
and examination of the sister office is accorded full faith and 
credit. 
We should quickly move toward universal acceptance of color 
and digital drawings.  The Tri-lateral office of the USPTO, JPO, 
and EPO should assist smaller offices in obtaining the equipment 
and training the personnel to enable those offices to accept color 
and digital drawings. 
Translations remain a significant bone of contention as it 
relates to revenue, national pride, etc.  If we are to really resolve 
the harmonization issue, we need to find a solution to this 
problem, both at the prosecution level and in litigation. 
In a nutshell, I am encouraged that we are moving forward.  I 
think it’s important that we come to some type of agreement on 
issues on which we can find common ground, such as  prior art, 
grace periods, etc.—even if it means that we  bifurcate that process.  
But to truly achieve a meaningful harmonization scheme, we need 
to address the issues raised by the developing countries sooner 
rather than later as it is equitable and it is the right thing to do. 
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That’s it.  The other things—I had a whole presentation about 
where we’ve come from—I was going to go back to the Paris 
Convention of 1884 which I remember well.  I decided to pass on 
that.  Thank you. 
Special thanks to Jeff Anderson for his assistance in preparing 
these materials. 
3. Practitioner Perspective: Harry Gwinnell† 
A lot of what I will be presenting will touch on some of the 
things that have already been said, but here from the user’s 
perspective.  So there may be some differences compared to what 
the experts have spoken about.  But again, it is from the 
perspective that I have, that I think Brent Routman has, and that 
some of the folks that we know have, who are all really wondering 
about the possibility of harmonization.  As I ask in the title, is there 
really any hope for this? 
I think a lot of us have felt the same way that Jay spoke of 
earlier, and we are wondering, and trying to figure out how many 
grands there were in the grand-children who might see this occur.  
But, I think that is the feeling for a lot of folks; that there is a lot of 
opportunity, but there is also a lot of work to be done. 
Again from a 10,000 foot perspective, I think there are things 
that are favoring harmonization, and it is clear from all of the 
activity described in the presentations you have heard already, that 
we have really come a long way.  There are a lot of groups pointed 
in the right direction.  There is certainly interest, and certainly 
enthusiasm for it.  The PCT is a perfect example of not only just 
pulling it off in the first place, but of the improvements and 
modifications for the users that have come about, those still on the 
drawing board, and those that will continue to come about.  These 
developments are a very encouraging sign.  I haven’t met anybody 
who doesn’t think harmonization is a good idea.  That is 
encouraging as well. 
To me one of the most significant pieces, and I’ll touch on this 
a little bit more, are the economic drivers for getting it done.  I 
think it was in the Cabaret musical in which it was said that, “Money 
makes the world go round.”  I think about that often, because the 
economic drivers are so strong that they are really getting things 
done here.  In my opinion, that is one reason that harmonization 
 
       †   Cargill, Inc., Minneapolis. 
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will happen. 
On the other side of the coin, the experience thus far could 
have been better.  We continue to hit what appear to be significant 
stumbling blocks from time to time which can be discouraging if 
you are not willing to keep at it.  What we have been involved in is 
trying to get agreement by committee.  Occasionally you can 
actually get it done.  However, this is a committee in grand form, 
with 100-plus nations trying to agree on one form or another.  It is 
very difficult to get done. 
There are some economic drivers in the other direction which 
will take away from it as well.  I think the translation business, for 
one, is quite a cottage industry in quite a few countries.  So you will 
be taking dollars from some folks as one of the issues that we solve 
in reducing the cost of translations. 
One of the encouraging signs, over the course of my career, 
was the establishment of the PCT process.  I was actually in the 
Patent Office when that came about.  I was very encouraged with it, 
and that is one reason I left: because of the new opportunities this 
appeared to present.  The advances made in Europe, as we just 
heard, are very significant, and continue to be significant.  
Nevertheless, the activities on the community patent (that is a 
European community patent) are tough.  However, I think the 
differences were sharply defined at the last meeting, as best I can 
understand, and clearly stating the problem is always a big step to 
solving the problem.  I think there are some encouraging signs 
there. 
The government tri-lateral group was mentioned as one 
activity that is taking place, and there has been significant progress 
made with the government tri-lateral group.  Also, from my 
perspective, I have been a little closer to the industry tri-lateral 
group recommendations, and that is another initiative where folks 
are really trying to facilitate, and energize the whole process as well. 
I believe that these can be perceived as ignoring or 
overlooking the interests of some developing companies, but I see 
it more as a straw proposal to facilitate, or to move, a whole 
initiative a little bit more quickly.  I do not really see it as against 
the developing countries’ interest, but rather as a straw proposal to 
get the process moving a little more quickly. 
From my perspective, I think it will happen as a result of 
economic drivers, because there is tremendous industry pressure to 
get it done.  I will get into a little more detail as to why I think there 
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is a lot of industry pressure to get it done later.  However, I believe 
that industry pressure is also translating into government pressure 
to get it done, with industry pressure and government interest both 
being part of that push. 
I notice that there are a lot of legislative changes taking place.  
It is a continuing process.  We see it in the United States with the 
Patent Reform Bill.  A lot of that bill, in my mind, is an attempt to 
harmonize the laws of the United States with the laws of other 
regions and other countries.  I see that as another point of 
pressure, and another positive response . . . . 
I think, as was mentioned earlier, the PCT is really at the heart 
of the universal patent application.  Interestingly, the things I’ve 
read from both of the tri-lateral groups point to the PCT model, 
and it is interesting that everybody points to the PCT as the real 
objective. 
Then of course there remain other issues—and again they’ve 
been touched on before—such as, agreeing on what represents 
prior art, the novelty and obviousness issues, and developing a 
single search across geographies.  I think this is one that will go a 
long way if we can get to where a search in one jurisdiction, or one 
region, can be applied globally.  That, in itself, would be a huge 
advance.  I don’t see that as being that far away.  I think that is 
something which is doable, and which would have a tremendous 
impact on the whole globalization initiative. 
Some of these again were already mentioned, such as a 
universal grace period and a clearly defined and universally applied 
set of patent validity elements.  I think we can not overlook the 
subsequent issues too.  Again I will touch on that, but it is very 
important to the industry folks to not only obtain the patent, but to 
know what happens afterwards, and that can not be overlooked in 
the whole harmonization. 
I think another issue that is going to have to be resolved 
somewhere down the line is the compensation to inventors.  That 
issue seems to be getting more and more attention.  Especially 
from industry users of the system, both throughout Europe and 
from Japan, where we are seeing some scary headlines.  Especially 
for a global company, where you may have inventors in one region, 
who will be compensated independent of where they originate for 
patent issuance in other regions.  Again, I think the harmonization 
debate has got to include some resolution of these issues. 
I think the regional aspects are another noteworthy event, 
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because the individual regions, and the EPO is a perfect example, 
can harmonize their laws.  I think the pieces that you have to put 
together are getting bigger, so there are fewer pieces that you have 
to put together.  I think that will really facilitate the whole process. 
I am hearing some rumblings about some possible regional 
coverage in Asia now, which is another encouraging sign.  That is a 
very encouraging development. 
In the interest of time, I am just going to touch very quickly on 
the Casablanca Compromise versus Brazil-, Argentina-, and India-
led opposition.  When I first read about that, it felt like a significant 
setback.  But, I think with all of these developments, there is some 
silver lining in the setbacks.  I think there were some good things 
that came out, especially in clearly defining the issues of 
importance to all parties.  The better job you do on really clarifying 
what the real stumbling blocks are, I think the better chance you 
have of resolving those issues.  Not necessarily a bad thing. 
The reason this issue is so important to industrial users of the 
system is that, as I think we all know, we have limited resources 
available for international filing.  I know, and I have been with four 
different companies now, we always face the tough decisions on 
where to file, because there is a limited budget and limited 
resources.  You really have to start picking and choosing.  
Sometimes it is very difficult with these limited resources to decide 
where to file.  It is not just the patent acquisition and the patent 
filing in these countries, because whether or not you have a patent 
in these countries really determines what goes into those countries 
from a technology perspective.  If you do not have good patent 
coverage for these countries, then we have made decisions not to 
send our best technology into certain countries, because of the 
softness of the patent system, or the fact we didn’t have enough 
resources to get patent coverage in those countries. 
Economically, long term, especially for the developing 
countries, it can take them longer to develop under those kinds of 
circumstances.  It is almost circular.  I think it is important for all 
member countries that the move toward harmonization be made.  
The long term benefit for all countries is really there. 
From my perspective, the bottom line is that it will be a slow 
process, but it is evolving.  I see signs that the pace is picking up.  I 
think a few years ago I would have agreed with Jay that one of those 
grands of grand-children would not live to see harmonization.  I do 
not feel that way any more.  Optimistically, I think it could be in the 
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ten to twenty-year range where we will really see some significant 
harmonization.  Those who are still practicing will look back and 
say that they thought it would take longer. 
I think there is going to be constant pressure from industry, 
and from different governments.  We are seeing activities that look 
somewhat disconnected, but there are little points of light in all 
types of different areas.  Everybody wants harmonization to 
happen.  I really, truly believe that we will see it sooner than we 
think. 
4. U.S. Perspective: Charles Pearson† 
In the area of international patent law a number of treaties 
have been developed which you have heard a lot about today.  Of 
course you heard about the PCT. Also, the Standing Committee on 
the Law of Patents has worked on the PLT and has been working 
on the Substantive Patent Law Treaty (SPLT).  Because of certain 
controversies among the member states in WIPO, some of the 
activities have moved outside of WIPO, so I’ll try to deal with that a 
bit today. 
Of course, you have heard a lot about the PCT.  The PCT 
simplifies the process of filing foreign patent applications.  It 
provides for the filing of a single international patent application 
having the effect of a national application among the 128 member 
countries.  The PCT regulates the formal requirements of the 
international application and results in a preliminary, but non-
binding, opinion on issues such as novelty, inventive step and 
industrial applicability. 
The PCT is not perfect.  It has a few disadvantages.  It does 
require prosecution in each of the designated states, or the 
regional offices.  It does not regulate the substantive requirements 
that are left up to the national law.  The PCT does not require 
designated states to abide by the [resulting] opinion on 
patentability.  Most importantly, as far as the USPTO is concerned, 
it probably results in substantive work duplication by the national 
and regional offices which can be very expensive and inefficient. 
The PLT, as you heard earlier, was adopted in 2000 and has 
just recently entered into force.  The ratification and 
implementation process in the United States is still pending.  
Implementing legislation has been prepared by the USPTO and 
 
       †  Office of PCT Legal Administration, U.S. Patent and Trademark Office. 
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sent across the river.  [It is] still languishing over there. 
The PLT does harmonize the formal procedures in national 
and regional patent applications and patents and does so by 
incorporating the formal requirements in the PCT right into the 
PLT. However, the disadvantages of the PLT are similar to those 
discussed regarding the PCT.  Once again the PLT requires 
prosecution in each member country to obtain multiple patents 
and does not regulate the substantive requirements.  Like the PCT, 
it also results in work duplication and inefficiencies in the national 
and regional offices. 
The proposed SPLT originally sought a very deep 
harmonization so that the underlying practice would be 
harmonized.  This would reach way down and create a single set of 
guidelines for the entire world.  The idea was to focus on the best 
practices of the various issues involved in drafting, filing and 
examination of patent applications.  In the negotiations, sometimes 
delegations prefer a position because it mirrors the way that 
country operates.  That was not the intent.  The intent of 
negotiations was to look at the various options and determine 
which one was best for the patent system. 
The intended result of the SPLT was to provide for a single 
application that would then be examined in each of the member 
countries and provide consistent worldwide examination results.  
This idea would result in work sharing, cost reduction for both the 
applicants and the offices, and a more efficient system. 
Of course there have been a number of controversial issues 
that have been involved in the SPLT—issues such as patent eligible 
subject matter and exceptions to patentability.  For example, our 
U.S. business-method patents caused a great deal of concern 
around the rest of the world.  Things like computer programs and 
inventions dealing with human, animal, and plant life have 
certainly created a number of issues. 
Probably the biggest issues that have confronted the 
delegations during these negotiations have been those issues 
relating to genetic resources and the disclosure of traditional 
knowledge.  A number of developing countries are very concerned 
about these issues, which has caused the slow down in the entire 
negotiation process.  In addition, many developing countries are 
concerned about social development and public health.  Certainly 
the AIDS epidemic is a prime example of their concern, which 
certainly affects the developing world more so than it does the 
54
William Mitchell Law Review, Vol. 32, Iss. 4 [2006], Art. 8
http://open.mitchellhamline.edu/wmlr/vol32/iss4/8
13PCTTRANSCRIPT.DOC 6/5/2006  8:33:09 AM 
2006] 2006 PCT SYMPOSIUM 1657 
United States or the rest of the developed world. 
There are also questions about the appropriateness of norm 
setting at WIPO.  Many of the developing countries already feel 
that the World Trade Organization’s (WTO) agreement on Trade-
Related aspects of Intellectual Property rights (TRIPs) is too 
onerous.  They are very leery of any other treaties that might result 
in additional requirements that they feel would be imposed upon 
them. 
Because much of the activity at WIPO has stalled, efforts 
outside of WIPO have emerged, which seek to advance substantive 
harmonization.  Certainly the EPO, the JPO, and the USPTO, 
together known as the tri-lateral offices or the tri-lateral, have been 
discussing these issues.  In addition there has been a meeting of 
industry groups to come up with certain proposals.  The goal here 
is to make progress in harmonization.  As a result of these 
meetings, consensus has been reached that it would be best to have 
a simplified first package to proceed with, in the hope that we 
might arrive at some near-term success. 
In the tri-lateral, the working group meeting in February 2004 
discussed the idea of having a first package of simplified issues. 
Basically this package would include proposals on the definition of 
“prior art,” deal with the grace period, and deal with novelty and 
inventive step.  The tri-lateral offices introduced this first package 
at the SCP and it unfortunately was not adopted.  In addition, the 
tri-lateral has come up with a working group on formats and forms, 
which was established last November. 
As I mentioned, the first package that I talked about was not 
adopted at the 2004 meeting of the SCP.  In fact, there was no 
agreement as to what form any future work would take.  The U.S. 
and Japan did introduce this first package to the WIPO assemblies 
in 2004.  However, it was not adopted there.  In addition, this first 
package has been discussed at meetings of the SCP.  For the most 
part, the developed countries support negotiations on this first 
package, or reduced package. However, the developing countries 
generally support the inclusion of all the proposals, an approach 
which looks at everything as we move toward a substantive treaty. 
A new working group has been formed among the tri-lateral 
offices to discuss patent application forms and formats.  This arose 
out of a recommendation from the industry group.  I certainly feel 
that this would be a good proposal for applicants and offices.  The 
standardization would result in more efficient filing and processing 
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of applications.  We generally refer to this project as the 
International Standard Application Format, or the ISAF.  The idea 
is that you can allow practitioners to prepare one application in 
one format and take that directly to the national offices.  This is 
something a little bit outside the PCT, but I think it is worth 
exploring at this time. 
Another group that has been formed is referred to as the 
Alexandria group, or the B+ Group.  This group basically comprises 
the industrialized countries at WIPO.  It is generally the 
industrialized countries who met in Alexandria at an exploratory 
meeting in February of 2005.  The purpose of that meeting was to 
assess the current state of harmonization and to formulate a plan 
on how to proceed. 
As a result of this meeting, a statement of intent was 
developed.  The statement indicated an intent to have 
coordination on key issues.  Primarily, this coordination involved 
taking a look and hopefully making progress toward a substantive 
patent law treaty.  In addition, the group decided that it needed to 
look at issues related to intellectual property and development.  
Certainly the developing world is eventually going to have to be 
brought back into the process and their needs should not be 
ignored.  Certain working groups were established and the group 
decided that a plenary meeting and a strategy meeting were to be 
held.  Of course, like I say, this is another effort outside of WIPO 
and the feeling is that this group, B+, may be able to make progress 
where that progress has been thwarted at WIPO. 
The group met twice in Munich last year and a meeting is 
scheduled for next month in Tokyo.  Considerable progress has 
been made.  I do not want to imply that we are near an agreement, 
because certainly a number of political issues remain, but progress 
is actually being made. 
Several issues are on the agenda and are being discussed.  
Certainly a big issue in the U.S. is whether the system would be a 
“first-to-file” or “first-to-invent” system.  The treaty is drafted from a 
first-to-file perspective.  I think it is safe to say that if there is going 
to be substantive patent law harmonization, it will have to be on a 
first-to-file system. 
Another big issue that is being discussed is the grace period.  
Of course the U.S. is pressing for a rather expansive twelve-month 
grace period.  The rest of the world has certain reservations.  Some 
are pushing for a six-month grace period.  There are additional 
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issues, such as who benefits from the grace period—is it the 
inventor, or the inventor’s successors in title?  Plus, it is unclear if a 
published patent application would be covered in a grace period.  
All these issues are being considered. 
Concerning inventive step, current language in the proposed 
treaty discusses the differences and similarities between the claimed 
invention and prior art.  That has been an area of contention.  It 
contains a possible clause that talks about reasonable expectations 
of success.  These are issues yet to be resolved. 
Another major issue is the prior art effect of prior filed 
applications.  The U.S. stands pretty much alone here and basically 
feels the 102(e) effect of a prior application should extend both to 
novelty and inventive step.  Primarily the EPO and a few other 
countries feel that it should be limited to novelty only.  However, a 
few countries, such as Japan, Canada, and Australia have proposed 
a “novelty plus” standard.  Here, the prior art effect of prior-filed 
applications would extend to novelty, plus it would take into 
account the general knowledge of the skilled artisan.  That is 
another issue that we have been discussing quite a bit. 
Of course, concerning eighteen-month publications, the U.S. 
excludes applications from publication where the applicant has 
indicated they will not be filing abroad.  That is another issue that 
is being addressed.  Certainly we are in the deep minority there. 
Concerning the abstract—whether the abstract forms a part of 
the contents of the application as a whole for prior art purposes is 
another issue being discussed.  The group also has discussed 
whether we should have provisions similar to those found in 35 
U.S.C. § 102, where secret commercial uses and other activities 
could cause a loss of rights.  Once again, the U.S. is proposing this 
and we are in the minority.  Under the Hilmer Doctrine in the U.S., 
you can go back to the U.S. filing date for prior art effect, under 
102(e).6  Certainly the U.S. is also advocating that position and is in 
the very small minority. 
Jay Erstling alluded to a few different proposals under 
consideration.  I think he referred to the patent prosecution 
highway earlier.  I will refer you to the materials here on the new 
route.  It is very similar to the patent prosecution highway, but 
there is another proposal that makes a lot of sense to me, which is 
being discussed in the tri-lateral.  If you have corresponding 
 
 6. See In re Hilmer, 359 F.2d 859 (C.C.P.A. 1966). 
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applications filed in each one of the tri-lateral offices, and the 
application is ready for examination, the first office will then 
provide or create an office action, and will put it on a tri-lateral 
dossier access system.  The other offices may then rely upon these 
results and do their own searches.  The idea is, for example, the 
USPTO does a pretty good job of searching U.S. patents.  Certainly 
the Japan Patent Office does a much better job of searching 
Japanese language documents.  The EPO, once again, does a very 
good job in handling certain other languages.  If the three offices 
could coordinate their activities and cooperate, we feel that this 
would certainly result in a much higher quality patent. 
In summation, I just want to say that international patent 
protection is very important in the global economy.  The current 
situation is not acceptable.  Costs are too high.  There is 
duplication of work.  Right now, unfortunately the prospects of a 
successful conclusion at WIPO appear dim.  However, certain 
efforts outside of WIPO appear to be promising.  I just hope that 
we can move forward. 
5. European Perspective: Brian Derby†  
Well, thank you very much.  I have a fairly short presentation 
to make today.  I want to speak to you about patent law 
harmonization and the patent cooperation treaty as seen from the 
point of view of the EPO, which is the largest international search 
and international preliminary examining authority under the PCT. 
I [begin with] the early 1990s failure of the PLT.  That PLT, 
which Isabelle Boutillon mentioned to you this morning,7 
attempted to deal not only with formal aspects for international 
patenting, but also with the substantive aspects of international 
patenting.  It was generally considered in the early 1990s, when the 
negotiations were wound up, that the entire exercise had been 
something of a failure. 
Was it a failure?  That depends on your perspective.  If the 
object was to conclude a comprehensive deal on international 
patent law harmonization, then I don’t think you can put any other 
spin on it.  You have to acknowledge it didn’t succeed.  But if you 
take a slightly more cynical view and you ask, “Was the objective to 
 
       †   European Patent Office, Munich.  The views expressed are personal to 
the speaker and do not necessarily represent the views of the EPO. 
 7. See supra Part II.B.1. 
58
William Mitchell Law Review, Vol. 32, Iss. 4 [2006], Art. 8
http://open.mitchellhamline.edu/wmlr/vol32/iss4/8
13PCTTRANSCRIPT.DOC 6/5/2006  8:33:09 AM 
2006] 2006 PCT SYMPOSIUM 1661 
conclude a comprehensive deal on international patent law 
harmonization, or was the objective really to make everyone feel 
they’d not lost out in the negotiations?”  Then you could say it was 
a resounding success! 
American negotiators could certainly feel confident when the 
exercise finally broke up because they were able to say to their 
domestic constituency, “Look we were under all sorts of pressure 
from abroad, particularly the Europeans, to give up all the things 
we hold sacred in our patent system—like first-to-invent and utility 
and industrial applicability.  We came under all that pressure and 
we resisted it!  And we still have our patent system pretty much 
intact.”  The Europeans could say to their constituency, “Well, you 
know everyone on this side of the Atlantic really knows that the 
European patent system is the best patent system in the world.  We 
came under a lot of pressure to change our standards in the 
interest of international patent law harmonization and we resisted 
all that pressure.  We still have everything that we hold dear intact.  
It looked as though we might have actually had to give things up 
that we like.”  As it transpired, they played hardball, so both sides 
could walk away and say, “No deal.” 
Was anyone that terribly disappointed?  My own very personal 
opinion is that they weren’t.  It may come across as a very cynical 
perspective, but I think that the expectations during the course of 
those negotiations had diminished anyway.  So no deal was done.  
All sides may have wanted progress but I don’t think anyone was 
desperately disappointed, rather took it philosophically. 
Now we are faced with another attempt at patent law 
harmonization under the guise of the WIPO standing committee 
on patents.  We have two opportunities, I would say now, to tackle 
the issue of international patent law harmonization.  We have the 
SCP dealing with substantive patent law issues and we have PCT 
reform.  Now, if we’re serious about achieving some kind of 
harmonization this time around, I think we have to avoid the 
mistakes that were made in the early 1990s concerning the PLT.  
We have to get down to some serious negotiations. 
Charlie Pearson mentioned some initiatives that were 
happening at the moment in the tri-lateral context.  That’s true.  
There is some interesting work being done within the tri-lateral.  
Some serious discussion is taking place on these thorny aspects of 
international patent law: first-to-file, first-to-invent, industrial 
applicability versus utility, concept of novelty and inventive step, 
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and so forth.  That’s promising, but in today’s context we have 
another dimension.  That is the developing countries. 
We’re trying to achieve progress in the tri-lateral—and actually 
it’s not just the tri-lateral it’s what’s called tri-lateral plus, it’s the 
EPO, JPO, and USPTO, plus certain EPC contracting states and 
Canada and Australia.  I think there is a willingness on the part of 
those countries to tackle some of the thorny issues, but now we 
have the developing countries who say, “Well we don’t really like 
that approach.  We don’t like industrialized countries going off and 
trying to carve up a deal amongst themselves and then coming back 
with a fait accompli’ and saying look, look how successful we’ve been.  
We’ve achieved progress, the kind of progress we couldn’t achieve 
in the 1990s.  This is the basis that we’re going to work on.” 
Whether that’s a reasonable perception or not, it’s a perception 
and developing countries don’t like it.  Their view is, “We don’t 
want any reduced package.  We don’t want any side deals.  What we 
want is for talks on international patent law harmonization to 
continue under the auspices of WIPO.”  If we can agree on 
everything, that’s good.  If we can’t agree on everything, then we 
keep trying.  But they are wary of tri-lateral-plus discussions and 
they’ve made that perfectly clear. 
Where does that leave us then?  Well, I wouldn’t be quite as 
pessimistic as Jay Erstling when he said that maybe the bottom line 
is that we will never actually come to the stage where we can take 
our pens and sign off on a deal, on a patent law treaty.  From the 
point of view of the EPO, I think the experience of our 
organization is that, though progress is tortuous and slow, that 
doesn’t mean that you should give up on the ultimate prize. 
The ultimate prize in this case is a deal, a comprehensive deal 
on international patent law harmonization.  It seems a difficult 
prize to achieve at the moment, but if you take the example of the 
EPO, the idea for a European patent system emerged in the late 
1950s.  During the 1960s people said, “Well there are just too many 
problems with this whole project to ever see the light of day.  We 
have so many differences between U.K., France, and Germany.”  
Just one example is inventive step. 
Germany, the German Patent Office, took a traditionally strict 
attitude towards inventive step.  They set the bar at a pretty high 
level for the applicant to satisfy them that the application satisfied 
the inventive step requirement.  The U.K. Patent Office, on the 
other hand, was seen as adopting a slightly lower threshold for 
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satisfying the inventive step requirement or at any rate approached 
the issue in a different way.  How do you reconcile such 
differences?  Lots of people said you can’t do it.  Yet we have a 
standardized provision in the EPC.  The inventive step requirement 
is anchored in Article 56 EPC and has been defined in the EPO 
Board of Appeal case laws which by and large sets the standard at 
the European level. 
There was also a difference between the culture and 
philosophy of the U.K. and Germany on the question of scope of 
protection and infringement by equivalents.  The U.K. approach, 
traditionally, is a literal approach to the scope of protection.  What 
did the applicant actually intend when he was drafting his claims?  
Much focus is given to the intent of the applicant and the actual 
wording of the patent specification.  Particularly in Germany there 
is less focus on what the applicant intended and the literal wording 
of the application and more focus on “functionality”—hence the 
protocol to Article 69 EPC—a kind of “middle ground.” 
Despite not actually being able to come to a meeting of minds 
on all these different approaches during the EPC negotiations, the 
EPC was signed into life in 1973 and came into force in 1978. 
What I’m trying to get across is that you can’t always achieve 
consensus in advance when there are such differences at 
international level; you will not always achieve consensus.  But that 
doesn’t mean that you should give up. 
If you look at the European patent system today we have thirty-
one member states, stretching right across Western Europe and 
behind what used to be referred to as the Iron Curtain.  Our 
newest member states come from Eastern Europe.  Latvia was our 
most recent accession to the EPC during the course of 2005.  No 
one would have thought that possible twenty years ago. 
Obstacles remain to development.  Obstacles can remain 
within a system.  But that doesn’t necessarily stop development.  To 
tackle those problems within the European patent system we’ve set 
up all sorts of mechanisms such as, for example, the judge’s 
symposium, which takes place every two years.  The European 
patent judges come together and discuss practical issues which are 
perhaps impeding harmonization of jurisprudence.  We try to 
narrow down the differences at the European level. 
A similar first instance mechanism exists, a body called 
EuroTAB.  The national offices of the EPC member states and EPO 
come together to discuss differences in practice and see whether a 
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harmonized approach is possible. 
The point is that it is unrealistic in a modern environment to 
expect agreement, or total agreement, on all aspects and points of 
difference that emerge during negotiations, and even beyond the 
negotiations into the actual practice.  That isn’t meant to say that 
you become hung up on those individual items.  I think what has to 
be done is you say, “Yes, we have differences.  Maybe we can’t 
resolve them all in advance but we acknowledge each other’s 
differences, we try to find common ground and we accept that 
actual harmonization, harmonization in practice, is something 
that’s going to continue well beyond the actual signing of a treaty.” 
Another example from the European patent system.  One of 
the speakers this morning mentioned translation costs and the fact 
that the European patent system was hindered by the high cost of 
translations.8  Well at the European level it looks as though we are 
making progress on “the London Agreement,” which is an 
agreement whereby the EPC states, not all of them—certain EPC 
member states—have agreed to say, “We won’t insist on a 
translation of the entire patent specification.  We will restrict our 
translation requirement by and large to the claims only, with a full 
translation only in the event of litigation.” 
For example, Germany would say, “Under the EPC, we are 
entitled to insist on a translation of the entire European patent 
specification.”  What we will do instead is say, “If a translation of the 
specification is available in a certain nominated language, say for 
example English, we will accept that.  We’ll still need a translation 
of the claims into German and a full translation prior to 
enforcement.”  Other countries are expected to follow the same 
example.  The U.K. and Germany have recently ratified the 
London Agreement.  We still haven’t arrived at the stage where we 
have enough ratifications for it to enter into force, but that’s 
expected to happen within the next few years, if France ratifies. 
I think that’s a concrete example of progress on a very difficult 
issue, the translation issue, even though at an earlier stage people 
said, “Well, translations are sacred; there will never be any progress 
on that.”  It doesn’t mean that it’s true.  It might be difficult but 
progress is possible. 
So what does the European experience tell us in the context of 
international patent law harmonization?  I think it tells us two 
 
 8. See supra Part II.A.2. 
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things.  It tells us that despite difficulties—and there are certainly 
difficulties at the moment in the SCP—you can still finally arrive at 
your goal, which is the conclusion of a treaty. 
The second aspect of the European experience is that even 
when you actually get people to sign up to a treaty, and I think that 
we will eventually get people to sign up to some form of patent law 
treaty, that isn’t the end of the road.  Because even when you have 
everyone signed up, even when you have some form of harmonized 
legislation and harmonized principles, the European experience 
tells us that there is a lot of work to be done beyond that stage.  
Differences in practice still persist.  I think it would be naïve to 
assume that even if we do get signatures on some form of patent 
law harmonization treaty, that overnight everyone is going to 
abandon what they’ve been doing in the past and we’re all going to 
be witnessing absolute, crystal clear perfect harmonization.  We’re 
not.  I think that the situation is that even if we get a deal, for the 
next twenty to thirty, maybe forty years, there’s still going to be an 
enormous amount of work to be done on de facto harmonization. 
So what happens in the meantime?  Where does that leave us?  
Rather conveniently it brings us to the PCT.  Jay Erstling 
mentioned that the PCT delivers a form of de facto international 
harmonization.  I tend to agree with him on that.  It certainly 
doesn’t have the glamour of the SPLT; it’s not a headline grabber.  
You’re never going to open your copy of Financial Times and see 
headlines screaming out at you which say, “WIPO Member States 
Agree on Uniform Time Limit Under Articles 22–39 PCT,” or, 
“International Search Reports to be Accompanied by Preliminary 
Opinion on Patentability.”  That’s not going to happen.  It’s not 
that kind of treaty. 
It’s an on the ground, low-key kind of treaty, but it delivers 
very concrete results.  I think at the outset of the PCT reform 
exercise, which we started in 2000, a sensible decision was taken, to 
split the reform proposals into two batches. 
The first stage was reform proposals which would be 
implemented by way of change to the PCT rules, the regulations, 
without having to call a diplomatic conference to revise the treaty 
articles.  Under that heading we’ve made progress.  As I say, we 
came up with a uniform time limit for entry into the national phase 
under Article 22 and 39.  We agreed to introduce the international 
report on patentability for all applications which accompanies the 
search report.  And we made a number of small-scale, relatively 
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small-scale, changes to PCT which made it easier for applicants to 
use the treaty. 
We made changes to the rules on non-unity, for example, that 
entered into force in April 2005.  From the EPO perspective I can 
make something of an announcement.  We filed a number of 
reservations during the course of the PCT reform exercise because, 
though we agreed on the changes in principle, we couldn’t actually 
implement them because they were inconsistent with the EPC as it 
stood. 
The EPC was revised in 2000 but the necessary number of 
ratifications was not achieved until December of last year to allow it 
to enter into force.  We now have the necessary number of 
ratifications.  EPC 2000 will enter into force in December 2007.  So, 
I can tell you today that a number of reservations that the EPO has 
filed, concerning, for example, the new rules on missing parts and 
restoration of the right of priority which was mentioned this 
morning9—those reservations that we filed, or filed on an interim 
basis—are expected to be lifted by the latest in December 2007.  
We will also be able to implement the single-stage, non-unity 
procedure. 
As I think Isabelle mentioned this morning, the changes that 
were implemented in the PCT reform exercise by way of rule 
change—we’ve pretty much gone as far as we can go with that 
exercise.  There’s not much more that can be done by way of rule 
change. 
So we come to the second stage of reform.  There’s some 
suggestion that we should now embark on a deeper reform 
program for the PCT; that we should tackle other issues like, 
maybe, making the international search reports, the international 
preliminary examination reports, binding under certain 
circumstances for those contracting states which would be 
interested in developing the treaty in that way.  That’s one 
possibility. 
The EPO’s perspective is that we have changed a lot during 
the course of the last five years.  We’ve changed a lot for the better 
and there have been a lot of changes that applicants and national 
offices and international authorities still haven’t entirely come to 
terms with. 
The EPO’s opinion is that, before we embark on any second-
 
 9. See supra Part II.B.1. 
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stage of reform, or any fundamental reform which would involve 
changing the treaty articles, we should allow adequate time for 
those changes to filter through into everyday practice.  So we’re not 
in favor of embarking on deep reform at this stage. 
Jay mentioned this morning that during the course of the tri-
lateral discussions, some delegations had come up with ideas 
representing alternatives to the PCT.  He said that he hoped that 
phase was at an end.10  I think the PCT certainly has come a long 
way, but not everyone is entirely satisfied that it is “the” vehicle to 
lead us into the future.  There are certainly some ideas floating 
around that there should be some kind of alternative to PCT. 
Once again I’d like to stress that the EPO is fully committed to 
developing the treaty.  We’re not really interested in developing 
alternatives to the PCT.  I just want to give briefly some reasons why 
that is so. 
As you can see from the chart, we are the largest international 
searching authority.  That chart is taken from 2004 when we 
carried out 56% of all international search reports.  Preliminary 
figures suggest the number of preliminary examinations has gone 
down last year, but we’re still the leading international authority; 
we still carry out the international search and preliminary 
examination reports in just over 50% of all cases. 
In the earlier days of the PCT, the number of applicants who 
filed Euro-direct—in other words filed the European Patent 
Application without using the PCT at all—and the number of 
applicants who filed the European Patent Application via the PCT 
was more or less equal.  You’ll see this if you look at the chart 
figures from 1995. 
By 2004 you can see that the number of Euro-direct 
applications was 58,500, whereas the number of Euro-PCT 
applications had risen dramatically to 120,000.  So roughly two-
thirds of all European patent applications now come via the PCT. 
The EPO, almost uniquely among international authorities, 
has embraced the principle of universal competence.  That means 
that we say we act as searching authority for any PCT contracting 
state which wishes to use us as an international searching authority.  
We don’t restrict our competence to our own nationals or 
residents.  The reason for that is that we see the PCT as a truly 
international system and wish that to continue. 
 
 10. See supra Part II.A.1. 
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There was some mention of delays in issuing search reports.  
That’s true.  In some fields we have to hold our hands up and say, 
“Yes, we have been guilty of delays in issuing international search 
reports, though in some cases that is beyond our control.”  We 
could solve that problem by restricting our competence to 
European applicants only.  We don’t want to do that.  We want the 
PCT to remain truly international and we’re committed to playing 
our part in that. 
We see the advantages of the PCT particularly in the fact that it 
delivers non-binding reports which are not a threat to national 
sovereignty, and also in the fact that it is attractive not only to 
developed countries but to developing countries.  We saw this 
morning impressive statistics for PCT growth, particularly in Asia. 
I just want to wrap up with a few words about future trends.  
We mentioned this morning that the number of PCT Chapter II 
demands has gone down very much.  It used to be the case that in 
80% of all PCT applications a demand for Chapter II was filed; now 
it is about 20%.  That’s also our experience, as you can see from 
the chart.  Just a word of caution: at the EPO we see a certain 
amount of confusion still on the part of applicants and their 
attorneys concerning usage of PCT Chapter II.  There’s a certain 
impression on the part of applicants that you simply file a PCT 
Chapter II demand and you’re going to get something more than 
you would have had under Chapter I.  That’s not the case.  There is 
absolutely no point in filing a PCT Chapter II demand unless you, 
as the applicant, are either willing to file amendments to your 
international application or are willing to counter the statements 
which have been made in written opinion of the international 
searching authority.  If you’re going to do that, you shouldn’t wait 
for a second written opinion issued by the EPO.  There’s still a 
perception on the part of applicants that they are entitled to two 
written opinions following a demand in Chapter II and that’s not 
the case. 
The international preliminary report on patentability under 
Chapter I, in our case, becomes a first written opinion if you file a 
demand in Chapter II.  You will not usually get another written 
opinion.  We will then go straight to issuing the international 
preliminary examination report, unless you file Article 34 
amendments, or unless you put forward good arguments 
countering statements which have been made in the written 
opinion.  Those arguments/amendments will always be taken into 
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account before issue of the final report but won’t usually prompt a 
second written opinion.  I just wanted to make that clear. 
And then, finally, the next step from the perspective of the 
EPO is that we should pursue the SPLT negotiations, but we should 
avoid over ambitious expectations.  We should enhance the PCT by 
striving towards continued simplification.  We should develop the 
electronic filing infrastructure and we should develop the quality 
management provisions so as to bolster confidence on the part of 
authorities in each other’s work. 
I want to close with one important point that Charlie 
mentioned in his presentation: that there is still a lot of duplication 
under the PCT.11  This is a common point of view brought forward 
in the PCT reform negotiations, that we could solve many of the 
problems under the PCT if authorities simply avoided duplication 
and accepted the results of other international searching 
authorities. 
Let me just say from the point of view of the EPO that we don’t 
think we have gotten to that stage yet.  We acknowledge that there 
are problems with timing.  We have acknowledged that there are 
sometimes problems with backlogs.  We’re working, as are all of the 
Authorities, on solutions; but quality is absolutely fundamental to 
the service which is delivered under the PCT.  Before you get to the 
stage where you can place any more extensive reliance on the work 
of other authorities, you need a much more developed quality 
management infrastructure.  You need more progress on 
international patent law harmonization.  You need more clarity on 
outsourcing.  None of which we really have at the moment.  We’ve 
made progress, but we still have a long way to go. 
With that I’d like close my presentation and thank you very 
much for your attention.  Thank you. 
IV. THEME THREE: MAKING THE BEST OF THE PCT 
A. Topic 4: Strategies, Considerations, and Best Practices 
1. WIPO Perspective: Isabelle Boutillon† 
In the first part, I’m going to raise questions or issues.  I’m not 
 
 11. See supra Part III.A.4. 
       †  Office of the PCT, Geneva. 
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going to provide answers.  There could be, for some, as many 
answers as there are today people in this room, or yet even more if 
we asked one of the questions to other PCT applicants and users.  
This is because the circumstances differ, as well as the reasons why 
you would use the PCT, what you expect to see coming out of it, 
and, generally, what is your patent strategy.  Even in private 
practice, for different clients you would have different reasons for 
using one feature or another. 
PCT filing is usually a subsequent filing, but it can be a first 
filing.  If it is the latter, it gives you the same benefits as a first 
national filing followed by a subsequent filing, claiming priority 
under the Paris Convention.  A PCT first filing can be used as a 
priority filing for subsequent filings, within twelve months, in non-
PCT countries. 
Another example: the time limit for national phase in PCT 
countries is thirty months from the priority date.  That’s the usual 
national phase entry time limit.  It is a guarantee for all your 
applications that you don’t have to do anything until then.  No 
national office can ask you to comply with anything until the thirty-
month time limit or, for many now, even thirty-one months.  For 
example, a number of national offices, because of the applicable 
national laws, require payment of maintenance fees two years after 
filing of the application.  In case you do not claim priority, your 
time limit for paying those fees would happen before thirty months 
from the priority date.  All of these requirements have to be pushed 
back to thirty months, and it has been for a lot of them after a lot of 
discussions with us.  But eventually, this is in place for all now.  It is 
to be seen as a sign of what the PCT has done.  It is a significant 
element when you look at the cost of patent protection and how 
soon are you prepared to pay additional fees and other costs. 
Do you just want a defensive publication?  The PCT can do 
that.  It’s not the only system that allows this to be done, but it can.  
PCT applications become widely known as part of the prior art 
when there are published.  They enter immediately in the PCT 
minimum documentation that must be looked into by each and 
every PCT Searching Authority. 
Do you want an effective defensive publication?  Then it may 
be a matter of language.  It depends on whether the language of 
the PCT publication is the official language of a country of 
particular interest to you, such as the country in which is one of 
your competitors or potential competitors.  We haven’t gone that 
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far in PCT.  It’s linked somewhat to the issue of multiple language 
publication, which Jay mentioned this morning. 
Do you want to secure your rights almost world-wide at the 
cheapest cost, at a time when, just months after the first filing, it is 
still quite uncertain what will happen to the invention, even to the 
company, to this area of research, whether the funding will be 
there on next year’s budget or not?  The PCT allows you, with a 
very simple filing process and minimum requirements to be 
complied with, to secure rights in 128 countries today at minimum 
cost.  And then you see what happens.  And maybe you’re going to 
be happy in a year and a half from now that you made this filing 
because the prospects are better and you can pursue the 
application in more countries. 
Do you want to know more about prior art in languages other 
than English?  Well, you can choose a particular authority that 
works in other languages.  And now with the possibility for you to 
use the Korean IP office, you would have access to Korean language 
documents being searched by the Korean examiner, but also by all 
other examiners provided there is an English translation of the 
abstract.  But nothing prevents them from citing documents for 
which there is nothing in English at all.  The PCT minimum 
documentation is what must be searched by all the offices.  But they 
are absolutely free to search more; that’s what they have in their 
own files, and many of them do.  So, in that case, you get access to 
the original text of applications published elsewhere, patent 
documents, or non-patent literature documents that could be 
useful to you in a particular area.  That will not be the case every 
time.  But if it’s good enough for you in one case out of 100, and 
that is an important case, then the system has allowed you to get 
that benefit. 
Do you just want a filing date?  PCT allows you to do that.  You 
file, you don’t pay any fees.  You can achieve the same result with a 
provisional in the U.S. or another application elsewhere.  Yes, 
indeed.  It’s just another alternative in that case. 
Do you want to find out about the areas of specialization of 
certain offices that are available for certain examinations?  That is 
kind of related to one of my previous points about Korean 
language documents—that is, with what are the areas of technology 
that the Korean office is more specialized in?  Why?  Because for 
national applications the main companies filing in Korea are the 
Samsung, the LG Electronics, and the others.  If these are in the 
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same areas as your own technologies or your client’s technologies, 
maybe it is not totally useless to look at the WIPO website, search 
for the cases which have been searched by the Korean office, and 
see what kind of documents they cite.  In this example, you don’t 
use the PCT to file a PCT application; you use the PCT system to 
get information about other applications, about what offices do. 
Do you want to be able to wait until almost the last minute to 
prevent an application from being published?  Almost the last 
minute, because we have what we call “technical preparation” time: 
fifteen days, fifteen calendar days.  (Of course, as you know, 
sometimes things happen; we have to say we’ve had once from time 
to time, but hopefully not very often, a case where we could not 
prevent publication.)  But it’s been fifteen calendar days from day 
one in the PCT system, when we got 1000 applications in one year 
or so, in the very early days, or today, when we get 130,000 
applications.  We can still maintain the fifteen calendar days, which 
is the time before which we must know whether you want to let the 
case go published or not.  We are, I think, on the top list of offices 
which can give you such a service at such a late time. 
Do you want to have amended claims published in the PCT 
process, even if you do not intend to pursue the application?  
These are the so-called “Article 19 amendments to the claims” that 
you can file after you get your search report.  They will get 
published with the application and distributed widely.  If you don’t 
want to pursue the application, you would not do this for seeking 
patent protection.  But it’s a manner of possibly preventing others 
from getting patent protection for certain claims that are in your 
application, as amended since they are published.  When they are 
published, they are “published.”  You file in English, we publish in 
English.  The coverage you get is pretty wide.  So, why not 
sometimes consider that? 
Now I move onto best practices.  A couple of things dealing 
with habits that maybe you should reconsider.  And I am sure, some 
of this you have considered.  One thing that people sometimes say 
about PCT is that it is too complex because it has too many options.  
Well, Jay said this morning that the PCT issues many forms and 
many things.12  But you can avoid getting so many forms by having 
the minimum in order on day one.  Now, of course, if you work in 
private practice—I used to, so I know—it is, like, impossible.  You 
 
 12. See supra Part II.A.1. 
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can’t do that.  Because you get the instructions from the client on 
the day which is the last day of your time limit, of the one-month 
reply or other.  Yes, but it’s not always the case.  And you can 
anticipate some of that.  Of course, you need to put some system in 
place in your company, in your patent department, or in the firm. 
You have complete application papers on day one.  You do not 
pay the fees.  Then you’ll have to worry about it.  Of course, if you 
have to advance money for the client, maybe it’s a little bit unsure. 
You do not file incomplete declarations, for example, for the 
right to file, the right to claim priority, or the inventorship 
declaration for the U.S.  You make sure that one is signed properly.  
It will go through the international phase into the U.S.  And the 
others in many other countries. 
You ensure that you have at least one qualifying applicant 
signing on day one.  That’s an effect of reform.  You no longer 
need to have all your applicants sign the application at any point in 
time in the entire international phase unless you want to file a 
withdrawal.  If you withdraw, say, the application, you must get 
everyone to sign the notice of withdrawal or the power of attorney.  
Then it’s another complication.  But to get your filing date and not 
get an invitation to comply with missing requirements, you just 
need one applicant who qualifies to sign. 
Papers should be reasonably well formatted.  Use A4 size, not 
letter size or legal size; we see less of those, nowadays.  But that’s a 
very simple thing to do.  It can avoid some of the minor 
inconveniences.  And do not overlook drawings.  This is still one of 
the major problems that we see, both in paper filings and 
electronic filings. 
Now, anticipate timing for critical decisions.  When you are 
working in a corporate patent department or in a law firm, you 
have to deal with the PCT process, of course, and then with what 
you have to do either in terms of workflow and getting 
management decisions.  That’s about continuing with the 
application or not, or having budget cuts for this area.  And if it’s a 
client, when do you get to see the client?  When can you ask the 
client and get an answer so you can align the times when you need 
to make these decisions to the PCT time limits as much as possible?  
And, really, you only have two events in the PCT to be worried 
about.  That’s filing PCT or not at twelve months; and at thirty 
months you enter national phase or you don’t, and where you 
enter.  Everything else should be managed in the back of the scene.  
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You shouldn’t need to involve the agent or the client or the 
company management for each and every piece of paper that 
comes with each and every invitation. 
An exception: You may have two other critical events.  
Publication or not.  That is the most critical other event, because it 
has many more effects outside of just the PCT process.  And 
Chapter II.  You heard this morning that there are less and less 
Chapter II demands being filed.13  But there are still some, and 
maybe because there are so few left, the reasons why they should be 
filed requires more thinking today than it did two years ago. 
This really shows that if you have to be careful about certain 
events, they are really limited to two and sometimes one or two 
others.  And in these two cases, usually you would never have the 
two additional ones together, because if you don’t let the 
application be published, then you don’t have to worry about the 
Chapter II demand. 
So that was all I wanted to say.  Once again, it was just raising 
issues, not finding the answers.  And I’ll let my colleagues and 
counterparts offer their suggestions on these and other matters. 
2. Practitioner Perspective: Philip Goldman† and Thomas Berry††  
Philip Goldman: 
First of all, I will start by saying that on behalf of Fredrikson, 
who is sponsoring this event today, welcome to everyone.  And 
thank you to Ken and the rest for putting this together. . . . 
Tom Berry, from Medtronic, and I are going to play tag team a 
little bit on our perspectives of various strategies and tips.  We will 
start by talking about a couple things.  First of all, just the in-house 
and outside counsel perspectives, and then some practice tips and 
some practicalities.  So I’ll turn it over to Tom to start with the in-
house perspective. 
Thomas Berry: 
Thanks Phil.  Good afternoon.  I thank you for inviting me to 
speak here today. 
The inside law firm model for your client is going to vary, 
obviously, by business.  And since we’re in the medical device and 
medical industry business I’ll talk about the topic from that 
 
       13. See supra Part II.B.2. 
       †  Fredrikson & Byron, P.A., Minneapolis. 
       †† Medtronic, Inc., Minneapolis. 
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perspective.  One of the things you are going to want to do when 
you’re looking at supporting your business is your understanding of 
your business’s needs and the urgency of those needs.  For 
Medtronic, what that means is early filing dates and early issuance 
dates.  The medical device industry is a very litigious industry.  
Everyone seems to know that.  There is very little licensing except 
for, perhaps, the settlement of litigation.  Accordingly, on the 
device side of the business, we have to be careful to file a regular 
non-provisional patent application and then, if it is foreign-file, 
we’ll go through the PCT almost exclusively.  We probably file 
internationally 40% of our first-filed U.S. cases. 
On the research and development side of the business, we’re 
focused a lot more in the area of biologics, chemical compounds, 
which we almost always try to obtain a provisional U.S. patent for 
and then file PCT.  If you go internationally, you get a twenty-one 
year term, which for a patent on a molecule of protein is usually a 
lot more important because the research disclosed is far more 
perspective than the advanced development disclosures obtained 
for the device side of our business. 
What I like about the PCT is—and this has been discussed 
several times today—it’s consistent, it’s transparent, and it’s easy to 
do.  If there is turnover among your in-house staff, the new people 
can pick up the files and they’d know how to handle a PCT case.  
As a result of these practices, we rarely file Chapter II any more, 
except if there is something that we want to challenge or clean up. 
This is different from prior practice, as you would always file 
Chapter II to obtain the benefit of keeping your options open for 
the thirty months.  As in-house counsel, I’m always interested in 
keeping my options open as long as possible. 
Thomas Berry: 
First of all I’m also going to mention that just as an aside, I 
don’t think there’s any chance for harmonization until we can 
agree with the Europeans on how to spell harmonization.  I cannot 
imagine reconciling two patent systems until we can agree on the 
word. 
Putting that aside.  I will provide a bit of the outside counsel 
perspective and actually a little bit of a transitional perspective, 
because for many years I was in Ted’s spot at 3M.  I was there while 
I attended law school at William Mitchell, spent about eleven years 
there, and then moved over to the firm.  So this functions to 
balance my perspective I think.  I’ve seen the progression of both 
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in-house and outside counsel, and I’ve also seen the growth of the 
PCT back when Harry was in the patent office and I was at 3M.  I 
remember back in the old, old days, there was no PCT; there was 
foreign filing, and it was something you started about a month 
before your twelve months was up.  You had to copy all these 
things, usually with carbon paper, and you had to sit there at the 
IBM Selectric and write all these letters to the associates and get 
them out the door at about eleven months.  You just kind of got 
used to that process, and I remember they marched us all down the 
hall and we had a presentation on this new thing called the PCT.  I 
remember thinking it was kind of a fad.  I’m not an early adopter 
of those kinds of things, so I kept plugging away with my old ways of 
doing things until almost everyone else tested the waters.  And then 
I got into it.  I think I’m kind of like that still.  I’m trying to 
reconcile the in-house practices that I learned there with the way 
the PCT has evolved.  I remember when we were there, I think even 
before Ted, we probably got rid of all these back when Dale had his 
scrappy day and we were all encouraged to throw out all our old 
stuff.  But we used to have a three-ring binder on foreign filing 
practice.  And in there was a tab for every country and it would tell 
you what countries had absolute novelty and so forth.  There was a 
primer at the beginning, I think, that Don G—— in all likelihood 
wrote.  They gave tips for writing applications with foreign filing in 
mind.  I’ve kept a lot of those tips and tried to apply them, but we’ll 
get to those in a second.  I also think another goal of the outside 
counsel is one of understanding the whole process and then 
adapting it to the unique circumstances of the in-house counsel or 
the client, whatever they may be.  When we handle PCT practice, 
it’s very different if we’re doing one on behalf of Medtronic versus 
one on behalf of a person when it is going to be their one and only 
PCT application.  In the latter situation, there is typically no in-
house counsel, and we do it all.  We make the recommendations 
and we suggest what Chapter II might be.  But the person typically 
has no idea whether they should do it or not, so they will rely 
heavily on our recommendation.  So I think it’s been an interesting 
process to see unfold.  Looking into the future; if the PCT changes 
as much in the next twenty years as I’ve seen it from the day I 
thought it was a fad, I think it will be a tremendous system.  I think 
it will have lots of potential. 
Practice tips.  I think it might be alright if we can bounce 
around a little bit here.  Some of the basics that I remember are 
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just simple things like the length of the application, and that the 
translations costs are enormous but if you have a twenty-page 
application, it’s going to cost half as much as a forty-page one.  So, 
if you can be concise and you can leverage applications and 
translations, if you happen to be filing in Mexico and already have 
a Spanish translation, think about that and use it when you get all 
the way through Europe and enter Spain.  There are a lot of big 
and little ways in which you can try to conserve costs.  The units is 
another example.  It’s easy to think they will file in non-metric 
units, not realizing that somewhere down the road somebody is 
going to have to pay time and attention and dollars to converting 
those to metric units. 
So, there are a lot of ways.  I suppose on the length of the 
application, I liked all of Ted’s suggestions, they actually were 
things where . . . he wasn’t afraid to say what the PCT ought to do.  
I think one of them that deserves emphasis is that there’s really no 
reason why we have to write a sixty-page application if forty pages of 
it are from somewhere else.  We’re building on an old technology 
or we’re combining the old parts of whatever it might be, yet 
there’s no opening to incorporate by reference or to rely on other 
things that have already been done . . . we have to pile it all on 
there.  So, there would seem to be a lot of ways where the system 
itself plus our practice, down to even our simple day-to-day 
practices, would facilitate the process itself and conserve costs. 
Another thought on translations, and then I’ll turn it over.  I 
hammer the guys from Fredrikson all the time on this issue, and it 
is getting away from long, drawn out, convoluted patents, these 
kind of things, where the here and the fore, said second 
appendage, releasably, slidably, whatever it is.  And if you’ve had 
the chance—and maybe you should take the chance—to take one 
of your applications, get it translated wherever it’s going to be 
translated, and then take a snippet of it, and putting the U.S. 
version that it came from aside, have it retranslated into English 
again and then compare the two.  It’s like night and day.  
Whenever I write, I try to think of that poor person who has an 
overnight period to work on this and who is going to try to take this 
long, cumbersome, arcane language and convert it into Japanese 
and in a way that we’re not going to have to come back and try to 
rectify errors and so forth.  I think we can mitigate and even 
prevent a lot of those errors just by adjusting the way we think 
about it from day one. 
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Translations costs are awful.  Keeping the length down 
certainly is something you really want to try to do.  In terms of the 
translation, in terms of the accuracy or the errors, you really do 
want to try to write very, very simply.  The audience for a patent is 
not the inventor; he can look at it and say what great thing he’s 
invented.  It’s for the jury and the judge.  They’ve got to be able to 
do this.  And if you write for those people, then the person who is 
going to do a translation is automatically going to get a document 
that is presented more simply and will be easier to translate and will 
be more accurate. 
The overall length—one thing to think about, depending on 
what your invention is: you don’t pay by the claim to PCT, you pay 
for the page, and so you might take a strategy where you’ll stack up 
a good number of claims in a PCT case—you’re dealing with unity, 
not restriction practice.  You can survive that when you get back 
into the U.S. national phase.  But then you can make a pivot later.  
Again, keeping your options open on what you want to do in the 
U.S. is important, given the fee structure is that you don’t pay until 
you enter the national stage.  So, that’s something to think about. 
Philip Goldman: 
And that goes to the second point.  As if you’ve seen the 
coming wave of changes in the patent office, having to do with 
continuation practice and number of claims and so forth, it’s going 
to be mind-boggling to just figure out how to deal with that—let 
alone how to deal with the ripple effect back to your PCT practice.  
If you’re going to have to pay an enormous amount for your U.S. 
claims and will be very strictly limited on how many continuations, I 
know that the patent office recognizes that there is going to be a 
cause and effect and everyone else is going to think, well I’ll do this 
or I’ll do that in the PCT and so forth, so there’s this kind of 
moving, a stuttering kind of movement towards some sort of 
agreement, but basically it’s going to have a profound change on 
both our practice in the U.S., but also by virtue of the PCT 
application that gets us there.  And how that’s going to all unfold, I 
don’t know. 
Thomas Berry: 
One of the other things they’re talking about for change, 
obviously, is going to a first-to-file system.  And then on the inside, 
we’re always concerned with budgets.  One of the reasons we don’t 
file 40% of our patents outside the U.S. is a budgetary reasons.  
Now, in all of our businesses, we generally have some sort of 
76
William Mitchell Law Review, Vol. 32, Iss. 4 [2006], Art. 8
http://open.mitchellhamline.edu/wmlr/vol32/iss4/8
13PCTTRANSCRIPT.DOC 6/5/2006  8:33:09 AM 
2006] 2006 PCT SYMPOSIUM 1679 
backlog of both inventions to be reviewed, to be pursued or not 
pursued, and things to be filed, things we prepare.  If you go to the 
first-to-file system, you can’t have much of a backlog any more.  So, 
in this current budgetary planning cycle that I’m in right now, I’m 
already increasing my filings, which may mean I may have to 
reduce my old U.S. filings to take out that money.  So keep that in 
mind as you watch those changes progress.  As near as I can tell, 
the first-to-file system will ultimately happen.  It’s just a matter of 
when it gets through Congress. 
Let me just make one other point.  People have talked quite a 
bit about some of these other things—such as a choice of searching 
authority and so forth.  I’ll just mention one other thing that I 
learned just this morning.  Tom had mentioned the value of 
examiner interviews in the U.S. and does that translate into PCT, 
and Jay confirms that it does.  Examiner interviews are an option in 
the PCT.  In fact, they are required if by phone, and optional or 
discretionary if in person.  So I think we . . . I never would have 
thought of actually using these.  I use it all the time in U.S. cases, 
but never would have thought of using it in the PCT case as well. 
Philip Goldman: 
Just one last thing on filing, we hardly ever go PCT first.  The 
first thing you’ve got to remember is to get a foreign filing license, 
and I just don’t want to deal with that.  What I really don’t like 
about it, though, is delayed U.S. prosecution.  If you use the U.S. as 
the preliminary examining authority or the searching authority, 
they’ll take your application out of sequence.  But I want a faster 
U.S. issuance date, which is usually why we don’t use the U.S. as a 
preliminary examining authority.  The one exception we’re playing 
around with now is where you have a medical procedure invention 
along with your medical device.  Because those claims are 
patentable in Europe; I can file that in the U.S. now, get my foreign 
filing license, and then take those claims out and file the advice 
claims over in the PCT side.  This allows me to have as many claims 
as I want and then make the pivot on the U.S. side when I come 
back in the national phase. 
The last slide.  Maximizing with potential of the PCT versus, in 
effect, just using it as a holding pattern.  I think this goes back to 
what Ted said as well, which, in my mind, is that maximizing your 
use of it and the flexibility of it and so forth can be difficult.  A 
useful analogy I came up with this week is buying consumer 
electronics.  When I buy electrical equipment, electronics, cameras 
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and things, I always go for the best and newest model with all the 
features and gadgets and so forth, but inevitably I hit the record 
button and that’s all I ever do.  And to me the PCT is kind of like 
that.  There’s so much potential in there and all I ever do is file it.  
Most of the time I file it here and I come out thirty or whatever 
months later, and that’s how I use it.  I know there’s a lot of 
potential there.  I have a sense of when and how to use it, but it’s a 
difficult thing.  To me it’s just like buying fancy electronics and 
only using the simplest mode. 
Thomas Berry: 
I think we do pretty much the same thing.  Medtronic’s 
business is only about 20% revenue outside the U.S.  We’ve got a 
number of patents across Europe and many other countries.  We 
do very little litigation there.  And as I said before, we do very little 
licensing.  But one thing we do want to do—keep in mind I’m on 
the inside—is that if you’re a multinational company and you’re on 
the inside, all of your subsidiaries are set up as subsidiary 
agreements.  And you use those agreements to expatriate funds 
back to the U.S. parent corporation.  And you do that on the basis 
of IP.  So you need to have a base amount of intellectual property 
in these countries to support your subsidiary arrangements. 
And the last two, I hate to keep picking on Ted here, but I will.  
Maximizing the potential plays in a little bit to the last two points.  
The first has to do, in my mind, with accommodating differences in 
attorney and agent styles and perspectives over time.  It is a long 
process.  I mean, it’s up to five years between writing your first 
application and going into the regional phase of lodging the 
application in Europe and so forth.  And people change.  Like the 
people handling the application.  I might not ever see it after filing 
the first application.  Somebody in-house in Medtronic picks it up 
and runs with it.  In my case, I left 3M in ’92 and Ted was there by 
’95.  He was probably handling things I had put in place in ’92.  
Yet, if there is some strategy that I had in mind, he probably didn’t 
know it unless I left a pretty good memo to the file, which you’re 
inclined not to do. 
I am not sure what to do or what to say about that sort of 
problem, but to me it’s a reason to kind of put it in there and come 
out at thirty months.  To do anything more has to be a very 
intentional effort, as opposed to kind of an institutional continuum 
that these things are often on. 
The last thing I’ll mention is that I think the concern about 
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harmonization—and this goes, I guess, to harmonization with an 
“s” or a “z.”  It’s the binding effect and what we do or say or don’t 
do or say in the PCT.  It’s great to have the options for 
amendments.  You can make a lot of progress, especially if it’s a 
European search and it’s a European application and so forth, but 
other than that, I think our general tendency—for whatever 
reasons—is to say as little as possible until you are really in there 
with an examiner that’s going to be handling and granting you a 
patent or not.  Until we have some sort of a reciprocity or binding 
effect, those looming fears and concerns, or what you’re saying on 
one side of the ocean having an impact some day being used 
against you on the other side, especially when it’s different people 
at different stages and so forth, can be very unwieldy. 
Philip Goldman: 
We experience the same thing.  We have changes in staff.  
People will be promoted, move to different businesses, that kind of 
thing.  And having a very simple, common system that’s transparent 
is a lot better for us.  The thirty months is also good in terms of 
keeping your options open to give you some pivots on recent 
changes in U.S. law.  Sometimes, some sort of precedent will come 
down and make you rethink how you want to take the direction of 
the claims, and, if you’ve got a whole collection that are in a thirty-
month window, you may have options with all of those claims. 
3. Practitioner Perspective: Heinz Goddar† 
Ladies and gentlemen, we are colleagues.  We are friends for 
about fifteen minutes to talk about something that might first 
sound a little bit strange to you, because I wish to talk about 
strategies of using PCT by small and medium-sized enterprises and 
universities in Germany.  Why do I wish to talk about this?  First, we 
have heard this morning from Jay already that a major number of 
clients are not the giants.  They are small companies, even in the 
United States, if they use PCT.  Typically the same applies for the 
clients of a German IP firm or a European IP firm, like my firm.  I 
work in Munich in a larger IP firm, I would say; probably one of the 
largest ones in Germany, even.  Our typical clients are, as far as 
they are domestic clients, small and medium-sized enterprises and 
recently—since two or three years, I will briefly refer to that—
universities.  Why is that so?  Big German companies may be 
 
       †  Boehmert & Boehmert, Munich, Germany. 
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different from companies in the United States and certainly 
different from Japan.  They don’t make use of outside counsel.  
They have huge in–house legal departments.  If a company has 
more than 1000 employees, I would say, usually they would have an 
in-house patent department, which essentially is able to draw up all 
patent applications, etc.  They make use of the services of firms like 
from other European colleagues who will speak later or my firm 
just, I think, in case of conflicts.  When it comes to invalidation, 
there is opposition litigation.  Why?  Not because we are better, but 
they have to blame somebody later on if the case is lost.  Nobody 
wishes to be responsible for this. 
I think there is something to learn also for smaller companies 
here, for pre-practitioners here, for the students, but also for even 
big corporations.  I wish to share a little bit of my personal 
experience that I have with my clients and particularly why my 
clients take certain steps in the wonderful PCT world and don’t 
take other steps.  They use, as you will see at the end of today, PCT 
just in order to buy time. 
First of all, what happens if a smaller German company or the 
university wishes to protect a certain invention?  The first step is 
generally, and they always will recommend this, to file a national 
application at the German Patent and Trademark Office with an 
immediate request for full examination.  The reason is very simple.  
To conduct such a patent application, to have it prepared by a 
patent attorney, and to file it, you will have a total cost of about 
3000 to 5000 euros.  This is a very conservative figure; it’s based on 
broad experience, I can tell you.  So, 3000 to 5000 euros to prepare 
the application, to pay the official fees, to pay the expense of a 
patent attorney, and to file the whole thing.  If you have done this, 
you get an accelerated examination procedure, which means a 
phone call with the responsible examiner, which is enough.  You 
get this within ten months, guaranteed, after the filing date of your 
first examination report.  File it in your own language (German).  
You get a qualified examination report.  And you have spent, keep 
this in mind, 3000 to 5000 euros. 
If you would do something else, if you would go a way which 
colleagues in other countries sometimes recommend, maybe to do 
external searches—of course, I would recommend that my clients 
do internal searches—in a library or on the Internet, but this would 
involve a higher cost.  If you go to an outside search plus 
evaluation, you have already spent about 4000 euros just before you 
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make a decision whether to file.  This money is enough to 
guarantee a filing date in Germany and to draft the application and 
to pay the official fees.  And you are now, ten months later, in a 
much better position, because if you don’t go ahead with this 
invention and the protection thereof, you have spent about the 
same amount of money you would have paid for an external search 
plus evaluation anyway.  But if you go ahead, you already have a 
filing date, which is ten months earlier and you can’t lose that time 
any more because some competitor might have had the same 
brilliant idea as you, have particularly if you work in the highly 
competitive field of technology. 
So, this is the way they go.  And now you have to go into the 
decision, of course, ten months after which you’re deciding 
whether to file abroad or not. 
All of my clients, I would say, go through PCT.  Even if it is a 
small- or medium-sized enterprise, or whether it is a university.  It 
doesn’t matter.  They do this for a simple reason: it doesn’t cost 
them at that stage more than the amount of money which I have 
mentioned above, that is, about 4000 euros.  Hereby, a first priority 
is created. This procedure has always been followed in Germany, 
since we have a first filing tradition as long as Germany has had a 
patent system.  Of course, there are several times when further 
applications of improvements are filed.  Applications are filed at a 
very early stage of development of an invention.  So, very often you 
end up towards the end of the Paris Convention one year, that you 
have several applications which you easily can, at least with a rather 
generous consideration of whether the invention is uniform or not.  
You can put it to one application and save at least at that stage a lot 
of money. 
So, maybe 4000 euros and—this figure is important later on—
4000 to 5000 euros and you are now in PCT.  I would say based on 
my experience nowadays in the globalizing economy, out of about 
ten applications we may file for a certain domestic client in 
Germany per year, maybe about five to seven go into PCT.  The 
other three or four are dead by that time; not so much even 
because the first examination report of the patent office in 
Germany may show that there is no hope for the application 
because it’s not novel, not inventive, or whatever, but because it has 
commercially died.  Look at pharmaceuticals.  They may be 
beautiful candidates to start with, ones that you file immediately, 
but may later be proven as ineffective or toxic—I don’t know 
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what—and at least you don’t wish to go ahead with it anymore.  So, 
maybe five to seven out of ten go into PCT. 
Now, what happens thereafter?  Certainly not requests for 
Chapter II or anything like that.  My clients don’t even react usually 
to the search report.  The costs are kept as low as possible.  The 
whole procedure has only one purpose: to shift the decision time 
for going into international filings, which are very expensive, from 
the twelve months of the Paris Convention to the thirty months or 
even thirty-one months at the EPO, but usually other 
considerations play a role, of course.  So thirty months after prior, 
if you are under PCT. 
Now, what is to invest now?  I would like to draw your attention 
a little back to the cost-saving effect of PCT, even if you don’t make 
use of this “funneling” effect.  By this effect I mean—you may go 
from the ten applications originally to only about two applications 
out of ten, when you come to the nationalization after the 
international phase of PCT.  But even if you don’t do this, look at 
the cost.  You now have to file in all the countries that you have 
chosen under PCT and which you finally wish to use for patent 
protection afterwards—and that will cost you per country, I would 
say, 4000 to 5000 euros.  This is an average figure internationally 
under PCT.  It might be a little bit more expensive in the United 
States, but I think if you look at five to ten countries or so, you 
come to a cost of 4000 to 5000 per country.  And if this is ten 
countries, which is not atypical, you have invested a cost of 40,000 
to 50,000 euros.  These 40,000 to 50,000 euros, and I think not only 
our smaller companies and clients in Germany know this, but this is 
the reason why big companies in Japan, big clients of mine in the 
United States—some of them manufacturing semiconductors on 
the west coast, for example—go only through PCT.  I think they 
have to file these applications in the ten countries at 40,000 to 
50,000 euros in total twelve months after your first filing date or, in 
the case of PCT, eighteen months later.  The bank interest, which 
you save on 40,000 to 50,000 euros by shifting the investment date 
by eighteen months, is about 7500 euros on a very conservative 
basis. 
Now, you have saved the interest of 7500 euros just by making 
the decision to go PCT, even if you would have known exactly 
already after one year where to go.  But now you shifted; 7500 
euros saved.  That means a total cost savings, even if you don’t look 
at the additional advantage of narrowing down the number of cases 
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which you file, of 3000 per application.  This is just saved money 
which you can put into your pocket, and if a company files 500 or 
1000 applications of this type per year—which happens very often 
as you all know—this is a real considerable savings.  I mean, this is a 
savings which takes place even, once again, without this narrowing 
down effect where you go to a smaller number of cases because 
certain months after you start you are much wiser than twelve 
months after you start as to whether the invention will fly and 
whether it is worthwhile to prosecute.  You just have saved this 
money. 
I would like to stress, however—and I was very much surprised 
when I saw this morning the example from 3M—that very little use 
is made obviously of this narrowing down effect.  I am personally of 
the opinion that one of the alternatives which you have described 
happens here which I observe also with my clients very often, that 
not a reasonable reconsideration of the filing strategy at that point 
takes place.  I think that to put a few people, to hire two or three 
people—I heard from one client that “our machine is not big 
enough to make that decision again after thirty months” (West 
coast, northern part we are talking about)—I think it would be very 
wise to invest in two or three people there, who before that takes 
place, before the thirty months expire, really say, “Okay, no we 
don’t do this now” and other things.  So the various stages give a lot 
of flexibility.  But even if you don’t do all of this, you have saved 
3000 Euro per application. 
Now, let’s discuss how German universities and small 
enterprises structure their filing strategy.  They go to PCT.  They do 
this as a rule, because universities have no chance to commercialize 
their inventions in foreign countries themselves by manufacturing 
and exporting.  It normally doesn’t happen.  But they have, if they 
wish to make use of it, outside of Germany, they have to go into 
licensing or some kind of collaboration.  Very typical.  It’s useless 
for a German manufacturer of bicycles to have an application and a 
patent later on in Brazil if they don’t find a corporation partner 
who is willing to open the market to manufacturing the thing 
there.  So they rely on the filing date of the German application 
and try to find a collaboration partner.  If they don’t find it, after 
thirty months or just before the thirty months, usually on the last 
day of course, thirty months, the small and medium-sized 
enterprises find in a few foreign countries—I don’t see more than 
you’ve got five countries maybe outside of Germany, that’s it–where 
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they finally nationalize.  Not more.  But still, PCT has paid already.  
We have seen this.  They have their 3000 euros in their pocket, but 
now they go into five countries only.  One country finances itself 
already by the saved bank interest.  So, that’s also a nice 
consideration here. 
The universities in Germany.  I know particularly well a central 
technology licensing office of the Berlin universities because they 
are the central one for all Berlin-based research institutes and their 
universities.  Three years ago, the law changed in Germany.  We 
don’t have a professor’s privilege any more.  The professors don’t 
own their inventions.  They must give it to the university.  The 
university takes it, must file patent applications, and commercialize.  
If the university, thirty months after the original filing date, has not 
found a licensee collaboration partner, they quickly give the 
pending PCT application back to the inventor or inventors.  That is 
necessary by German law; they are required to do so.  They cannot 
just drop the application.  They give it back to the inventors and 
say, “good luck.”  And then the inventors can invest the 40,000 or 
50,000 Euro if they like for foreign filings, but there is so little 
hope—and I always tell this to my clients also in the university 
field—there is so little hope, if after thirty months of very diligent 
and intense efforts to find a licensee, you have not found 
somebody, that you find someone in the next year.  That is not 
worth the effort.  Under special circumstances, if you are already in 
promising negotiations with some licensees somewhere in another 
country, this might be a different situation.  But otherwise, the only 
person on earth who doesn’t believe this is the inventor.  He 
believes that next month the big miracle will take place.  So what 
they do is they give it back to the inventors.  No German university 
goes further than PCT international phase.  The nationalization 
later on has to be paid by the licensee somewhere or another 
collaboration partner, otherwise—at least in my personal opinion 
of experience.  Maybe it is different in other cases.  In other cases, 
they don’t keep these applications alive themselves anymore. 
Last, but not least, maybe introducing by this a little bit to the 
next scene, we have developments and perspectives, not only in 
Europe but particularly in Asia.  For a strange reason, for my clients 
at least, it is a big, big burden that they have always to make the 
most of the PCT application.  It’s a wonderful channel to get 
cheaply into foreign countries that they can’t designate, in any 
manner whatsoever, like Taiwan.  Because when you look into 
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China and you wish to have patent applications in China—we will 
talk about this later on, maybe a little more—it is not just one 
national market.  The Taiwanese market and the Chinese market 
are so closely interrelated that if you don’t have patent protection 
in Taiwan for the mother company of a Chinese unit in Taiwan, it 
is so easy to outsource or to shift the technology into Taiwan where 
you may not have patent protection or the other way around.  So 
always, if you are looking at China, you must make an early 
application in Taiwan, already with additional cost, of course.  If 
that could be included into the PCT, that would be a miracle, of 
course.  And I think there would be a way if the PCT office spins off 
and is no longer under WIPO, because refused only that Taiwan—
for good reasons, I think, from their viewpoint—becomes a 
member of the WIPO.  But if the PCT office would work as an 
agency for WIPO for their outsourced intellectual property work, 
this would be a different story.  China (the People’s Republic of 
China) allows Taiwan and the People’s Republic of China to 
coexist in international organizations like WTO, under the name—
of course—of “Chinese Taipei.”  Not only in WTO is this is the case, 
but even, since last summer, we have, in LES International, a 
chapter “LES Chinese Taipei” with the approval of LES China and, 
indirectly, the Chinese government.  I think if the PCT office would 
have a second “head,” acting as WIPO agency, that might be a good 
idea. 
B. Topic 5: Looking East, Looking West: Optimizing the PCT in Europe 
and Asia 
  1.  Asian Perspective: Xu Yiping† 
Today the Organizer of this Symposium wants me to introduce 
PCT in China.  I greatly appreciate your attention.  I’ll give you 
some information about the PCT system in China. 
My presentation will focus on three main points.  The first one 
is the history of patent system in China; the second one is the 
present status of PCT in China; and the last one is the 
characteristics of PCT in China. 
Actually, the Chinese patent system is a very young patent 
 
       †  Chairman, Board of Directors Shanghai Patent & Trademark Law Office, 
LLC. 
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system.  As you know, the Chinese Patent Law was issued by the 
National People’s Congress in 1984.  And then this law was into 
force on April 1, 1985, so that we have a very young patent system. 
But this patent system running in China is very successful.  You 
may find more and more new applications filed to the Chinese 
Patent Office year after year. 
For the PCT system, I think it is booming in China now.  
Actually, China’s government signed agreement with WIPO to join 
the PCT in 1993.  PCT filing started in China since January 1, 1994. 
According to the agreement signed with WIPO, the Chinese 
Patent Office is a PCT receiving office, a search authority, and a 
preliminary examination office.  But at that time, we hadn’t 
amended our Chinese Patent Law yet.  Chinese Patent Law was first 
amended in 1992.  The second amendment was in 2000 and so we 
add some contents relating to PCT in our new amendment in 2000.  
This new amendment of the patent law went into force in July 1, 
2001.  It added to Article 20 of the Patent Law and Chapter 10 of 
Implementing Regulations of the Patent Law. 
Of course, for the PCT case examination, we had to amend 
our patent examination guideline at the same time.  So in the new 
guideline we added Part 3 for PCT Chinese national phase filing. 
Since then, Chinese applicants have filed more and more PCT 
cases.  According to the report from WIPO, China has a ranking of 
number ten among PCT member countries for filing PCT 
international applications.  It also ranks number two among the 
developing member countries in filing PCT international 
applications. 
So, as you see, China still does not have the larger 
international filing cases as in United States, Japan, and the 
European countries.  PCT international applications filed by 
Chinese applicants at the Chinese Patent Office as a receiving 
office increased from 103 cases in 1994 to 2438 cases in 2005.  You 
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China is a very big country.  Here I list the top ten provinces 
for international applications of the year 2004.  You may find most 
provinces are located in the eastern part of China, the more 
developed area in China. 
 
Top Ten Provinces for International Applications of Year 2004 
 
 
Then I also give you some information about the percentage 
of technology occupation in PCT international patent filing.  
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The subject matter of PCT international filings are mostly in 
telecommunications, optics, materials, electronics, mechanics, 
pharmaceuticals, and chemistry. 
I don’t think the 2438 PCT international filings made last year 
is a big number; but I believe that the increases made last year show 
more international filing from China will be happening in the next 
five years. 
Then I will discuss a little bit about PCT Chinese national 
phase applications.  Because China is a very big country and a very 
huge market, all of the companies, not only domestic companies 
but also foreign companies—all pay more attention to put the 
goods into such an attractive market.  Of course, they consider 
intellectual property protection in China.  According to the report 
from the Chinese Patent Office, the total cases received by the 
Chinese Patent Office was 476,264 last year.  Eighty percent of the 
total cases are domestic.  About twenty percent of the total cases are 
from abroad.  You may find that 40,761 cases filing used the PCT 
into Chinese phase.  It means that nearly half of the foreign cases 
use PCT into Chinese phase. 
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You can see that the PCT Chinese national phase cases 
increased very quickly during 2002-2005. 
 
 
PCT Chinese National Phase Applications from 2002 to 2005 
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applications in China (2001-2003). 















You may find the cases using the PCT into Chinese phase from 
the United States is number one and Japan is number two, and 
then some European countries and Asian countries like Korea. 
Also here I list the top five foreign companies in the years of 
2001-2003 in filing Chinese national phase applications.  You find 
Philips, Matsushita, Siemens, Nokia, and Sony file to most PCT into 
Chinese national phase applications. 
 
Top Five Foreign Corporations in 2001-2003 in Filing Chinese 









This is the basic situation of the PCT in China.  I would guess 
that in the coming three to five years quite a lot of the foreign 
leading companies will use PCT into Chinese national phase.  I 
believe that the more PCT cases that enter Chinese national phase, 
the more and more business these companies will do in China. 
Next topic: I would like to discuss and compare the Chinese 







US JP DE NL Other FR GB SE CH KR FI AU IT CA DK
 Nation Applicant Number
Netherlands Royal Philips Electronics 2355
Japan Matsushita Electric Industrial Co., Ltd. 1750
Germany Siemens AG 1071
Finland Nokia Corporation 1008
Japan Sony Corporation 962
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foreign applicants are very interested in characteristics of the 
Chinese PCT system.  Actually, we have a lot of question dealing 
with this field. 
First of all, according to the Chinese Patent Law and its 
Regulations, the Chinese Patent Office is a receiving office and an 
international search authority and a preliminary examination 
authority for PCT international applications.  So, I think this is the 
reason why there are a lot of Chinese companies that could use this 
system to file more PCT cases every year. 
Either Chinese or English versions of the application can be 
used for international application received by the Chinese 
Receiving Office.  Because China uses the early publication and 
deferred examination system for examination, so if Chinese 
language is used and later on entered into the Chinese national 
phase, the statutory protection for the pending year can be traced 
back to the date of international publication.  According to the 
Chinese Patent Law, the applicant can enjoy the provisional 
protection during this pending period in China.  So that for the 
PCT international case, if an applicant uses the Chinese version for 
filing in the international phase, they can enjoy the provisional 
protection. 
The second, for the Chinese national phase applications, 
demand of Chapter II is no longer needed.  So all international 
applications can enter China in thirty months. 
Here I have to mention that in China an additional two-month 
grace period can be used by paying extra fees.  So, if you pay the 
extra fee you can enjoy thirty-two months.  But there is no 
extension at all. 
Another thing I have to mention: entering China before the 
eighteen-month international publication is applicable, but no 
official filing receipt will be issued until the international 
publication is available.  Because in this case the Chinese Patent 
Office hasn’t got any information of this case from WIPO PCT 
department.  So until the international publication reached the 
Chinese Patent Office, the applicant would not get the formal 
official filing receipts. 
Also here I mention that the national phase for either 
invention application or utility model application is available for 
international applications filed after January 1, 2004. 
Here I also have to mention, sometimes the case deals with two 
or more subject matters during the international stage; the search 
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authority just searches the main subject matter.  Unsearched parts 
of the international application can also enter the Chinese national 
phase.  Of course, applicants have to pay the restoration fee for 
unity of the invention application. 
Another important thing is the cost for translation.  Actually 
Chinese translation is necessary and must be filed together with the 
application forms (i.e., late filing for Chinese translation of 
specification and claims is not accepted). 
Also here I have to mention that the specification of the 
international publication is the basis of the national phases.  
Official fees and translation fee are charged based on this version, 
based on the international publication version.  The amendment’s 
decrease of claims at the time of entry cannot decrease costs; 
amendments are allowed but should be filed as substitute pages. 
When the PCT case enters into the Chinese national phase, 
bibliographic data of national phase should be precise with those 
in the international publication.  Any amendments should be made 
either in the international stage or after the Chinese national phase 
filing. 
The priority document, assignment document or name change 
certificate, if not provided in the international stage, shall be 
provided in the national phase. 
2. Asian Perspective: Shigeyuki Nagaoka† 
Good afternoon.  I am Shigeyuki Nagaoka, Director of JPAA—
Japan Patent Attorneys Association.  Today, my presentation 
includes three parts.  The first part deals with how Japanese 
applicants use the PCT.  The second part deals with statistics and 
analysis.  And the third part is my proposal to make the PCT more 
user-friendly. 
How do Japanese applicants use the PCT?  In a short answer, 
they use the PCT when it is most cost-effective, or when it is more 
optimal than the Paris Convention for the Protection of 
Intellectual Property.  For example, an applicant will use the PCT 
when the applicant cannot decide in which country the application 
should be filed.  An applicant will also use the PCT when the 
application should be filed in many countries, when there is no 
available time for translation, when the applicant wants to delay fee 
payment, or when the applicant wants to use the ISA (International 
 
       †  Japan Patent Attorneys Association, Tokyo. 
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Search Authority) as a prior art searching agent.  Finding prior art 
before translation is very, very important.  The ISA finds secret 
prior art.  The secret prior art is an application filed before an 
applicant’s application but published after an applicant’s filing 
date.  An applicant does not know that secret prior art exists when 
he or she files a PCT application.  The ISA finds this preceding 
application as a category E prior art. 
An applicant will also use the PCT when patentability of the 
invention seems to be relatively unlikely.  In this case, we expect 
that ISA will find the strong prior art.  Then we will show the prior 
art to the inventor, so that inventor will stop working on his or her 
invention.  A particular ISA has the best prior art information in a 
particular area of technology in the world.  For instance, the Japan 
Patent Office has the best prior art information about 
semiconductor technologies.  So, if the invention relates to 
semiconductors, we use the Japan Patent Office as the ISA. 
The advantage of the PCT is that the PCT is able to rectify 
obvious errors and correct translation errors.  The disadvantage of 
the PCT as compared to the Paris Convention is that the PCT is 
more expensive.  Expense for the international phase is avoided if 
an applicant uses the Paris Convention route. 
U.S. Patent Law section 102(e) states that no prior art effect is 
given to a PCT application if the PCT application is published in 
the Japanese language. 
The written opinion prepared by ISA is confusing because it 
often misleads the applicant.  This is because the written opinion is 
prepared based on different patentability criteria.  Patentability 
criteria of one ISA are different from those of another ISA. 
Statistics and analysis: Japan is now the number two PCT user 
country.  Japan caught up with Germany in 2003 and has become 
the second biggest PCT user.  The number of PCT applications 
filed by Japanese applicants increases every year.  In 2004, more 
than 20,000 PCT applications were filed in Japan.  The top three 
PCT user countries are the United States, Japan, and Germany. 
The JPO (Japanese Patent Office) report indicates that 61,000 
patent applications originating in Japan were filed in the United 
States in 2003.  Among those, PCT applications account for only 
5000 applications.  This means that 56,000 applications were filed 
through the Paris Convention.  Use of the PCT accounts for only 
8%.  What does it mean?  It means that Japanese companies do not 
highly value the advantages of the PCT because they need not 
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designate so many countries.  Further, PCT applications are 
expensive.  Additionally, a PCT application is not given a prior art 
date in the United States. 
Japanese companies do not need written opinions.  
Additionally, the standards of unity of invention are different in the 
United States from Japan. 
When do Japanese applicants appreciate the value of the PCT?  
The applicants value the PCT when they abandon the PCT 
application during the international phase.  In the international 
phase, there is no cost for translation and no expense for 
prosecution.  So the reality is a little ironic, I think.  Many people 
say that the PCT is very good, but the PCT shows its power when 
the applicant gives up the application. 
Now my proposals. 
I think the ISA written opinion practice should be amended so 
that the written opinion is optional.  Some applicants do not want 
to receive the ISA written opinion.  Thus, the ISA written opinion 
should be prepared for the applicant only when the applicant 
wants it.  Written opinion has, at least psychologically, a binding 
effect and it can be a final decision.  Written opinion is prepared 
based on different patentability criteria.  Inventive step criterion of 
one ISA is higher than another ISA.  Also, the definition of the 
prior art is different in many countries.  The PCT examination 
guidelines admit such differences.  Therefore, the written opinions 
often confuse the applicants. 
My second proposal is to amend U.S. patent law section 102(e) 
to avoid the language discrimination.  Some applicants do not use 
the PCT because of section 102(e).  And section 102(e) issues are 
invisible.  An applicant will not know if his or her application or 
patent is used or not used as a prior art reference until a patent is 
issued to his competitor. 
My third proposal is to allow multiple ISA searching.  Prior art 
searching is one of the most attractive features of the PCT.  
Currently, only one ISA performs prior art searching.  If the 
applicant can ask another ISA for a supplemental search, 
predictability of patentability will be improved dramatically. 
My last proposal is to amend the all-inclusive designation 
system.  The all-inclusive designation system takes away a very 
fundamental right of the applicant.  Every applicant should be able 
to decide which country should be designated and which country 
should not be designated.  This right of applicants is taken away by 
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the all-inclusive designation system.  The current all-inclusive 
designation system is not a truly all-inclusive designation.  The 
current system is an all-plus-one designation system.  “One” is your 
own country.  The PCT was originally designed to file patent 
applications in foreign countries.  You need not designate your 
own country. 
The true all-inclusive designation system is designation for all 
the PCT member states, except for an applicant’s own country. 
The current all-inclusive designation system forces the 
applicant to file two applications in his own country.  If a PCT 
application claims priority based on a national application, the 
applicant will have a PCT application and the national application 
for the same invention because a filing date is given to the PCT 
application, even if the PCT application does not enter the national 
phase in each country. 
The PCT permits designation of your own country, but this is 
an exception.  This exception, however, becomes a non-exception 
under the current all-inclusive designation system. 
3. European Perspective: Sandra Pohlman† 
First of all, I want to say thank you that I can be here today on 
behalf of the DFMP in Munich and be part of this distinguished 
group of speakers.  I also find the conference extremely 
interesting—long, and I am tired as well—but interesting.  As you 
might have heard, I actually come from the United States, yet here 
I am speaking about the European perspective.  I started my career 
in the United States and did my legal training here, but have been 
practicing in Europe for the past ten years.  So, this is really part of 
my daily experience and life and the way I think about things.  How 
does this compare with what is going on in the United States?  
What is Europe doing?  What are the good things about what 
Europe is doing?  What are the good things about what the U.S. is 
doing?  The bad things, and so on and so forth. 
I, for one, am very much a proponent of harmonization.  Or at 
least, I also do not think maybe we will have perfect harmonization.  
That may be utopia, but at least it is very encouraging that things 
are proceeding in the right direction.  There are all kinds of 
different initiatives—not just with the PCT.  The tri-lateral efforts, I 
think, were also very interesting.  I work in the biotechnology area 
 
       †  Dörries, Frank-Molnia & Pohlman, Munich. 
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and the tri-lateral paper regarding nuclei-type sequences and 
orphan receptors has really changed the way we practice.  It has 
reduced the number of filings, but it has also caused us to think 
about when we should file—more specifically, the timing of our 
filings.  Many years ago there was a lot of investment and a lot of 
open questions.  People really did not understand what to do with 
these things.  I refer to that paper a lot.  These kinds of projects are 
very helpful.  So, I just want to thank those people who are really 
involved in the harmonization process. 
As a general comment, talking about optimized PCT practice, 
at least for me, an optimized practice does take into account other 
systems.  I often hear people saying, “oh this is the way it is done in 
the U.S.,” and “this is the way it is done in Europe,” or “this is the 
way it’s done in Asia.”  One thing that is very good about this 
conference is that we are much more on a level of trying to 
compare and contrast.  This approach is also part of optimized 
practice.  We should be interested in understanding other systems.  
Of course you, as U.S. attorneys, or someone practicing in Europe, 
you can only really be an expert in one field.  It is not possible to be 
an expert in the patent systems of every country.  But, it is 
important to make an effort to know about this and be interested 
in and open for exposure to other systems. 
Coming from the United States, especially when I think about 
law school and when I was starting to practice in the United States, 
I found that it was very hard to get information about Europe, 
about the PCT, and I hope that this is changing.  I have seen some 
changes in this regard.  Actually, there are law school programs in 
Munich that provide training on globalized patent systems.  This 
global training is really important.  I just wanted to make that 
comment here because this is part of the optimized practice. 
Michael also mentioned the practice of taking one application 
and using it for every country.  One question I would pose is: Why 
not optimize it from the start?  Why not start with the optimized 
kind of application?  Now this is, of course, very difficult because 
actually to get that template you would have to, I think, involve 
practitioners from at least a few jurisdictions; at least the main 
jurisdictions that you care about.  You can have your U.S. attorneys 
draft it but then maybe develop some sort of template where we 
say, no that is actually not so good, or at least you should have this 
other language.  It is not so easy.  What happens with added 
matter?  The EPO is almost crazy about this issue.  Furthermore, 
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sometimes you get examiners that if you do not have the literal 
language, you really have a problem.  As a result, you come into 
these issues when getting into re-writing claims—such as method of 
treatment claims when you want a medical-use claim.  I would think 
that is clearly supported, but you do run into these problems and 
also in the way you write an application. 
Something that I have noticed—or that is often said in Europe 
or at the EPO—about American applications is that they are so 
long.  They really are very long compared to applications from 
other countries.  I understand the rationale for this.  Much the 
length has to do with the development of the U.S. case law.  After 
all, let’s face it, the U.S is still the most important market and you 
want to make sure that it is going to stand up in court. On the 
other hand, maybe you should think about whether more is always 
better.  I am not really sure it is.  I have had experiences trying to 
litigate or interpret something for a client that had very little 
disclosure.  In a way, that was the broader patent because you did 
not say what it meant, you did not say what the certain terms 
meant, things were more open.  So this is another thing to think 
about.  Your applications from the U.S. are huge compared to the 
rest of the world.  Is more really better? 
The main thing I wanted to talk about today, and then I will 
turn it over to Steve, is the EPO and its acting as a PCT authority.  
And also, the role of the EPO as an international search and 
preliminary examination mechanism. 
Now a lot of it has already been said, so I will try to avoid being 
repetitive.  I am going to try just to give you some insight that 
comes from things that the EPO have recently published.  This 
information is hard for you to get in the United States.  Since I 
came all the way over here, I might as well let you know what the 
EPO is saying in the bulletins about how it is doing PCT practice. 
We have seen statistics basically stating that 50% of applicants 
use the EPO to do their searches or preliminary examination.  It is 
pretty obvious that the EPO is playing an extremely important role.  
The way the EPO is doing the PCT is actually quite likely to be 
familiar with this because in fifty percent of the cases that is who is 
handling the PCT search and examination. 
We have seen these numbers before.  I mean in terms of 
applicants, the U.S. is quite dominant.  Actually, with the EPO as a 
receiving office, it is ranked only third.  But again, if you go to the 
statistics, international search and examination, the statistics based 
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on the numbers from 2004, we are up at 50% and the U.S. actually 
goes down quite a bit compared to Europe.  It is a fact that many 
other countries are using the EPO to do the search and the 
preliminary examination.  The country that is probably doing it the 
most is the United States.  There are a lot of advantages to doing 
this.  As was mentioned before, the EPO is basically available to be 
the search authority.  It is available to U.S. applicants but not just to 
U.S. applicants.  This has advantages.  People take advantage of this 
because it often streamlines the EPO procedure.  There are also 
cost benefits to this.  All of this I will touch upon now. 
One thing that happens is that the EPO did limit its 
confidence as an international searching authority just for the 
United States because, at some point, it got to be too much.  It is 
clear from the numbers, and we have heard that this also has to do 
with a lot of volume and work-load problems.  There were some 
restrictions that the EPO came up with.  For example, they will not, 
if there are any claims relating to business methods, process any 
international applications filed after March 1, 2002.  Actually, last 
year there was a decision to extend this further.  Thus, the EPO is 
clearly against business methods.  If you have any claim relating to 
a business method, you cannot have it searched by the EPO. 
There was also a limit on biotechnology, but this no longer 
applies.  It has been phased out.  This limitation has to do with the 
fact that there were so many sequence-type applications.  Now this 
has really been reduced, I think, because the biotech industry has 
changed its practice in this regard, so that restriction has been 
lifted.  There were also similar restrictions to acting as the 
international preliminary examining authority on business 
methods, biotech and telecommunications claims.  But again, the 
only one that was extended in 2005 was applied to business 
methods. 
Another interesting aspect of the EPO is the rationalize 
procedure.  I do not know if any of you have heard of this 
procedure.  Okay, well this actually no longer applies.  It was an 
interim opinion and a substantive examiner was never going to be 
involved.  That was an EPO effort to reduce its workload, because it 
has a huge workload.  You had to ask for a detailed process.  Now 
this step has been phased out, but it has basically spilled over into 
how the EPO is going to act as an examination authority.  Now, of 
course, they are following the enhanced international and 
preliminary examination procedure—not the recognized 
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procedure anymore.  It was already confirmed that the EPO, 
according to the new guidelines under these rules, was basically not 
going to issue a second written opinion.  They are going to 
consider the WO, ISA as the first written opinion. . . .  Thus, if you 
have a negative written opinion and you want to do something 
about it, you basically have to do something about it right away.  
You have to file arguments and convincing evidence and deal with 
the issues otherwise you’re just going to get another negative 
opinion. 
This was also recently made clear by the EPO.  This is 
something that they just published in the guidelines.  The PCT 
guidelines under the new regulations give discretion to the 
examining authorities to allow a second opinion—to grant a 
second opinion—but the EPO has clearly said in the official 
statement, “no basically we are not going to do this, it is up to you 
to change the case and to do so quickly when you file with them.” 
The EPO has also issued a notice about interviews with EPO 
examiners handling the preliminary examination under Chapter II.  
The EPO has essentially said that if a request is timely filed, we will 
grant you one interview by telephone.  This is not a personal 
interview—it is a telephone interview.  We will normally grant this.  
You have to give a written request that you want an interview.  This 
request should be filed as soon as possible, ideally with the 
demand.  You should give a clear indication of what should be 
discussed in the interview.  If you just make a generic request, at 
least according to this notice, your request might not be accepted.  
Or, at least if the request is not very helpful, they will not 
appreciate it.  So you should definitely give a clear indication of 
what you want.  It also says that although second interviews are at 
the discretion of the examiner, very likely it probably will not go 
ahead.  You definitely do not have a right. 
Just thinking about the EPO acting, under the PCT, this was a 
new thing that I want to talk about.  There are a few reasons to use 
the EPO.  One reason is that it will help streamline your procedure 
in the regional phase because, and maybe in other countries as 
well, the EPO is quite influential.  But clearly, if you have a positive 
search, or actually anything, any search, they will not search again.  
They will just use the results over again.  If you have a positive 
search at the EPO, then you can go into the regional phase 
expecting either office action, essentially asking you to clean up the 
application and bring it in condition for grant . . . .  This is one 
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reason we are potentially going to streamline your regional phase. 
Another reason is experience.  The EPO has done a lot of 
applications—you can see it from the numbers.  Compared to the 
other national offices, the EPO has a lot of experience.  It is 
generally said, and I think it is true, that it is a very high quality 
search and preliminary examination.  As we know, actually none of 
us are really doing preliminary examination anymore.  But it really 
is a high-quality search. 
Basically, interestingly enough, there is a new Rule 44A.  The 
EPO had basically decided to conform to the PCT rules and now 
you do not just get a search report, supplementary European 
search report, or a supplementary search report.  But, you will also 
get an opinion on patentability with your EPO search.  It is an 
extended search report.  So now even in EPO proceedings this is 
getting pushed forward. 
If you recall, if you have to do a supplementary search report, 
because we are talking about going into the PCT-EP, then at some 
point you will be asked whether you want to proceed further in the 
European phase after you have seen the search report.  Now you 
can make an even more informed decision because you have this 
opinion of patentability.  This applies to applications that were filed 
after July 1, 2005. 
This is just a chart to show you how this new Rule 44A breaks 
down.  You can see that the search fee goes up if the European 
search is reporting.  The examination fee went down a little bit. 
Now, if you could see the whole overview, it is quite a complicated 
system.  Don’t worry, I am not going to explain it.  This is just to 
give you an idea that, depending on who is the ISA, there will be 
different fees involved.  The EPO fee structure clearly prefers using 
the EPO as the ISA.  It is much cheaper for you, even under this 
new system. 
You will see there are other national offices which cost very 
little for the search.  There is also discussion at the EPO, I do not 
know how advanced this is, but there are other national offices who 
want to get into this picture.  You see it is only a barely nominal fee 
of 150 euros.  Then, if you take into consideration the examination 
fee it is basically the same.  For example, other national offices 
where you want to get it are from former Eastern European 
countries.  They also want to have this recognition.  Now there is a 
lot of discussion about this. 
Okay, we have talked about the quality of the EPO search.  Can 
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we be guaranteed that if this happens, then this quality is still 
there?  Maybe not.  I think this is just a concern that the user might 
have with this happening. 
Also, if you look at the third column coming from the United 
States, it is going to be more expensive.  There is a little bit of a fee 
reduction if the USPTO does a search.  But, if you compare it to 
the EPO doing the search, it is significantly more expensive.  So 
this consideration is also part of the choice. 
In terms of optimized practice, there was one comment I 
wanted to make: when do you enter the EP phase?  The EPO 
basically says that they will not examine an application until the 
end of the thirty-one-month period.  But, if you want, you can enter 
the EP phase earlier.  You just have to file an early processing 
request, which is just a piece of paper that indicates you want early 
processing.  It does not cost you anything.  They are going to 
mention that you might want to enter, why wait?  I would also say it 
depends on your client, of course, but why wait?  Especially if you 
already have a favorable opinion, you were at the EPO as an ISA, 
why wait?  You are going to wait ten months?  What does that really 
gain you? 
I also thought of something that you might really lose in not 
going in early.  I actually only thought about this sitting here 
because of what Ted mentioned.  The EPO, or a prior filed 
application, a WIPO application, has no prior effect unless it enters 
the EP phase, unless you have paid the national fee.  So, for a 
certain period of time, and if you are talking about ten months, 
that might be quite significant.  This PCT application, though 
published, has no prior art effect.  You are losing that time.  You 
might miss an opportunity there.  Maybe something grants and you 
have missed the opportunity. 
The last thing I want to do is address the question that came 
before that—the diagnostic method.  If you still want the answer?  
You’re talking about the decision for a diagnostic?  Yes, basically 
the problem with what was said about this decision was that there 
were a lot of boards going and in a very strange area.  Basically 
saying that it did not have anything to do with a human body and 
this was a diagnostic method.  Then there were other boards taking 
a very restrictive approach that said, well, you basically have to take 
all the stuff to the doctor.  That is where you have to claim different 
perspectives including the deductive reasoning of making a 
diagnosis.  Luckily the board of appeals came out with the more 
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restrictive view.  Really, unless you claimed something and 
described it that way, so you cannot claim it any other way.  It 
doesn’t change anything. 
4. European Perspective: Steven Howe† 
I’m going to talk about the international regional phase in 
Europe.  This is the bit after the PCT—the bit that gets the patent 
granted. . . . 
To get a granted patent you have to go into the national or the 
regional phase and you have to convince the national or regional 
patent offices—under their rules and their laws—that you should 
be entitled to a patent.  The rules and laws of all national and 
regional offices are not necessarily the same.  As we have heard, we 
are not harmonized yet.  I’d like to talk a bit about things in 
Europe to help you get your PCT patent applications through to 
granted patents. 
Now what I want to do is—and perhaps this might be a 
reoccurring theme—is concentrate on three areas or three effects: 
to get your patents granted in a way that gives you better 
protection; in a way that you can get your protection more quickly, 
or more efficiently, if that is what you need; to save costs to get your 
protection cheaper. . . . 
Now what I’m actually going to do is to split the talk into three 
areas.  I’m going to talk first about countries and the way you can 
get protection in different countries in Europe.  In particular I’m 
going to talk about the choice between national applications, which 
just cover individual European countries, and the European 
regional patent application, and why you may wish to choose the 
national or regional approach depending upon your particular 
criteria. 
As far as the regional phase application is concerned, I’ll talk a 
bit about contracting states and extension states—terms you may 
have heard but which you may not be too sure about the 
difference, so we’ll talk about those, and I’m going to talk about 
claims—things that you can do, perhaps when you enter Europe to 
save costs and save time. 
If I’ve managed to save enough time, we’ll talk a little bit at the 
end about accelerating prosecution—ways you can get your patent 
granted more quickly. 
 
       †  Lloyd Wise, London. 
102
William Mitchell Law Review, Vol. 32, Iss. 4 [2006], Art. 8
http://open.mitchellhamline.edu/wmlr/vol32/iss4/8
13PCTTRANSCRIPT.DOC 6/5/2006  8:33:09 AM 
2006] 2006 PCT SYMPOSIUM 1705 
Let’s begin with national phase.  National phase—as opposed 
to European regional phase applications which we’ll talk about in a 
minute, where many European countries are covered by a single 
application, means filing a national application in individual 
countries where you want protection.  To file national applications, 
perhaps in two or three European countries, you file a separate 
national application in each of those two or three countries.  You 
pay your filing fees, other official fees, you appoint a local agent 
and if necessary you file a translation into the national language of 
that country. . . .  
Why would you want to file national applications in just the 
two or three countries perhaps, rather than a European 
application?  One reason is because it is generally quicker.  We’ve 
heard a little bit about the delays in the European system.  That 
sometimes is a problem.  Often it’s not a problem.  Often people 
want to delay things as long as possible.  But in general, if you need 
quick patents in a European country, it’s often quicker to file a 
national application.  Certainly that’s the case in the U.K.  I think 
that’s also the case in Germany. 
It may also be cheaper to file a national application.  Coming 
back to the core reoccurring topics here: how to make protection 
cheaper.  If you only want protection in one or two countries, it is 
probably cheaper to file individual national applications in those 
countries rather than the European application. 
There are also disadvantages.  National applications are not 
available in all countries.  There are some countries in Europe—
France is one of the notable ones—where you can’t enter the 
national phase through a PCT application. So, if you want to get 
protection in France based on a PCT application, you have to file it 
as a European application.  That’s the only way to get protection in 
France.  That’s one of the disadvantages of going the national 
route. 
Another disadvantage is that it is more expensive if you are 
going in a large number of countries.  We normally think that if 
you going in three countries, or more, it’s probably cheaper at the 
end of the day to file the European application rather than 
national applications. 
The other thing is, it’s much more expensive to start with.  
One of the key advantages of the European application is that the 
expensive costs, which are primarily the translation costs, are left 
right to the end—when you already know that you’ve got a patent 
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granted.  If you file in national countries to begin with, you have to 
file the translations up front and pay all the official fees upfront, 
making it much more expensive to start with. 
The other potential disadvantage is more objections.  If you 
file three national applications with three different patent offices, 
you’ve got three different sets of examiners and they’ll probably 
come up with three different sets of objections.  Whereas at least 
with the European system you’ve only got one set of examiners 
looking at your case. 
So, it’s something to think about.  When you’re converting 
your PCT application, think about the countries, think about how 
quickly you need protection, think about whether you’re prepared 
to put the money upfront or whether you want to defer costs as 
long as possible and you may decide it’s better to file national 
applications rather than European regional applications.  There 
are also a few European countries which still haven’t adopted the 
longer thirty-month period under Chapter I, and so it may be too 
late to file national application in some countries. 
Okay, most of the time people are filing European regional 
phase applications, rather than filing national applications and 
that’s what I’ll actually talk about from here on. 
Now I have to show you this [map of Europe] because it was 
colored in by my children.  It’s not quite right, apologies.  But 
basically what we’ve got here is a map of Europe.  The [countries 
in] dark blue are the countries which are contracting states of the 
European Patent Convention.  The ones colored in red, grouped 
together towards the bottom, are what we call the extension states 
of the European Patent Convention.  When you look at the front 
page of your PCT application you’ll see that there is a list of 
countries which are covered by the European designation.  You 
won’t find the extension states listed in there.  The extension states 
are listed separately. 
What does it mean—designated states, contracting states, and 
extension states?  Under the PCT system, we’re all used to 
designating states, or to have designated states.  What it means 
under the PCT system is that those are the countries where you can 
eventually file national applications to try and get patent 
protection.  Designations in Europe are slightly different.  You still 
designate states to begin with when you start filing your European 
application but then the application will be examined by the EPO 
and they will decide whether a patent can be granted or not.  Once 
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they’ve decided that a patent can be granted, you can then validate 
that patent in any of the states that you designated.  That’s a formal 
procedure.  There is no further examination of your application by 
the national offices.  Once the EPO has decided to grant you a 
patent it’s a formal procedure to make that patent effective in any 
of the designated states where you want protection. 
Unlike the PCT system, you do have to pay a separate 
designation fee for each of the contracting states that you want to 
cover by your European application.  There are thirty-one countries 
at the EPC.  Each would normally attract a separate designation fee.  
So, when you enter the European regional phase, you would need 
to work out which countries you wish to designate and pay a 
separate fee for them.  However, if you pay seven designation fees, 
that’s enough to cover all of those dark blue countries, as 
designated or contracting states. 
What does this mean in terms of efficiency and cost when 
you’re trying to get your European protection?  It means you can 
make a saving if you don’t want to go in very many countries.  If 
you want protection in two or three countries and you know that 
up front, just pay the two or three designation fees to cover those 
countries, rather than paying seven designation fees—you’ve made 
yourself a cost saving. 
However, if you were to go into perhaps five or six countries, 
you may be able to get a great increase in efficiency by paying the 
few extra fees.  Let’s say you know you want to go ahead in six 
countries, you need to pay six designation fees.  For the payment of 
just one extra designation fee, you can keep open your options for 
protection in all thirty-one of those countries. 
When your patent actually comes to being granted, you don’t 
have to validate it in every single country you designated.  You can 
just select the ones that you want protection in at the time of grant.  
So, you’re keeping your options open in those countries.  You’re 
not committing yourself to have to get protection in those 
countries. 
The extension states in many ways are similar but they’re not 
full party to the EPC, so they’re not covered by the designation 
fees.  In other words, if you want protection in any of those 
countries, you’ll have to pay a separate extension fee for each of 
those countries where you want to extend your European patent.  
Again, you have to pay that when you’re entering the European 
regional phase. 
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Okay, so part two was amending claims.  Why would you want 
to amend claims?  The first is to try and reduce costs.  The very 
obvious way where amending claims can reduce costs is reducing 
the number of excess claim fees, but also if you amend claims and 
put them in a better form for the European Patent Office, you can 
perhaps reduce objections and that will reduce costs.  The other 
thing, if you amend the claims and get them in a better form, you 
can hopefully get a grant much quicker. 
When to amend?  On entering the European regional phase—
as we know that’s normally within thirty-one months of priority of 
filing, or shortly after entering. 
After you enter the European regional phase, the Patent 
Office will send an invitation giving you an opportunity to make 
voluntary amendments at that time.  There are advantages of 
making amendments at this stage, shortly after entry.  As we know, 
we don’t always get ready to file the European application far 
enough in advance to consider amendments to the claims on filing.  
It’s nice if we have to make a decision to file the application, file it 
and then have a short period afterwards to try to think about 
making claims.  I find that one really good advantage of being able 
to amend claims at around this stage, is you can just put them in as 
voluntary amendments.  You don’t have to put in any comments.  
The main advantage is that there is nothing on the public file 
which is going to come and haunt you in subsequent U.S. litigation 
in years to come.  You’ve just put the claim amendments on file 
without commenting. Of course, you can make amendments 
during prosecution, but then you’d lose lots of the advantages of 
making those amendments early. 
Excess claim fees, I mentioned.  Excess claim fees are due for 
the eleventh and subsequent claims.  So if you have eleven claims 
you have to pay one excess claim fee.  Twenty claims you pay ten 
excess claim fees. 
The claim fees in themselves are not a lot individually, but they 
start mounting up.  If you have a PCT application that was searched 
and examined by the USPTO, you need to pay search and 
examination fees to the EPO.  If your application includes seventy-
six claims, the total cost of the excess claim fees is more than all the 
rest of the official fees put together.  So you’ve doubled your cost. 
If your application was searched and examined by the EPO, it’s 
even more noticeable.  As soon as you get to forty-five claims, 
you’ve doubled the costs.  That’s a very good reason to try to shrink 
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down the number of claims if you can. 
How can you do it? 
We can add multiple dependencies. 
We can combine claims using alternatives. 
We can delete claims that are no longer commercially 
important. 
You’ve used the PCT to buy yourself some time.  You’re now 2 
½ years from when you first filed the application.  Things that were 
commercially important when you filed the application may not be 
commercially important now.  So what’s the point in keeping 
claims in there and paying a fee for them if they’re not 
commercially important? 
The same applies for claims that don’t add to the novelty or 
inventiveness.  You’ve had your search report, you know more 
about the prior art, and if that has identified claims that are never 
going to help you in terms of showing you have a patentable claim 
there, why pay the fees for them?  Let’s reduce the cost now and 
make the most of the system. 
Also, deleting claims that won’t be allowed.  We can talk about 
those a bit more.  Claims that may not be allowed include multiple 
independent claims.  The EPO doesn’t like you to have more than 
one claim in each claim category.  There are a few cases where you 
are allowed to have them, but in general only one independent 
claim per category. 
It might be a good idea to keep multiple independent claims 
in your application.  For example, it keeps your options open for 
longer as to which claims you want to proceed with.  It gives you the 
opportunity to get the EPO to do further searches in respect to 
claims that haven’t been searched before.  But there are 
disadvantages.  It increases the excess claim fees that will be payable 
on claims that won’t be allowed.  The first thing that’s going to 
happen is the EPO will say that the claims aren’t clear.  There are 
too many independent apparatus claims here.  There is no point in 
paying the fee for them if you’re just going get that formal 
rejection.  You may even find that you have to pay this excess claim 
fee twice for the same claim.  Because if you have to delete the 
claim, to meet the formal requirements, and then you file it in a 
divisional application, the divisional application may also have 
more than ten claims in it.  Then you have to pay the excess claim 
fee a second time on the divisional application.  So each extra 
claim that you have in is not going be allowed but requires payment 
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of two excess claim fees.  Of course this delays allowance and 
increases costs because there are more official actions.  It decreases 
the efficiency of the system and it’s longer before you get a granted 
patent. 
Claims directed to what we call excluded subject matter could 
also be deleted.  Subject matter you can’t get protection for in 
Europe.  Claims to non-technical inventions like computer 
programs, business methods, presentation of information and 
medical methods.  If you’ve got claims to these things in your 
application, you may want to consider deleting those claims 
because again what is the point of you paying money for them 
which you’re never going get back, it’s going to lead to an 
objection, it’s going to slow the whole process down. 
Next, onto other amendments you may consider.  You may 
consider trying to overcome the formal objections you get from the 
EPO by putting your claims in the two part form, by including 
reference numerals, by including SI equivalents to non-SI units.  
Those sort of things will help speed up the process of getting your 
patent allowed in the EPO and will reduce objections and reduce 
costs. 
If you know there are novelty and inventiveness objections, 
again take the opportunity to make some amendments to address 
these, to overcome clarity objections, or other objections, that 
you’re aware of, if you feel that’s the right thing to do.  You don’t 
have to comment on why you’re making those amendments. 
So for all those reasons it’s good to amend claims, if 
appropriate, but I think always consider from the European 
practitioner’s point of view whether that is the right thing to do.  
The last thing you want to do is just go crossing claims out if there 
was actually a better way to keep them in or a value in keeping 
them in. 
Very quickly, accelerating allowance—how to get your patent 
granted more quickly.  You can help by entering the European 
regional phase early, by putting the application in the best possible 
form and by responding quickly to office actions.  It goes without 
saying, that the quicker you respond to an office action, the quicker 
you can overcome the examiner’s objections. 
We have a system in Europe for accelerated search and 
accelerated examination.  I understand it’s much easier than in the 
United States.  You write to the EPO and just ask them to accelerate 
the search or accelerate the examination and they generally will do 
108
William Mitchell Law Review, Vol. 32, Iss. 4 [2006], Art. 8
http://open.mitchellhamline.edu/wmlr/vol32/iss4/8
13PCTTRANSCRIPT.DOC 6/5/2006  8:33:09 AM 
2006] 2006 PCT SYMPOSIUM 1711 
it.  They’ll try and get an examination report to you within about 
three months of making the request for accelerated examination 
rather than perhaps two years which it might otherwise be. 
If you do need patent protection quickly, you should be aware 
that we do have a system of provisional protection in Europe.  I 
think you’re aware of that from more recent U.S. practice.  But you 
should be aware that to get provisional protection in Europe you 
do need to make sure that you have the claims in the language of 
the country where you want protection.  So if your application is in 
English and you want provisional protection, that’s protection from 
the date of publication, in German for example, you need to file a 
German translation at that time. 
5.  James Cleeve† 
Thank you, good afternoon.  I am originally from the U.K. and 
have the funny accent.  I spent ten years working there in private 
practice, qualifying as a European patent attorney and in the U.K.  
Then, evading tax authorities or whatever reason, I went to 
Singapore.  I collected another few letters there as a Singapore 
patent agent and then got bored.  I don’t know if any of you have 
been to Singapore.  It is interesting for a while, but afterwards not 
quite so interesting.  Then, really merely on a dare, I moved to 
Beijing in late 2004 and I’ve been there ever since.  Except, 
obviously, at this very point in time. 
So, I’m basically speaking to you as a patent attorney, obviously 
a Westerner, but with experience of some sort in both East and 
West, and I hope some understanding of the Western outlook and 
the Western expectations of patent systems in Asia and, particularly 
for me, China and Singapore.  Fortunately for you, much of what I 
was going to say has been said before, so I’ll try not repeat too 
much, unless I have a slightly different slant, which I try to have 
occasionally. 
This is one of my favorite quotes and at last I have a chance or 
reason to put it up somewhere, if you can read it.  Is it a bit dark?  
“East is East and West is West and never the twain shall meet”—
Rudyard Kipling.  Rubbish!  Or, I think to translate in to the local 
language—Garbage or trash.  I like confrontation.  I’m English. 
My experience is that really East and West are not so different.  
Yes, as countries . . . in many Asia countries, they love their 
 
       †  Lloyd Wise, China. 
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bureaucracy and quite often there are requirements relating to all 
sorts of things that appear to have no grounding in this world, or 
any kind of logical reality.  But that isn’t the case with patents.  
When it comes to patents I would say that the approach taken by 
both East and Western patent laws are quite similar.  Even in Asian 
countries with no history of imperial occupation.  Indeed when 
comparing approaches to patent prosecution in Europe, Asia and 
the U.S.A., it tends to be the U.S.A. that is the odd man out. 
We’ve actually heard from the office of the PCT today, from 
various applicants from other U.S. lawyers about the advantages of 
the PCT and I’m afraid, much as I hate to admit it, I must join the 
cheerleading group. . . .  
As I say, much as I hate to admit it, I have to admit that the 
WIPO and the PCT can, although maybe not should, be thanked 
for quite a positive effect on the way East and West patents work.  
In that respect I do say that the PCT does work. 
I’m not saying that the PCT is best practice.  I’m not saying it’s 
perfect.  But I think, as has been mentioned before, it is still an 
awful lot better than having to file in every country, independently 
from scratch—or at least at twelve months.  We all know what 
clients are like at the last minute. 
So, you have all these various advantages and I’ll skip most of 
this.  Filing date—without a headache.  Reduction of formalities.  
Now in fact the interesting thing is reduced formalities even when 
you’re not using a PCT.  I think we’ve all seen a reduction in the 
formalities required just for standard national filing, which is, of 
course, a very good thing. 
Now I’ve written here similarities and national phases.  Most of 
you reading that list will probably assume that I live on another 
planet.  Maybe too much time spent in Asia.  What do I mean 
patentable subject matter is similar around the world?  Come on, 
how can I really say that?  There is a great divide over computer 
software, over business methods, over methods of treatment, but 
leaving those aside, the rest is in fact quite similar.  Even with those 
particular subject matters the world tends to fall into two groups.  
So in both East and West, at least we know what the problem is.  
You as American attorneys, lawyers, whatever, will tend to know that 
the problem in one country, say China over computer programs, is 
similar to Europe.  It’s not completely off the scale.  That is at least 
one advantage—that it’s not everyone doing something differently. 
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a. Patentability, Novelty Inventive Step, Practical Applicability 
Yes, again there are differences, but everyone in this room 
basically knows what we’re talking about when we talk about these 
terms.  At least almost everyone in the room I guess.  If you go out 
into the street, and go up to the average lawyer and you talk about 
novelty inventive, practical utility, industrial applicability, even the 
other ones, added matter, sufficiency, unity, most people would 
have no idea what you’re on about. 
Now the fact is that yes, we disagree as to what these things are, 
but we all have an idea that these are important and that the core, 
the core of most of these ideas, is quite similar.  There’s at least a 
good deal of overlap if they’re not identical. 
b. Form and Content 
My view is that you could, that it is possible to have a single 
identical patent specification that you could in fact get granted in 
the U.S., Europe, China, or other countries, which in fact—in each 
case—is just a translation.  We’ve all agreed on this idea of the 
description, claims, drawing, abstract.  It is so much better than it 
could possibly be.  This is a glass and it’s half empty/half full 
matter. 
c. Similarities of Procedures in the National Phase 
Again, everything is quite similar now.  We enter the national 
phase, you use a form.  The office of the PCT will send the 
specification to the various offices.  You then just have to, you 
know, put in a few details in the form, etc.  There will be 
publication possibly at eighteen months.  You have examination.  
After examination, there is grant and possibly revocation.  I see 
these things in Europe.  I see them in Asia.  I assume you see them 
in America as well.  It’s all quite similar. 
d. Infringement/Enforcement 
Yes, okay.  Different ideas of what infringement is.  But at least 
we’re all using claims to work out infringement (except for the 
Germans).  Okay, we’re all banking it on claims.  Infringement and 
enforcement, what are we going to try and do with enforcement?  
Get injunctions?  Possibly damages, if you’re lucky.  Even China 
does this.  I know legend is that they don’t, but China does enforce 
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patents and you can get damages and injunctions. 
e. Some Differences 
It’s not all hunky-dory, it’s not all that great.  Here are some 
differences.  What have you got for differences?  EPO.  Claim fees 
on claims for regional phase entry.  This is something my 
colleague, Steven, will talk about later.  I think you all know when 
you enter the European regional phase you have to pay excess 
claims fees.  You can amend the number of claims at that point.  
But then as Mr. Xu just said, for a Chinese application, you can’t.14  
You can amend the claims, but you’re still stuck with paying the 
claims fees based on the number of claims you filed earlier. 
f. Examination Emphasis 
This is one of the ones I find quite interesting.  In the EPO you 
might have noticed, occasionally, they seem to be almost insane 
when it comes to the question of added subject matter.  They love 
this one.  But also they’re very insane on novelty and inventive step.  
But in China, I’d say, less than 50% of the actions I see mention 
novelty, or inventive step, or even added matter.  What they’re 
really concerned about is support and clarity.  Until everything is 
excessively clear and supported, you’re not going to get anywhere 
in China. 
Singapore is fairly unique, and it may be a bit of an 
experimental system.  They don’t have their own examiners, even 
for national phase applications.  They use Australia, Austria, and 
Denmark.  Each of those has their own way of examining things 
and their own emphasis.  In fact it actually doesn’t matter what they 
say, in Singapore, if you don’t like the examination results, or 
you’re bored with it all and don’t want to spend any more money 
(well it’s not that much more money), you can just request grant 
anyway.  So you can get a grant even if the examiner is saying it’s 
not new.  It doesn’t matter, you get the grant anyway. 
Actually one point was made earlier today about interviews 
with examiners in the U.S. and maybe doing that elsewhere, and 
also in the international PCT phase.  In Singapore you can’t 
actually get an interview with the examiner because the examiner is 
in Australia, Austria or Denmark, and if you try, he won’t talk to 
 
 14. See supra Part IV.B.1. 
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you.  I tried it once.  He said, yes he’ll look at the file, and then he 
never called back.  Eventually I had to call him and he said, “sorry, I 
can’t talk to you”.  I had to go indirectly, had to go through the 
Singapore Patent Office, no oral communications are allowed with 
the examiners. 
What else have we got?  EPO opposition, post-grant 
opposition.  Well, that’s a quite useful thing in the EPO.  I’m not 
trying to contrast it anywhere. 
g.   China—Timing of Voluntary Amendments 
That’s another bugbear for everybody.  In China, generally, 
once you’ve started the examination, you can’t actually make 
voluntary amendments.  There is a term, well there’s an early 
period in which you can, but once you request examination, then 
you enter the examination procedure, and you’re given a term of 
three months after the entrance to examination procedure to file 
voluntary amendments.  After that point, you cannot make any 
voluntary amendments.  Any amendments you make have to be 
made in response to an objection of the examiner from then on.  
So if you decide at a later time, that, for example, the U.S. claims 
have been granted and are rather nice and you want those, you 
cannot file those.  You have to go through a divisional application 
process. 
h.   Specifications in the International Phase 
One thing I mentioned is that China really emphasizes support 
and clarity.  The support part can be a nightmare; they’re really 
keen on it for chemical cases in particular.  If you have a chemical 
case and you’ve only got one or two examples, maybe even three, 
that just gives you, as far as most examiners are concerned, the 
right to claim a monopoly over those two or three examples.  It 
won’t give you the right to claim a monopoly over the whole group.  
You’ve got to show the examiner why it is that a skilled person 
would think that, from those examples, all examples you’re trying 
to cover would most definitely work and have the same advantages 
as your invention.  The same goes for ranges.  You want to claim a 
range.  You’ve got to make sure you have something at the 
beginning of the range, something at the end of the range, and a 
few examples in the middle—that you’re covering the whole thing.  
Without that you might not be able to get your range. 
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i. Claim Numbers 
Well, we’ve got this problem that some people, at least the 
impression I was getting, is that some people think you’re better off 
putting in a lots of claims at the PCT stage because you don’t have 
extra claims fees.  But we’ve got this problem with China, you do 
have extra claims fees.  You have to think of some ways of keeping 
those down.  Multiple dependencies?  Maybe putting alternatives, 
combining alternatives, into single claims?  No one likes them 
ultimately, but at least those keep the fees down. 
Oh, there is something I suppose I should just reiterate 
because it is one of the big problems: this whole question of the 
countries that are not in the PCT.15  A number of times when I was 
working in Singapore, you’d see applicants writing at thirty months, 
“please enter the national phase in Singapore and Malaysia.”  The 
scary thing was they hadn’t even noticed that Malaysia wasn’t 
designated.  Fortunately, in Malaysia there is, in fact, a grace 
period—twelve months from a publication that is due to the 
applicant’s own activities. 
j. Other Issues 
Some sweeping generalizations—because I like those.  I call it 
views from the ground because that sounds slightly better than just 
sweeping generalizations. 
Europe—fairly mature in some ways, but immature in others.  
People doing the patents and businesses are fairly mature when it 
comes to patents.  They tend to think in terms of U.S., Europe, 
China, other countries.  They might well go PCT. 
Now my experience in Singapore and China is different.  Of 
course, as a European, the big let down for me is that Europe 
doesn’t exist as far as most people that I’ve ever met are concerned.  
It is dropped off the radar.  So it’s a big blow to the ego.  As for the 
U.S., you guys can feel happy.  The U.S. and China are seen as the 
important ones. 
Most Chinese that I’ve met—okay admittedly I haven’t seen 
the big filers, and there are some in China—they prefer just to go 
national.  They want grant as soon as possible.  They don’t want to 
go through the PCT.  They want to get that piece of paper on the 
wall as soon as possible.  They really don’t like, or trust, the PCT.  
 
 15. See also supra Part II.A.1. 
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It’s a big international thing.  It’s complex.  Just go for something 
simple, that’s what they prefer.  There’s also the cost aspect.  They 
really are quite tight on cost. 
The other thing one finds in China, there is quite a lack of 
understanding as to the differences between patents, designs and 
utility models.  A lot of Chinese inventors think they are getting a 
proper utility patent when all they are getting is a design patent.  
China is one of the world’s biggest filers of design applications.  I 
fear that part of the reason is that very one.  Although, again, there 
is also the quick grant, the piece of paper on the wall as well as 
being cheap. 
I’ve got three graphs.  I think you’ve seen most of these figures 
before.  This is just to give you an idea of scale of filings, PCT 
filings, and country of origin.  EP, what’s that?  Three-hundred 
million—350 million people.  Roughly a third of the population of 
China—1000 million.  At the moment China has 2500 filings in 
2005—PCT filings.  How long before they overtake Europe?  Five 
years?  Ten years?  It won’t be too long. 
Next one.  I’ve picked on Ireland as an example here.  Ireland, 
the Celtic Tiger—in Europe it is the country everyone is kind of 
jealous of, at least in terms of the economy and growth.  You look 
at their filings—2000-2004—it’s been quite steady growth.  You 
compare that with China, and its growth is more exponential.  So 
that’s just a showing that China is everywhere, or at least increasing.  
Now this is EP filings, not PCT filings. 
The next slide is U.S. grants.  Now in fact the U.S. grants are 
obviously several years further on from the filings.  However, 
they’re showing the same kind of levels, for China, as the EP 
applications are showing at the same time.  So, I think one sees that 
the Chinese are tending to file in U.S. first, or at least more in the 
U.S. before moving onto European filings. 
So that’s it!  East and West.  Sorry, they’re the same. 
V. CLOSING COMMENTS† 
Thank you so much for a day of very provocative and 
interesting presentations.  However, one thing just came to mind 
that I would like to share.  You have all been very practical and I 
just want to share a normative point of view—after all you are in a 
 
       †  Kenneth Port, Director of Intellectual Property Law Studies, William 
Mitchell College of Law, St. Paul. 
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law school. 
We have all been talking about this word “harmonization” as if 
we all agreed what it means.  It turns out if we went person-to-
person, country-to-country, we would not have a common 
agreement on what harmonization means.  Phil alluded to this 
when he was joking about the spelling.  It is not only the spelling; it 
is the core meaning of harmonization.  Does harmonization mean 
that we must make laws identical?  Does it mean we simply provide 
a close approximation of laws?  Or is the goal of harmonization 
merely to create a relationship between things to imply that there is 
some sort of accord? 
We need to come to one understanding of what 
harmonization means in order to have a conversation about it.  In 
the alternative, we need to realize that we are not necessarily 
talking about the same thing when we say, “harmonization.” 
I just want to leave you with this thought.  We have to think 
critically about the word harmonization and what it means in itself.  
It is really interesting, I think, that we have spent all day talking 
about harmonization without really defining it. 
Then finally, I’ve heard a lot about this notion of “the glass is 
half full or half empty.”  I always thought that George Carlin had 
that one right.  He just said the glass was just “too big”. 
Thank you so much speakers, we really appreciate it.  Thank 
you everybody for coming.  We are adjourned. 
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